Structures
Our database currently contains information about 3783 SARS-CoV-2 protein structures and 237 additional structures of other coronaviruses. Use the filters below to select rows with attributes of interest. Next to each filter value, the number of shown/total structures from the group is displayed. Multiple values can be selected across multiple panes. To select more than one value within a single search pane, press and hold Ctrl or Shift when selecting filters. Text search can be performed using the search box on the left below the filters.
PDB | Resol. | Released | Title | Method | Ligand IDs | Virus | Protein | Ligand category | R-work | R-free | R-merge | Synthetics | Ligand full name | Author List | Processing Software | Completeness | I/σ | Synchrotron/Beamline | Refinement Software | Deposition Date | PubMed ID | Metals | Molstack | Re-refined PDB | Re-refined MTZ | R-free after re-refinement | Re-refinement summary | Validation summary | Polymers | PQ1(PDB) | Issues | Re-refined? | Raw data | Ref. | PR-free | PRSRZ | PGeometry | RNA | Re-refinement comparison | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1p9s | 2.54 Å | 2003-05-20 | X-ray | DIO | H-CoV | NSP5 (3CLpro) | Functional ligand | 19.64% | 27.89% | 14.20% | 1,4-DIETHYLENE DIOXIDE | - | 9.1 | ELETTRA (5.2R) | REFMAC | 2003-05-12 | 12746549 | - | - | - | - | N/A | - | - | Replicase polyprotein 1ab - residue 2966-3265, 3C-like proteinase | - | - | No | - | 14.7 | - | 12.7 | - | ||||||||
1uk4 | 2.50 Å | 2003-11-18 | X-ray | ATO | SARS-CoV | NSP5 (3CLpro) | Functional ligand | 21.30% | 23.10% | N/A | 5-mer peptide of inhibitor | CHLOROACETONE | DENZO | 97.40% | - | BSRF (3W1A) | CNS | 2003-08-14 | 14585926 | - | - | - | - | N/A | - | - | 3C-like proteinase; 5-mer peptide of inhibitor | 12.6 | - | No | - | 53.9 | 29.9 | 12.4 | - | ||||||
1xjr | 2.70 Å | 2005-02-01 | X-ray | - | SARS-CoV | S2M/RNA | No functional ligands | 23.14% | 24.33% | 5.60% | s2m RNA | - | MOSFLM | 99.40% | 31.3 | SSRL (BL9-1) | REFMAC | 2004-09-24 | 15630477 | MG | - | http://covid-19.bioreproducibility.org/static/data/1xjr/1xjr-refined.pdb | http://covid-19.bioreproducibility.org/static/data/1xjr/1xjr-refined.mtz | N/A | - | - | s2m RNA | 63.0 | - | Yes | - | 41.8 | 95.7 | 97.6 | s2m RNA | - | |||||
1wof | 2.00 Å | 2005-08-30 | X-ray | I12 | SARS-CoV | NSP5 (3CLpro) | Functional ligand | 20.10% | 23.90% | N/A | N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]-L-ALANYL-L-VALYL-N~1~-((1S)-4-ETHOXY-4-OXO-1-{[(3S)-2-OXOPYRROLIDIN-3-YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE | N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]-L-ALANYL-L-VALYL-N~1~-((1S)-4-ETHOXY-4-OXO-1-{[(3S)-2-OXOPYRROLIDIN-3-YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE | HKL-2000 | - | - | ROTATING ANODE () | CNS | 2004-08-18 | 16128623 | - | - | - | - | N/A | - | - | 3C-like proteinase | 19.5 | - | No | - | 45.7 | 44.2 | 23.4 | - | ||||||
2ajf | 2.90 Å | 2005-09-20 | X-ray | NAG | SARS-CoV | Spike | Pathogen-host interaction | 21.80% | 27.50% | N/A | beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose; 2-acetamido-2-deoxy-beta-D-glucopyranose | 2-acetamido-2-deoxy-beta-D-glucopyranose | HKL-2000 | 93.10% | 20.5 | ALS (8.2.1) | REFMAC | 2005-08-01 | 16166518 | ZN | - | http://covid-19.bioreproducibility.org/static/data/2ajf/2ajf_refined.pdb | http://covid-19.bioreproducibility.org/static/data/2ajf/2ajf_refined.mtz | 27.60% | Placed the coordinates in a standardized location in the unit cell. | The coordinates are NOT in a standardized location in the unit cell. | Angiotensin-converting enzyme-Related Carboxypeptidase (Ace2) - residues 19-615; SARS-coronavirus spike protein - receptor-binding domain, residues 323-502 | 4.8 | minimal | Yes | Yes | - | 16.6 | 36.9 | 15.7 | - | |||||
2d2d | 2.70 Å | 2005-09-20 | X-ray | ENB | SARS-CoV | NSP5 (3CLpro) | Functional ligand | 20.90% | 28.20% | N/A | ETHYL (2E,4S)-4-[((2R)-2-{[N-(TERT-BUTOXYCARBONYL)-L-VALYL]AMINO}-2-PHENYLETHANOYL)AMINO]-5-[(3S)-2-OXOPYRROLIDIN-3-YL]PENT-2-ENOATE | ETHYL (2E,4S)-4-[((2R)-2-{[N-(TERT-BUTOXYCARBONYL)-L-VALYL]AMINO}-2-PHENYLETHANOYL)AMINO]-5-[(3S)-2-OXOPYRROLIDIN-3-YL]PENT-2-ENOATE | DENZO | - | - | ROTATING ANODE () | CNS | 2005-09-08 | 16128623 | - | - | - | - | N/A | - | - | 3C-like proteinase | 15.4 | - | No | - | 13.1 | 81.0 | 9.5 | - | ||||||
2alv | 1.90 Å | 2006-08-08 | X-ray | CY6 | SARS-CoV | NSP5 (3CLpro) | Functional ligand | 25.50% | 31.50% | 3.80% | N-((3S,6R)-6-((S,E)-4-ETHOXYCARBONYL-1-((S)-2-OXOPYRROLIDIN-3-YL)BUT-3-EN-2-YLCARBAMOYL)-2,9-DIMETHYL-4-OXODEC-8-EN-3-YL)-5-METHYLISOXAZOLE-3-CARBOXAMIDE | N-((3S,6R)-6-((S,E)-4-ETHOXYCARBONYL-1-((S)-2-OXOPYRROLIDIN-3-YL)BUT-3-EN-2-YLCARBAMOYL)-2,9-DIMETHYL-4-OXODEC-8-EN-3-YL)-5-METHYLISOXAZOLE-3-CARBOXAMIDE | DENZO; HKL-2000 | 98.60% | 32.4 | APS (14-BM-C) | CNS | 2005-08-08 | 16250632 | - | - | http://covid-19.bioreproducibility.org/static/data/2alv/2alv_refined.pdb | http://covid-19.bioreproducibility.org/static/data/2alv/2alv_refined.mtz | 29.50% | Placed the coordinates in a standardized location in the unit cell. Aded link between the inhibitor and Cys145, corrected. Corrected residues Leu50, Asn51, Val125, Ile286, 301-303. C38 atom of the inhibitor, moved 5-13 oxazol moiety of the inhibitor. | Several residues and the inhibitor can be corrected. The inhibitor is not linked to the protein. The coordinates are NOT in a standardized location in the unit cell. | Replicase polyprotein 1ab - 3CL proteinase, residues 3242-3543 | 1.3 | moderate | Yes | Yes | - | 5.4 | 27.6 | 15.1 | - | |||||
2gx4 | 1.93 Å | 2007-05-08 | X-ray | NOL | SARS-CoV | NSP5 (3CLpro) | Functional ligand | 20.53% | 24.88% | N/A | N-[(BENZYLOXY)CARBONYL]-O-(TERT-BUTYL)-L-THREONYL-3-CYCLOHEXYL-N-[(1S)-2-HYDROXY-1-{[(3S)-2-OXOPYRROLIDIN-3-YL]METHYL}ETHYL]-L-ALANINAMIDE | N-[(BENZYLOXY)CARBONYL]-O-(TERT-BUTYL)-L-THREONYL-3-CYCLOHEXYL-N-[(1S)-2-HYDROXY-1-{[(3S)-2-OXOPYRROLIDIN-3-YL]METHYL}ETHYL]-L-ALANINAMIDE | DENZO; CrystalClear | - | - | ROTATING ANODE () | CNS | 2006-05-08 | 16884309 | - | - | - | - | N/A | - | - | 3C-like proteinase - residues 1-306 | 36.8 | - | No | - | 36.5 | 68.9 | 44.4 | - | ||||||
2qiq | 1.90 Å | 2008-02-12 | X-ray | CYV | SARS-CoV | NSP5 (3CLpro) | Functional ligand | 23.30% | 27.50% | N/A | ETHYL (4R)-4-{[(2R,5S)-5-{[N-(TERT-BUTOXYCARBONYL)-L-SERYL]AMINO}-6-METHYL-2-(3-METHYLBUT-2-EN-1-YL)-4-OXOHEPTANOYL]AMINO}-5-[(3R)-2-OXOPYRROLIDIN-3-YL]PENTANOATE | ETHYL (4R)-4-{[(2R,5S)-5-{[N-(TERT-BUTOXYCARBONYL)-L-SERYL]AMINO}-6-METHYL-2-(3-METHYLBUT-2-EN-1-YL)-4-OXOHEPTANOYL]AMINO}-5-[(3R)-2-OXOPYRROLIDIN-3-YL]PENTANOATE | HKL-2000 | - | - | APS (22-BM) | REFMAC | 2007-07-05 | 17855091 | - | - | http://covid-19.bioreproducibility.org/static/data/2qiq/2qiq_refined.pdb | http://covid-19.bioreproducibility.org/static/data/2qiq/2qiq_refined.mtz | 25.30% | Placed the coordinates in a standardized location in the unit cell. The inhibitor was re-refined after truncation to terminal carboxyl groups, assuming that the ester groups had been eliminated by hydrolysis before crystal formation, a supposition that is supported by the well-defined and abrupt limits of the electron density at the ends of both carboxyl groups. | While a large central part of the inhibitor is well defined in the electron density, the ethyl and t-butyl ester groups of the inhibitor molecule lack any electron density. The coordinates are NOT in a standardized location in the unit cell. | Replicase polyprotein 1ab - 3CL proteinase | 4.6 | significant | Yes | Yes | - | 16.6 | 17.0 | 34.5 | - | |||||
3d0g | 2.80 Å | 2008-07-08 | X-ray | NDG, NAG | SARS-CoV | Spike | Pathogen-host interaction | 21.40% | 27.90% | N/A | 2-acetamido-2-deoxy-alpha-D-glucopyranose; 2-acetamido-2-deoxy-beta-D-glucopyranose | DENZO | - | - | APS (19-BM) | REFMAC; CNS | 2008-05-01 | 18448527 | ZN | https://molstack.bioreproducibility.org/project/view/hnlY2nbqOGN6OoG7s3qz/ | http://covid-19.bioreproducibility.org/static/data/3d0g/3d0g_refined.pdb | http://covid-19.bioreproducibility.org/static/data/3d0g/3d0g_refined.mtz | 25.50% | Placed the coordinates in a standardized location in the unit cell. Corrected carbohydrate names, added several new carbohydrates. Fixed several rotamer outliers. | Not connected NAG molecules, not satisfactory Zn ion coordination. Unlikely assignment of the carbohydrate moieties bound to asparagine side chains (NDG rather than the expected NAG). Several carbohydrate moieties can be added to those already present, as well as to a few additional asparagine side chains. Coordinates are outside of the unit cell (not according to standardised placement) | Angiotensin-converting enzyme 2; Spike glycoprotein - residues 324-502 | 3.0 | moderate | Yes | Yes | - | 14.5 | 27.3 | 18.5 | - | ||||||
3d0h | 3.10 Å | 2008-07-08 | X-ray | NDG, NAG | SARS-CoV | Spike | Pathogen-host interaction | 22.10% | 30.20% | N/A | 2-acetamido-2-deoxy-alpha-D-glucopyranose; 2-acetamido-2-deoxy-beta-D-glucopyranose | - | - | APS (19-BM) | REFMAC | 2008-05-01 | 18448527 | ZN | https://molstack.bioreproducibility.org/project/view/WrI2XslE978LiF95PQYo/ | http://covid-19.bioreproducibility.org/static/data/3d0h/3d0h_refined.pdb | http://covid-19.bioreproducibility.org/static/data/3d0h/3d0h_refined.mtz | 26.60% | Placed the coordinates in a standardized location in the unit cell. Corrected carbohydrate names, added several new carbohydrates. Fixed several rotamer outliers. | Not connected NAG molecules, not satisfactory Zn ion coordination. Unlikely assignment of the carbohydrate moieties bound to asparagine side chains (NDG rather than the expected NAG). Several carbohydrate moieties can be added to those already present, as well as to a few additional asparagine side chains. Coordinates are outside of the unit cell (not according to standardised placement) | Angiotensin-converting enzyme 2; Spike glycoprotein - residues 324-502 | 11.7 | moderate | Yes | Yes | - | 6.9 | 74.0 | 12.9 | - | |||||||
3d0i | 2.90 Å | 2008-07-08 | X-ray | NDG, NAG | SARS-CoV | Spike | Pathogen-host interaction | 22.40% | 27.80% | N/A | 2-acetamido-2-deoxy-alpha-D-glucopyranose; 2-acetamido-2-deoxy-beta-D-glucopyranose | - | - | APS (19-BM) | REFMAC | 2008-05-01 | 18448527 | ZN | https://molstack.bioreproducibility.org/project/view/tyBAIB4W8gsYJT2boa8Q/ | http://covid-19.bioreproducibility.org/static/data/3d0i/3d0i_refined.pdb | http://covid-19.bioreproducibility.org/static/data/3d0i/3d0i_refined.mtz | 26.20% | Placed the coordinates in a standardized location in the unit cell. Corrected carbohydrate names, added several new carbohydrates. Fixed several rotamer outliers. | Not connected NAG molecules, not satisfactory Zn ion coordination. Unlikely assignment of the carbohydrate moieties bound to asparagine side chains (NDG rather than the expected NAG). Several carbohydrate moieties can be added to those already present, as well as to a few additional asparagine side chains. Coordinates are outside of the unit cell (not according to standardised placement) | Angiotensin-converting enzyme 2; Spike glycoprotein - residues 324-502 | 4.4 | moderate | Yes | Yes | - | 15.0 | 39.2 | 13.1 | - | |||||||
3bgf | 3.00 Å | 2008-12-02 | X-ray | - | SARS-CoV | Spike | Pathogen-host interaction | 23.40% | 28.60% | 13.20% | - | HKL-2000; DENZO | 94.40% | 6.3 | NSLS (X12C) | REFMAC | 2007-11-26 | 19324051 | - | - | - | - | N/A | - | - | Spike protein S1; F26G19 Fab; F26G19 Fab | 17.3 | - | No | - | 11.4 | 74.7 | 22.1 | - | |||||||
3aw0 | 2.30 Å | 2011-12-14 | X-ray | - | SARS-CoV | NSP5 (3CLpro) | Functional ligand | 22.48% | 28.64% | 8.20% | peptide ACE-SER-ALA-VAL-LEU-HIS-H | - | HKL-2000 | 99.90% | 21.786 | Photon Factory (BL-6A) | REFMAC | 2011-03-09 | 22014094 | - | - | - | - | N/A | - | - | 3C-Like Proteinase; peptide ACE-SER-ALA-VAL-LEU-HIS-H | 5.4 | - | No | - | 11.3 | 40.5 | 19.9 | - | ||||||
3sci | 2.90 Å | 2012-02-08 | X-ray | - | SARS-CoV | Spike | Pathogen-host interaction | 22.59% | 28.26% | N/A | - | HKL-2000 | 93.40% | - | APS (19-ID) | CNS; REFMAC | 2011-06-07 | 22291007 | ZN | - | http://covid-19.bioreproducibility.org/static/data/3sci/3sci_refined_2_tls.pdb | http://covid-19.bioreproducibility.org/static/data/3sci/3sci_refined_2.mtz | 27.70% | Placed the coordinates in a standardized location in the unit cell. Added a water molecule to each Zn cation and added LINKs between Zn and each of the coordinating ligands. Removed Cl ions. Fixed someRamachandran outliers. Many more Ramachandran outliers are left; the refinement is stopped due to availability of better structures for the same proteins. Sugar moieties were not added. | Zinc cations are placed without proper coordination. There are also two Cl ions in the structure, chemically feasible, but with poor/lacking electron density. Multiple Ramachandran outliers. Some residues have electron density for the sugar moieties due to glycosylation. The coordinates are NOT in a standardized location in the unit cell. | Angiotensin-converting enzyme 2 - UNP residues 19-615; Spike glycoprotein - receptor binding domain (UNP residues 306-527) | 2.4 | minimal | Yes | Yes | - | 12.9 | 29.2 | 14.0 | - | ||||||
3sck | 3.00 Å | 2012-02-08 | X-ray | - | SARS-CoV | Spike | Pathogen-host interaction | 23.92% | 28.53% | N/A | - | HKL-2000 | 91.70% | - | APS (19-ID) | CNS; REFMAC | 2011-06-07 | 22291007 | ZN | - | http://covid-19.bioreproducibility.org/static/data/3sck/3sck_refined_tls_2.pdb | http://covid-19.bioreproducibility.org/static/data/3sck/3sck_refined_tls_2.mtz | 29.50% | Placed the coordinates in a standardized location in the unit cell. Added a water molecule to each Zn cation and added LINKs between Zn and each of the coordinating ligands. Removed Cl ions. Fixed someRamachandran outliers. Many more Ramachandran outliers are left; the refinement is stopped due to availability of better structures for the same proteins. Sugar moieties were not added. | Zinc cations are placed without proper coordination. There are also two Cl ions in the structure, chemically feasible, but with poor/lacking electron density. Multiple Ramachandran outliers. Some residues have electron density for the sugar moieties due to glycosylation. The coordinates are NOT in a standardized location in the unit cell. | Angiotensin-converting enzyme 2 chimera - SEE REMARK 999; Spike glycoprotein - receptor binding domain (UNP residues 324-502) | 11.7 | minimal | Yes | Yes | - | 11.8 | 72.9 | 8.9 | - | ||||||
3scl | 3.00 Å | 2012-02-08 | X-ray | - | SARS-CoV | Spike | Pathogen-host interaction | 23.88% | 29.18% | N/A | - | HKL-2000 | 97.70% | - | APS (24-ID-E) | REFMAC; CNS | 2011-06-07 | 22291007 | ZN | - | http://covid-19.bioreproducibility.org/static/data/3scl/3scl_refined_2_tls.pdb | http://covid-19.bioreproducibility.org/static/data/3scl/3scl_refined_2_coot.mtz | 29.00% | Placed the coordinates in a standardized location in the unit cell. Added a water molecule to each Zn cation and added LINKs between Zn and each of the coordinating ligands. Replaced Cl with water molecules. Fixed multiple Ramachandran outliers. Many more Ramachandran outliers are left; the refinement is stopped due to availability of better structures for the same proteins. Sugar moieties were not added. | Zinc cations are placed without proper coordination. There are also two Cl ions in the structure, chemically feasible, but with poor/lacking electron density. Multiple Ramachandran outliers. Some residues have electron density for the sugar moieties due to glycosylation. The coordinates are NOT in a standardized location in the unit cell. | Angiotensin-converting enzyme 2 chimera - SEE REMARK 999; Spike glycoprotein - receptor binding domain (UNP residues 324-502) | 11.5 | minimal | Yes | Yes | - | 9.4 | 70.1 | 13.5 | - | ||||||
4rsp | 1.62 Å | 2015-06-17 | X-ray | - | MERS-CoV | NSP5 (3CLpro) | Functional ligand | 16.18% | 20.27% | N/A | Peptide inhibitor | - | MOSFLM | 95.00% | - | APS (31-ID) | PHENIX | 2014-11-10 | 26055715 | - | - | http://covid-19.bioreproducibility.org/static/data/4rsp/4rsp_refined.pdb | http://covid-19.bioreproducibility.org/static/data/4rsp/4rsp_refined.mtz | 21.20% | Placed the coordinates in a standardized location in the unit cell. Reset occupancies to n/m integral values. | Many residues with unbelievable occupancies (0.74/0.26, 0.61/0.39 etc.). The coordinates are NOT in a standardized location in the unit cell. | Orf1a protein; Peptide inhibitor | 79.8 | minimal | Yes | Yes | - | 79.9 | 73.8 | 88.4 | - | |||||
5zuv | 2.21 Å | 2019-04-10 | X-ray | - | H-CoV-229E | Spike | Functional ligand | 20.19% | 24.81% | N/A | - | HKL-3000 | 99.40% | 18.9 | SSRF (BL19U1) | REFMAC | 2018-05-08 | 30989115 | - | - | http://covid-19.bioreproducibility.org/static/data/5zuv/5zuv_refined.pdb | http://covid-19.bioreproducibility.org/static/data/5zuv/5zuv_refined.mtz | 23.00% | Repositioned the coordinates with ACHESYM and improved the model by adding residue Leu8 in chain c (inhibitor peptide), correcting conformations of 13 residues (Lys23b, Gln788B/A, Glu789A, Asn790B, Gln791A/B, Leu794A, Val806C, Gln839C, Thr848B, Gln856A/B), and adding 43 water molecules. | Structure of good quality, without any additional ligands and without missing side chains. Most of the protein residues outside of the reference unit cell. The fusion molecule (HR1 motif and the peptidic inhibitor) is represented in the deposit as a single protein chain with consecutive residue numbering, not as separte chains (as in 5zvk and 5zvm). | Spike glycoprotein,Spike glycoprotein,inhibitor EK1 - UNP residues 785-873 | 47.3 | moderate | Yes | Yes | - | 37.0 | 45.2 | 87.6 | - | ||||||
5zvk | 3.31 Å | 2019-04-10 | X-ray | - | MERS-CoV | Spike | Functional ligand | 25.90% | 31.36% | N/A | - | HKL-3000 | 99.90% | 20.7 | SSRF (BL19U1) | PHENIX | 2018-05-11 | 30989115 | - | - | - | - | N/A | - | Structure of good quality, without any additional ligands and with no missing side chains. Most of the protein residues outside of the reference unit cell. | Human Coronavirus MERS HR1 motif - UNP residues 984-1062; pan-CoV inhibitory peptide EK1 | 7.4 | minimal | No | - | 5.6 | 26.1 | 47.8 | - | |||||||
5zvm | 3.30 Å | 2019-04-10 | X-ray | - | SARS-CoV | Spike | Functional ligand | 24.76% | 30.14% | N/A | - | HKL-3000 | 99.90% | 11.9 | SSRF (BL19U1) | REFMAC | 2018-05-11 | 30989115 | - | - | - | - | N/A | not done | The coordinates are NOT in a standardized location in the unit cell. | Spike glycoprotein - UNP residues 892-970; pan-CoV inhibitory peptide EK1 | 13.4 | minimal | No | - | 7.0 | 16.9 | 74.5 | - | |||||||
6u7e | 3.00 Å | 2019-11-13 | X-ray | NAG | H-CoV-229E | Spike | Pathogen-host interaction | 20.35% | 24.39% | 7.10% | 2-acetamido-2-deoxy-beta-D-glucopyranose | XDS | 99.80% | 11.06 | CLSI (08ID-1) | PHENIX | 2019-09-02 | 31650956 | ZN | - | - | - | N/A | - | - | Aminopeptidase N - ectodomain (UNP residues 66-967); Spike glycoprotein | 65.3 | - | No | 41.3 | 86.6 | 77.5 | - | ||||||||
6u7f | 2.75 Å | 2019-11-13 | X-ray | NAG | H-CoV-229E | Spike | Pathogen-host interaction | 19.04% | 22.51% | 6.80% | 2-acetamido-2-deoxy-beta-D-glucopyranose | XDS | 99.80% | 16.24 | CLSI (08ID-1) | PHENIX | 2019-09-02 | 31650956 | ZN | - | - | - | N/A | - | - | Aminopeptidase N - ectodomain (UNP residues 66-967); Spike glycoprotein | 76.1 | - | No | 60.0 | 86.4 | 84.4 | - | ||||||||
6u7g | 2.35 Å | 2019-11-13 | X-ray | NAG | H-CoV-229E | Spike | Pathogen-host interaction | 17.86% | 21.84% | 5.20% | 2-acetamido-2-deoxy-beta-D-glucopyranose | HKL-2000 | 99.70% | 14.9 | APS (23-ID-B) | PHENIX | 2019-09-02 | 31650956 | ZN | - | http://covid-19.bioreproducibility.org/static/data/6u7g/6u7g_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6u7g/6u7g_refined.mtz | 22.40% | Fixed minor issues with geometry and solvent | - | Aminopeptidase N - ectodomain (UNP residues 66-967); Spike protein - receptor-binding domain (UNP residues 292-432) | 55.4 | minimal | Yes | 66.6 | 35.5 | 83.3 | - | ||||||||
6u7h | 3.10 Å | 2019-11-13 | Cryo-EM | NAG | H-CoV-229E | Spike | No functional ligands | N/A | N/A | N/A | 2-acetamido-2-deoxy-beta-D-glucopyranose | - | - | () | 2019-09-02 | 31650956 | - | - | - | - | N/A | - | - | spike glycoprotein | N/A | - | No | - | N/A | N/A | N/A | - | |||||||||
6jx7 | 3.31 Å | 2020-01-15 | Cryo-EM | MAN, NAG | FIPV | Spike | No functional ligands | N/A | N/A | N/A | alpha-D-mannopyranose; 2-acetamido-2-deoxy-beta-D-glucopyranose | - | - | () | 2019-04-22 | 31900356 | - | - | - | - | N/A | - | - | Feline Infectious Peritonitis Virus Spike Protein | N/A | - | No | - | N/A | N/A | N/A | - | |||||||||
6noz | 1.95 Å | 2020-01-22 | X-ray | - | PEDV | NSP3: PLpro | No functional ligands | 14.47% | 19.31% | 16.40% | - | HKL-2000 | 100.00% | 6.4 | APS (31-ID) | PHENIX | 2019-01-16 | - | ZN | - | - | - | N/A | - | - | Polyprotein - UNP Residues 1688-1933 | 85.4 | - | No | - | - | 86.1 | 92.3 | 89.9 | - | ||||||
6lu7 | 2.16 Å | 2020-02-05 | X-ray | - | SARS-CoV-2 | NSP5 (3CLpro) | Functional ligand | 20.20% | 23.50% | 18.90% | N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~-((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3-YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE | - | xia2 | 100.00% | 6.3 | SSRF (BL17U1) | PHENIX | 2020-01-26 | 32272481 | - | https://molstack.bioreproducibility.org/project/view/x9jJQnlGN25TRBSRdxJm/ | http://covid-19.bioreproducibility.org/static/data/6lu7/6lu7_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6lu7/6lu7_refined.mtz | 22.50% | The phenyl group was removed from the inhibitor. After re-refinement of the model negative density disappeared. A few minor model corrections. | The terminal phenyl group of the inhibitor with negative difference electron density, possible hydrolysis. | main protease - 3C-like proteinase; N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~-((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3-YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE | 35.0 | moderate | Yes | Yes | - | 49.8 | 29.9 | 66.4 | - | |||||
6lvn | 2.47 Å | 2020-02-26 | X-ray | - | SARS-CoV-2 | Spike | No functional ligands | 21.48% | 25.80% | 13.24% | - | XDS | 99.22% | 19.06 | ROTATING ANODE () | PHENIX | 2020-02-04 | - | - | - | http://covid-19.bioreproducibility.org/static/data/6lvn/6lvn_refined_tls.pdb | http://covid-19.bioreproducibility.org/static/data/6lvn/6lvn_refined.mtz | 26.90% | Brought all four chains in one bundle. Modified residues: 18, 30, 2, 29. Added 34water molecules. | Structure of good quality. No ligands bound. No Ramachandran outliers, no rotamer outliers, and no missing side chains. Four helices are not placed in the ASU as a single oligomer, but as two independent dimers | Spike protein S2 - HR2 domain | 49.1 | minimal | Yes | Yes | - | - | 28.1 | 76.3 | 69.0 | - | |||||
6lxt | 2.90 Å | 2020-02-26 | X-ray | PG4 | SARS-CoV-2 | Spike | No functional ligands | 25.93% | 28.96% | 16.00% | TETRAETHYLENE GLYCOL | MOSFLM | 94.02% | 6.3 | ROTATING ANODE () | REFMAC | 2020-02-11 | 32231345 | ZN | - | - | - | N/A | not done | Structure of good quality. It has one Ramachandran outlier, probably justified. No missing side-chains. Several side-chain outliers, but most are not trivial to fix - a common problem at low resolution (% outliers is low). Most of the protein is outside of the unit cell. A metal cation (Zn2+) is missing between Asp1199 of chain B and Asp1199 of chain F. At the interface between Asp1163 and Asp1165 of chain B and a symmetry mate of Glu1188 and Asp1184 of chain A (crystallographic interface between two six-helix bundles), a molecule of PEG is modeled instead of, most probably, one or two Zn2+ ions. This PEG molecule is hilariously mismodelled: it has severe clashes with the protein residues, all contacts are polar-to-nonpolar, and it is too curled-up | Spike protein S2, Spike protein S2 - HR1 domain,HR2 domain | 10.6 | moderate | No | - | 10.1 | 49.9 | 30.3 | - | |||||||
6vsb | 3.46 Å | 2020-02-26 | Cryo-EM | NAG | SARS-CoV-2 | Spike | No functional ligands | N/A | N/A | N/A | 2-acetamido-2-deoxy-beta-D-glucopyranose | - | - | () | 2020-02-10 | 32075877 | - | - | - | - | N/A | - | - | SARS-CoV-2 spike glycoprotein | N/A | - | No | - | N/A | N/A | N/A | - | |||||||||
6vv5 | 3.50 Å | 2020-02-26 | Cryo-EM | NAG, PAM | PEDV | Spike | No functional ligands | N/A | N/A | N/A | PALMITOLEIC ACID | 2-acetamido-2-deoxy-beta-D-glucopyranose; PALMITOLEIC ACID | - | - | () | PHENIX | 2020-02-17 | 33378641 | - | - | - | - | N/A | - | - | Spike glycoprotein | N/A | - | No | - | N/A | N/A | N/A | - | |||||||
6vsj | 3.94 Å | 2020-03-04 | Cryo-EM | NAG | Murine-CoV-A59 | Spike | No functional ligands | N/A | N/A | N/A | 2-acetamido-2-deoxy-beta-D-glucopyranose | - | - | () | 2020-02-11 | 32150576 | - | - | - | - | N/A | - | - | Spike glycoprotein; Carcinoembryonic antigen-related cell adhesion molecule 1 | N/A | - | No | - | N/A | N/A | N/A | - | |||||||||
6vw1 | 2.68 Å | 2020-03-04 | X-ray | NAG | SARS-CoV/SARS-CoV-2 | Spike | Pathogen-host interaction | 19.70% | 22.88% | 8.10% | 2-acetamido-2-deoxy-beta-D-glucopyranose | HKL-2000 | 96.70% | 12.08 | APS (24-ID-E) | PHENIX; REFMAC | 2020-02-18 | 32225175 | ZN | - | http://covid-19.bioreproducibility.org/static/data/6vw1/6vw1_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6vw1/6vw1_refined.mtz | 24.00% | Placed the coordinates in a standardized location in the unit cell. MC - refined the structure | Zn2+ cations have abnormally high B factors (135 and 196 Å2) and do not make any contacts with their environment that would indicate proper coordination. Otherwise the structure seems to be in good agreement with the electron density. The coordinates are NOT in a standardized location in the unit cell. | Angiotensin-converting enzyme 2; SARS-CoV-2 chimeric RBD | 52.0 | minimal | Yes | Yes | - | 56.3 | 76.4 | 46.3 | http://covid-19.bioreproducibility.org/static/data/6vw1/6vw1_refinement_report.pdf | ||||||
6vww | 2.20 Å | 2020-03-04 | X-ray | ACY | SARS-CoV-2 | NSP15 | No functional ligands | 15.77% | 17.77% | 17.40% | ACETIC ACID | HKL-3000 | 98.50% | 10.0 | APS (19-ID) | PHENIX | 2020-02-20 | 32304108 | MG | - | - | - | N/A | - | - | Uridylate-specific endoribonuclease | 85.8 | - | No | 93.0 | 95.3 | 82.9 | - | ||||||||
6vxs | 2.03 Å | 2020-03-04 | X-ray | NHE | SARS-CoV-2 | NSP3: Macro | No functional ligands | 18.64% | 23.35% | N/A | 2-[N-CYCLOHEXYLAMINO]ETHANE SULFONIC ACID | 2-[N-CYCLOHEXYLAMINO]ETHANE SULFONIC ACID | HKL-3000 | 90.80% | 8.44 | APS (19-ID) | PHENIX | 2020-02-24 | 32939273 | - | - | - | - | N/A | - | - | Non-structural protein 3 | 74.3 | - | No | 51.6 | 89.6 | 85.0 | - | |||||||
6y2e | 1.75 Å | 2020-03-04 | X-ray | - | SARS-CoV-2 | NSP5 (3CLpro) | No functional ligands | 17.12% | 22.24% | 8.20% | - | XDS | 100.00% | 15.0 | BESSY (14.2) | REFMAC | 2020-02-15 | 32198291 | - | - | http://covid-19.bioreproducibility.org/static/data/6y2e/6y2e_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6y2e/6y2e_refined.mtz | 22.06% | Fixed minor issues with side chain rotamers. | Protein chains are modeled well. | Replicase polyprotein 1ab | 62.6 | minimal | Yes | Yes | - | 62.8 | 64.4 | 72.7 | - | ||||||
6y2f | 1.95 Å | 2020-03-04 | X-ray | O6K | SARS-CoV-2 | NSP5 (3CLpro) | Functional ligand | 17.79% | 21.91% | 7.60% | ~{tert}-butyl ~{N}-[1-[(2~{S})-3-cyclopropyl-1-oxidanylidene-1-[[(2~{S},3~{R})-3-oxidanyl-4-oxidanylidene-1-[(3~{S})-2-oxidanylidenepyrrolidin-3-yl]-4-[(phenylmethyl)amino]butan-2-yl]amino]propan-2-yl]-2-oxidanylidene-pyridin-3-yl]carbamate | ~{tert}-butyl ~{N}-[1-[(2~{S})-3-cyclopropyl-1-oxidanylidene-1-[[(2~{S},3~{R})-3-oxidanyl-4-oxidanylidene-1-[(3~{S})-2-oxidanylidenepyrrolidin-3-yl]-4-[(phenylmethyl)amino]butan-2-yl]amino]propan-2-yl]-2-oxidanylidene-pyridin-3-yl]carbamate | XDS | 100.00% | 15.5 | BESSY (14.2) | REFMAC | 2020-02-15 | 32198291 | - | - | http://covid-19.bioreproducibility.org/static/data/6y2f/6y2f_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6y2f/6y2f_refined.mtz | 20.60% | Re-refinement with a sodium cation modeled at the highest peak site. A few side chain rotamer corrections. Application of TLS parameters. | Structure of good quality. High positive peak coordinated by five carbonyl oxygen atoms and one water molecule; octahedral coordination. | Replicase polyprotein 1ab | 42.4 | moderate | Yes | Yes | - | 65.8 | 37.2 | 57.5 | - | |||||
6y2g | 2.20 Å | 2020-03-04 | X-ray | O6K | SARS-CoV-2 | NSP5 (3CLpro) | Functional ligand | 18.62% | 24.73% | 17.00% | ~{tert}-butyl ~{N}-[1-[(2~{S})-3-cyclopropyl-1-oxidanylidene-1-[[(2~{S},3~{R})-3-oxidanyl-4-oxidanylidene-1-[(3~{S})-2-oxidanylidenepyrrolidin-3-yl]-4-[(phenylmethyl)amino]butan-2-yl]amino]propan-2-yl]-2-oxidanylidene-pyridin-3-yl]carbamate | ~{tert}-butyl ~{N}-[1-[(2~{S})-3-cyclopropyl-1-oxidanylidene-1-[[(2~{S},3~{R})-3-oxidanyl-4-oxidanylidene-1-[(3~{S})-2-oxidanylidenepyrrolidin-3-yl]-4-[(phenylmethyl)amino]butan-2-yl]amino]propan-2-yl]-2-oxidanylidene-pyridin-3-yl]carbamate | XDS | 100.00% | 13.1 | BESSY (14.2) | REFMAC | 2020-02-15 | 32198291 | - | - | http://covid-19.bioreproducibility.org/static/data/6y2g/6y2g_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6y2g/6y2g_refined.mtz | 24.00% | Fixed minor issues with side chain rotamers and a couple of orphaned solvent molecules. | Protein chains are modeled well. | Replicase polyprotein 1ab | 46.9 | minimal | No | Yes | - | 37.8 | 78.5 | 52.9 | - | |||||
5r7y | 1.65 Å | 2020-03-11 | X-ray | JFM | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 17.94% | 23.67% | 11.30% | N-(2-phenylethyl)methanesulfonamide | N-(2-phenylethyl)methanesulfonamide | XDS | 99.40% | 5.8 | Diamond (I04-1) | REFMAC | 2020-03-03 | 33028810 | - | - | - | - | N/A | not done | Weak density for the ligand on the primary 2Fo-Fc map. | 3C-like proteinase | - | moderate | No | 48.3 | - | 51.2 | - | |||||||
5r7z | 1.59 Å | 2020-03-11 | X-ray | HWH | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.95% | 23.30% | 9.60% | ~{N}-[2-(5-fluoranyl-1~{H}-indol-3-yl)ethyl]ethanamide | ~{N}-[2-(5-fluoranyl-1~{H}-indol-3-yl)ethyl]ethanamide | XDS | 99.30% | 6.2 | Diamond (I04-1) | REFMAC | 2020-03-03 | 33028810 | - | https://molstack.bioreproducibility.org/collection/view/GqjIgzdHOk3yuQaO0ukE/ | - | - | 24.30% | not done | Weak density for the ligand on the primary 2Fo-Fc map. | 3C-like proteinase | 40.9 | moderate | No | 51.9 | 42.5 | 63.3 | - | |||||||
5r80 | 1.93 Å | 2020-03-11 | X-ray | RZG | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 17.30% | 23.46% | 11.30% | methyl 4-sulfamoylbenzoate | methyl 4-sulfamoylbenzoate | XDS | 98.60% | 6.0 | Diamond (I04-1) | REFMAC | 2020-03-03 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 24.5 | - | No | 50.4 | 33.0 | 41.0 | - | |||||||
5r81 | 1.95 Å | 2020-03-11 | X-ray | RZJ | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.20% | 24.94% | 16.20% | 1-methyl-3,4-dihydro-2~{H}-quinoline-7-sulfonamide | 1-methyl-3,4-dihydro-2~{H}-quinoline-7-sulfonamide | XDS | 99.90% | 4.0 | Diamond (I04-1) | REFMAC | 2020-03-03 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 37.2 | - | No | 35.7 | 64.3 | 50.5 | - | |||||||
5r82 | 1.31 Å | 2020-03-11 | X-ray | RZS | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.03% | 21.16% | 5.00% | 6-(ethylamino)pyridine-3-carbonitrile | 6-(ethylamino)pyridine-3-carbonitrile | XDS | 88.70% | 9.7 | Diamond (I04-1) | REFMAC | 2020-03-03 | 33028810 | - | - | - | - | 21.20% | not done | Weak density for the ligand on the primary 2Fo-Fc map. | 3C-like proteinase | - | moderate | No | 72.7 | - | 50.0 | - | |||||||
5r83 | 1.58 Å | 2020-03-11 | X-ray | K0G | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 17.58% | 21.49% | 10.00% | N-phenyl-N'-pyridin-3-ylurea | N-phenyl-N'-pyridin-3-ylurea | XDS | 99.60% | 6.7 | Diamond (I04-1) | REFMAC | 2020-03-03 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 58.6 | - | No | 70.0 | 59.9 | 61.8 | - | |||||||
5r84 | 1.83 Å | 2020-03-11 | X-ray | GWS | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 21.67% | 29.26% | 14.00% | 2-cyclohexyl-~{N}-pyridin-3-yl-ethanamide | 2-cyclohexyl-~{N}-pyridin-3-yl-ethanamide | XDS | 99.70% | 5.6 | Diamond (I04-1) | REFMAC | 2020-03-03 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 12.7 | - | No | 9.2 | 45.4 | 41.8 | - | |||||||
6m03 | 2.00 Å | 2020-03-11 | X-ray | - | SARS-CoV-2 | NSP5 (3CLpro) | No functional ligands | 19.62% | 24.58% | 3.90% | - | XDS | 99.50% | 16.29 | NFPSS (BL18U) | PHENIX | 2020-02-19 | 35380892 | - | - | http://covid-19.bioreproducibility.org/static/data/6m03/6m03_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6m03/6m03_refined.mtz | 24.21% | Placed the coordinates in a standardized location in the unit cell. Added TLS (9 groups), added waters, fixed ramachandran outliers, Flipped side chains GLN 74, HIS 164, ASN 203. Changed rotamers MET 17, MET 165, ARG 298, GLN 189. Added alternative conformation for PHE 294. | Flipped sidechains, missing rotamers. The coordinates are NOT in a standardized location in the unit cell. No ligands, no metals. | main protease | 51.7 | moderate | Yes | Yes | - | 39.5 | 68.9 | 70.0 | - | ||||||
6m17 | 2.90 Å | 2020-03-11 | Cryo-EM | NAG | SARS-CoV-2 | Spike | Pathogen-host interaction | N/A | N/A | N/A | 2-acetamido-2-deoxy-beta-D-glucopyranose; LEUCINE | 2-acetamido-2-deoxy-beta-D-glucopyranose | - | - | () | 2020-02-24 | 32132184 | ZN | - | - | - | N/A | - | Poor map | Sodium-dependent neutral amino acid transporter B(0)AT1; Angiotensin-converting enzyme 2; SARS-coV-2 Receptor Binding Domain | N/A | moderate | No | - | N/A | N/A | N/A | - | ||||||||
6vxx | 2.80 Å | 2020-03-11 | Cryo-EM | NAG | SARS-CoV-2 | Spike | No functional ligands | N/A | N/A | N/A | 2-acetamido-2-deoxy-beta-D-glucopyranose | - | - | () | 2020-02-25 | 32155444 | - | - | - | - | N/A | - | - | SARS-CoV-2 spike glycoprotein - ectodomain | N/A | - | No | - | N/A | N/A | N/A | - | |||||||||
6vyb | 3.20 Å | 2020-03-11 | Cryo-EM | NAG | SARS-CoV-2 | Spike | No functional ligands | N/A | N/A | N/A | 2-acetamido-2-deoxy-beta-D-glucopyranose | - | - | () | 2020-02-25 | 32155444 | - | - | - | - | N/A | - | - | Spike glycoprotein - ectodomain | N/A | - | No | - | N/A | N/A | N/A | - | |||||||||
6vyo | 1.70 Å | 2020-03-11 | X-ray | MES | SARS-CoV-2 | Nucleocapsid | No functional ligands | 15.92% | 20.53% | 13.10% | 2-(N-MORPHOLINO)-ETHANESULFONIC ACID | 2-(N-MORPHOLINO)-ETHANESULFONIC ACID | HKL-3000 | 99.70% | 6.9 | APS (19-ID) | PHENIX | 2020-02-27 | - | ZN | - | http://covid-19.bioreproducibility.org/static/data/6vyo/6vyo_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6vyo/6vyo_refined.mtz | 21.20% | - | - | Nucleoprotein - RNA binding domain | 76.5 | - | Yes | - | 77.9 | 68.4 | 85.6 | - | ||||||
6w01 | 1.90 Å | 2020-03-11 | X-ray | - | SARS-CoV-2 | NSP15 | No functional ligands | 16.05% | 18.49% | 11.20% | - | HKL-3000 | 99.30% | 13.11 | APS (19-ID) | PHENIX | 2020-02-28 | 32304108 | - | - | - | - | N/A | z | - | Uridylate-specific endoribonuclease | 80.8 | - | No | 90.3 | 72.3 | 82.9 | - | ||||||||
6w02 | 1.50 Å | 2020-03-11 | X-ray | APR | SARS-CoV-2 | NSP3: Macro | Functional ligand | 14.96% | 17.29% | 7.50% | ADENOSINE-5-DIPHOSPHORIBOSE | ADENOSINE-5-DIPHOSPHORIBOSE | HKL-3000 | 80.80% | 25.3 | APS (19-ID) | PHENIX | 2020-02-28 | 32939273 | - | - | - | - | N/A | - | - | Non-structural protein 3 | 85.3 | - | No | 94.4 | 89.6 | 83.5 | - | |||||||
6y84 | 1.39 Å | 2020-03-11 | X-ray | - | SARS-CoV-2 | NSP5 (3CLpro) | No functional ligands | 17.79% | 20.00% | 5.90% | - | xia2; DIALS | 97.50% | 9.7 | Diamond (I04-1) | BUSTER | 2020-03-03 | - | - | - | http://covid-19.bioreproducibility.org/static/data/6y84/6y84_refined_1.pdb | http://covid-19.bioreproducibility.org/static/data/6y84/6y84_refined_1.mtz | 18.60% | - | Structure of good quality. | Replicase polyprotein 1ab | 64.6 | minimal | Yes | - | - | 81.6 | 39.8 | 82.6 | - | ||||||
6lzg | 2.50 Å | 2020-03-18 | X-ray | NAG | SARS-CoV-2 | Spike | Pathogen-host interaction | 18.84% | 21.56% | 12.90% | 2-acetamido-2-deoxy-beta-D-glucopyranose | HKL-2000 | 100.00% | 26.7 | SSRF (BL17U1) | PHENIX | 2020-02-19 | 32275855 | ZN | - | - | - | N/A | - | - | Angiotensin-converting enzyme 2; Spike glycoprotein | 41.1 | - | No | - | 69.3 | 33.2 | 55.6 | - | |||||||
6m0j | 2.45 Å | 2020-03-18 | X-ray | NAG | SARS-CoV-2 | Spike | Pathogen-host interaction | 19.20% | 22.69% | 12.00% | 2-acetamido-2-deoxy-beta-D-glucopyranose | XDS | 100.00% | 24.2 | SSRF (BL17U) | PHENIX | 2020-02-21 | 32225176 | ZN | - | - | - | N/A | - | - | Angiotensin-converting enzyme 2; Spike receptor binding domain | 52.4 | - | No | - | 58.4 | 59.6 | 61.8 | - | |||||||
6m3m | 2.70 Å | 2020-03-18 | X-ray | - | SARS-CoV-2 | Nucleocapsid | No functional ligands | 25.78% | 29.34% | 10.43% | - | CrysalisPro | 99.50% | 14.97 | ROTATING ANODE () | PHENIX | 2020-03-04 | 32363136 | - | - | - | - | 28.90% | not done | Structure of good quality. No ligands. Some ramachandran outliers at the C-terminus. Many slashed side chains due to the lack of electron density – some can be built. | SARS-CoV-2 nucleocapsid protein - N-terminal RNA binding domain | 4.4 | minimal | No | - | 9.0 | 25.2 | 33.0 | - | |||||||
6w4b | 2.95 Å | 2020-03-18 | X-ray | - | SARS-CoV-2 | NSP9 | No functional ligands | 23.98% | 27.60% | 19.00% | - | HKL-3000 | 97.10% | 17.4 | APS (19-BM) | PHENIX | 2020-03-10 | - | - | - | - | - | N/A | - | - | Non-structural protein 9 | 6.6 | - | No | - | 16.1 | 24.0 | 36.6 | - | |||||||
6w4h | 1.80 Å | 2020-03-18 | X-ray | SO3, SAM, BDF | SARS-CoV-2 | NSP10/NSP16 | Protein-protein complex | 14.90% | 16.27% | 6.00% | S-ADENOSYLMETHIONINE | SULFITE ION; S-ADENOSYLMETHIONINE; beta-D-fructopyranose | HKL-3000 | 100.00% | 29.3 | APS (21-ID-F) | REFMAC | 2020-03-10 | 32994211 | ZN | - | - | - | N/A | - | - | SARS-CoV-2 NSP16 - UNP residues 6799-7096; SARS-CoV-2 NSP10 - UNP residues 4254-4392 | 62.5 | - | No | 96.6 | 16.1 | 87.0 | - | |||||||
6y7m | 1.90 Å | 2020-03-18 | X-ray | OEW | SARS-CoV | NSP5 (3CLpro) | Functional ligand | 20.62% | 25.76% | 4.80% | ~{tert}-butyl ~{N}-[1-[(2~{S})-3-cyclohexyl-1-[[(2~{S},3~{R})-4-(cyclopropylamino)-3-oxidanyl-4-oxidanylidene-1-[(3~{R})-2-oxidanylidene-3,4-dihydropyrrol-3-yl]butan-2-yl]amino]-1-oxidanylidene-propan-2-yl]-2-oxidanylidene-pyridin-3-yl]carbamate | ~{tert}-butyl ~{N}-[1-[(2~{S})-3-cyclohexyl-1-[[(2~{S},3~{R})-4-(cyclopropylamino)-3-oxidanyl-4-oxidanylidene-1-[(3~{R})-2-oxidanylidene-3,4-dihydropyrrol-3-yl]butan-2-yl]amino]-1-oxidanylidene-propan-2-yl]-2-oxidanylidene-pyridin-3-yl]carbamate | XDS | 99.40% | 12.8 | PETRA III, DESY (P11) | REFMAC | 2020-03-01 | 32198291 | - | - | http://covid-19.bioreproducibility.org/static/data/6y7m/6y7m_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6y7m/6y7m_refined.mtz | 25.60% | Added one water molecule. Some minor difficult to correction issues. | Structure of good quality. | Replicase polyprotein 1a | 29.2 | minimal | Yes | Yes | - | 28.6 | 45.7 | 60.0 | - | |||||
5re4 | 1.88 Å | 2020-03-25 | X-ray | SZY | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 19.91% | 26.64% | 22.80% | N-(4-methylpyridin-3-yl)acetamide | N-(4-methylpyridin-3-yl)acetamide | XDS | 99.50% | 3.3 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 30.1 | - | No | 22.0 | 59.9 | 54.3 | - | |||||||
5re5 | 2.07 Å | 2020-03-25 | X-ray | T0J | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.11% | 26.49% | 25.90% | N~1~-phenylpiperidine-1,4-dicarboxamide | N~1~-phenylpiperidine-1,4-dicarboxamide | XDS | 99.90% | 4.1 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 36.4 | - | No | 23.2 | 73.6 | 52.2 | - | |||||||
5re6 | 1.87 Å | 2020-03-25 | X-ray | O0S | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.57% | 25.05% | 23.00% | N-{4-[(pyrimidin-2-yl)oxy]phenyl}acetamide | N-{4-[(pyrimidin-2-yl)oxy]phenyl}acetamide | XDS | 99.80% | 4.3 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 46.0 | - | No | 34.8 | 64.3 | 68.4 | - | |||||||
5re7 | 1.79 Å | 2020-03-25 | X-ray | T0S | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 16.73% | 22.50% | 12.60% | N-[(4-sulfamoylphenyl)methyl]acetamide | N-[(4-sulfamoylphenyl)methyl]acetamide | XDS | 99.40% | 6.1 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 23.9 | - | No | 60.1 | 22.9 | 40.1 | - | |||||||
5re8 | 1.81 Å | 2020-03-25 | X-ray | T0V | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 19.03% | 24.83% | 17.10% | 1-(3-fluorophenyl)-N-[(furan-2-yl)methyl]methanamine | 1-(3-fluorophenyl)-N-[(furan-2-yl)methyl]methanamine | XDS | 99.80% | 4.6 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 34.5 | - | No | 36.8 | 52.1 | 56.2 | - | |||||||
5re9 | 1.72 Å | 2020-03-25 | X-ray | LPZ | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 16.72% | 22.48% | 8.20% | 2-(4-methylphenoxy)-1-(4-methylpiperazin-4-ium-1-yl)ethanone | 2-(4-methylphenoxy)-1-(4-methylpiperazin-4-ium-1-yl)ethanone | XDS | 98.70% | 8.0 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 18.0 | - | No | 60.5 | 13.3 | 35.9 | - | |||||||
5rea | 1.63 Å | 2020-03-25 | X-ray | JGP | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.52% | 22.82% | 9.60% | (azepan-1-yl)(2H-1,3-benzodioxol-5-yl)methanone | (azepan-1-yl)(2H-1,3-benzodioxol-5-yl)methanone | XDS | 99.50% | 6.2 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | - | - | No | 56.8 | - | 48.4 | - | |||||||
5reb | 1.68 Å | 2020-03-25 | X-ray | T0Y | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 17.55% | 22.37% | 9.30% | 1-[(thiophen-3-yl)methyl]piperidin-4-ol | 1-[(thiophen-3-yl)methyl]piperidin-4-ol | XDS | 99.50% | 6.9 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 40.4 | - | No | 61.6 | 29.3 | 65.7 | - | |||||||
5rec | 1.73 Å | 2020-03-25 | X-ray | T1J | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.26% | 23.71% | 12.10% | 2-{[(1H-benzimidazol-2-yl)amino]methyl}phenol | 2-{[(1H-benzimidazol-2-yl)amino]methyl}phenol | XDS | 99.60% | 5.9 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 49.4 | - | No | 47.7 | 64.3 | 61.8 | - | |||||||
5red | 1.47 Å | 2020-03-25 | X-ray | JJG | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.14% | 21.12% | 8.50% | 4-[2-(phenylsulfanyl)ethyl]morpholine | 4-[2-(phenylsulfanyl)ethyl]morpholine | XDS | 98.40% | 6.2 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 34.1 | - | No | 73.0 | 17.6 | 53.7 | - | |||||||
5ree | 1.77 Å | 2020-03-25 | X-ray | T1M | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.32% | 24.24% | 17.00% | (2R,3R)-1-benzyl-2-methylpiperidin-3-ol | (2R,3R)-1-benzyl-2-methylpiperidin-3-ol | XDS | 99.80% | 4.5 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 44.3 | - | No | 42.6 | 64.3 | 57.3 | - | |||||||
5ref | 1.61 Å | 2020-03-25 | X-ray | 6SU | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 19.81% | 24.61% | 12.10% | methyl 3-(methylsulfonylamino)benzoate | methyl 3-(methylsulfonylamino)benzoate | XDS | 99.10% | 4.7 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 38.9 | - | No | 38.9 | 55.9 | 59.0 | - | |||||||
5reg | 1.67 Å | 2020-03-25 | X-ray | LWA | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 17.92% | 22.72% | 11.90% | (2~{S})-~{N}-(4-aminocarbonylphenyl)oxolane-2-carboxamide | (2~{S})-~{N}-(4-aminocarbonylphenyl)oxolane-2-carboxamide | XDS | 97.20% | 5.2 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 21.4 | - | No | 57.9 | 21.0 | 38.8 | - | |||||||
5reh | 1.80 Å | 2020-03-25 | X-ray | AWP | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.71% | 25.73% | 18.00% | 1-cyclohexyl-3-(2-pyridin-4-ylethyl)urea | 1-cyclohexyl-3-(2-pyridin-4-ylethyl)urea | XDS | 98.70% | 5.4 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 26.4 | - | No | 28.8 | 59.9 | 39.6 | - | |||||||
5rei | 1.82 Å | 2020-03-25 | X-ray | T1S | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.32% | 24.01% | 16.90% | 4-[(3-chlorophenyl)methyl]morpholine | 4-[(3-chlorophenyl)methyl]morpholine | XDS | 99.80% | 5.3 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 53.1 | - | No | 44.7 | 68.7 | 67.6 | - | |||||||
5rej | 1.72 Å | 2020-03-25 | X-ray | T1V | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 19.00% | 24.05% | 18.20% | 1-{4-[(thiophen-2-yl)sulfonyl]piperazin-1-yl}ethan-1-one | 1-{4-[(thiophen-2-yl)sulfonyl]piperazin-1-yl}ethan-1-one | XDS | 99.50% | 4.0 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 41.0 | - | No | 44.4 | 52.1 | 61.4 | - | |||||||
5rek | 1.74 Å | 2020-03-25 | X-ray | T1Y | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.27% | 23.04% | 17.60% | 1-{4-[(3-fluorophenyl)sulfonyl]piperazin-1-yl}ethan-1-one | 1-{4-[(3-fluorophenyl)sulfonyl]piperazin-1-yl}ethan-1-one | XDS | 99.20% | 3.9 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 53.7 | - | No | 54.6 | 55.9 | 71.8 | - | |||||||
5rel | 1.62 Å | 2020-03-25 | X-ray | T2G | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.21% | 21.97% | 10.90% | 1-{4-[(3-methylphenyl)methyl]piperazin-1-yl}ethan-1-one | 1-{4-[(3-methylphenyl)methyl]piperazin-1-yl}ethan-1-one | XDS | 99.70% | 5.6 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 53.7 | - | No | 65.4 | 52.1 | 64.7 | - | |||||||
5rem | 1.96 Å | 2020-03-25 | X-ray | T2J | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 17.50% | 24.64% | 16.40% | 1 1-(4-(2-nitrophenyl)piperazin-1-yl)ethan-1-one | 1 1-(4-(2-nitrophenyl)piperazin-1-yl)ethan-1-one | XDS | 99.80% | 4.7 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 38.9 | - | No | 38.7 | 59.9 | 55.2 | - | |||||||
5ren | 2.15 Å | 2020-03-25 | X-ray | T2V | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 17.38% | 27.79% | 27.70% | 1-[(3R)-3-(1,3-benzothiazol-2-yl)piperidin-1-yl]ethan-1-one | 1-[(3R)-3-(1,3-benzothiazol-2-yl)piperidin-1-yl]ethan-1-one | XDS | 99.20% | 3.6 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 19.4 | - | No | 15.2 | 48.6 | 49.2 | - | |||||||
5reo | 1.88 Å | 2020-03-25 | X-ray | T2Y | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 16.76% | 22.68% | 21.10% | N-[(2H-1,3-benzodioxol-5-yl)methyl]acetamide | N-[(2H-1,3-benzodioxol-5-yl)methyl]acetamide | XDS | 99.60% | 4.5 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 53.1 | - | No | 58.4 | 68.7 | 53.9 | - | |||||||
5rep | 1.81 Å | 2020-03-25 | X-ray | T3G | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 17.83% | 23.11% | 15.80% | 1-{4-[(2,6-difluorophenyl)sulfonyl]piperazin-1-yl}ethan-1-one | 1-{4-[(2,6-difluorophenyl)sulfonyl]piperazin-1-yl}ethan-1-one | XDS | 99.70% | 5.3 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 63.1 | - | No | 53.9 | 78.5 | 68.6 | - | |||||||
5rer | 1.88 Å | 2020-03-25 | X-ray | T3J | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.72% | 25.26% | 21.10% | 1-[(2R)-2-(4-fluorophenyl)morpholin-4-yl]ethan-1-one | 1-[(2R)-2-(4-fluorophenyl)morpholin-4-yl]ethan-1-one | XDS | 99.80% | 3.8 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 47.4 | - | No | 32.9 | 78.5 | 58.6 | - | |||||||
5res | 1.65 Å | 2020-03-25 | X-ray | T3V | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.14% | 22.63% | 11.90% | 1-{4-[(2-fluorophenyl)sulfonyl]piperazin-1-yl}ethan-1-one | 1-{4-[(2-fluorophenyl)sulfonyl]piperazin-1-yl}ethan-1-one | XDS | 98.30% | 6.0 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 58.5 | - | No | 58.8 | 64.3 | 68.5 | - | |||||||
5ret | 1.68 Å | 2020-03-25 | X-ray | T47 | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.20% | 22.20% | 12.50% | 1-{4-[(3-chlorophenyl)methyl]piperazin-1-yl}ethan-1-one | 1-{4-[(3-chlorophenyl)methyl]piperazin-1-yl}ethan-1-one | XDS | 99.80% | 5.5 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 44.5 | - | No | 63.1 | 48.6 | 52.8 | - | |||||||
5reu | 1.69 Å | 2020-03-25 | X-ray | T4D | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.30% | 23.23% | 16.30% | 2-[(4-acetylpiperazin-1-yl)sulfonyl]benzonitrile | 2-[(4-acetylpiperazin-1-yl)sulfonyl]benzonitrile | XDS | 99.80% | 4.2 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 52.7 | - | No | 52.7 | 64.3 | 63.3 | - | |||||||
5rev | 1.60 Å | 2020-03-25 | X-ray | T4J | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 17.63% | 22.17% | 11.20% | N-[3-(thiomorpholine-4-carbonyl)phenyl]acetamide | N-[3-(thiomorpholine-4-carbonyl)phenyl]acetamide | XDS | 97.90% | 6.2 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 52.8 | - | No | 63.5 | 52.1 | 64.8 | - | |||||||
5rew | 1.55 Å | 2020-03-25 | X-ray | T4M | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.48% | 22.36% | 11.60% | N-[(1R)-1-(naphthalen-1-yl)ethyl]acetamide | N-[(1R)-1-(naphthalen-1-yl)ethyl]acetamide | XDS | 99.50% | 5.6 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 50.7 | - | No | 61.6 | 52.1 | 62.7 | - | |||||||
5rex | 2.07 Å | 2020-03-25 | X-ray | T4V | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 17.49% | 25.07% | 13.70% | 1-{4-[(naphthalen-1-yl)methyl]piperazin-1-yl}ethan-1-one | 1-{4-[(naphthalen-1-yl)methyl]piperazin-1-yl}ethan-1-one | XDS | 99.80% | 5.5 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 40.1 | - | No | 34.6 | 64.3 | 57.1 | - | |||||||
5rey | 1.96 Å | 2020-03-25 | X-ray | T4Y | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 19.58% | 27.35% | 20.90% | 1-{4-[(2-methylphenyl)methyl]-1,4-diazepan-1-yl}ethan-1-one | 1-{4-[(2-methylphenyl)methyl]-1,4-diazepan-1-yl}ethan-1-one | XDS | 99.60% | 3.6 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 33.1 | - | No | 17.5 | 55.9 | 68.8 | - | |||||||
5rez | 1.79 Å | 2020-03-25 | X-ray | T54 | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 20.15% | 27.21% | 15.00% | (1R,2S)-2-(thiophen-3-yl)cyclopentane-1-carboxamide | (1R,2S)-2-(thiophen-3-yl)cyclopentane-1-carboxamide | XDS | 99.30% | 4.9 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 25.3 | - | No | 18.3 | 59.9 | 47.9 | - | |||||||
5rf0 | 1.65 Å | 2020-03-25 | X-ray | T5D | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.11% | 22.64% | 13.10% | [1-(pyridin-2-yl)cyclopentyl]methanol | [1-(pyridin-2-yl)cyclopentyl]methanol | XDS | 99.80% | 5.5 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 57.7 | - | No | 58.7 | 55.9 | 75.3 | - | |||||||
5rf1 | 1.73 Å | 2020-03-25 | X-ray | T5G | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.62% | 23.61% | 13.00% | 4-bromobenzene-1-sulfonamide | 4-bromobenzene-1-sulfonamide | XDS | 99.50% | 5.7 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 50.1 | - | No | 48.7 | 64.3 | 62.3 | - | |||||||
5rf2 | 1.53 Å | 2020-03-25 | X-ray | HVB | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.17% | 22.16% | 9.40% | 1-azanylpropylideneazanium | 1-azanylpropylideneazanium | XDS | 99.00% | 6.1 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 62.3 | - | No | 63.6 | 59.9 | 75.7 | - | |||||||
5rf3 | 1.50 Å | 2020-03-25 | X-ray | T5V | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.53% | 22.10% | 9.80% | pyrimidin-5-amine | pyrimidin-5-amine | XDS | 98.60% | 6.2 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 56.9 | - | No | 64.1 | 48.6 | 75.6 | - | |||||||
5rf4 | 1.61 Å | 2020-03-25 | X-ray | T5Y | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.00% | 22.49% | 10.70% | pyridin-2-ol | pyridin-2-ol | XDS | 99.20% | 5.9 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 55.2 | - | No | 60.5 | 52.1 | 72.5 | - | |||||||
5rf5 | 1.74 Å | 2020-03-25 | X-ray | HV2 | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 17.76% | 23.06% | 14.60% | 1,1-bis(oxidanylidene)thietan-3-ol | 1,1-bis(oxidanylidene)thietan-3-ol | XDS | 99.80% | 5.4 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 48.2 | - | No | 54.5 | 55.9 | 61.2 | - | |||||||
5rf6 | 1.45 Å | 2020-03-25 | X-ray | NTG | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.06% | 21.74% | 9.30% | 5-(1,4-oxazepan-4-yl)pyridine-2-carbonitrile | 5-(1,4-oxazepan-4-yl)pyridine-2-carbonitrile | XDS | 98.10% | 5.4 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 50.8 | - | No | 67.6 | 48.6 | 60.3 | - | |||||||
5rf7 | 1.54 Å | 2020-03-25 | X-ray | T67 | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.04% | 21.69% | 8.80% | 1-(4-methylpiperazin-1-yl)-2-(1H-pyrrolo[2,3-b]pyridin-3-yl)ethan-1-one | 1-(4-methylpiperazin-1-yl)-2-(1H-pyrrolo[2,3-b]pyridin-3-yl)ethan-1-one | XDS | 99.30% | 6.5 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 59.4 | - | No | 68.2 | 55.9 | 69.3 | - | |||||||
5rf8 | 1.44 Å | 2020-03-25 | X-ray | SFY | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 17.73% | 21.32% | 7.80% | 4-amino-N-(pyridin-2-yl)benzenesulfonamide | 4-amino-N-(pyridin-2-yl)benzenesulfonamide | XDS | 98.00% | 6.7 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 65.0 | - | No | 71.3 | 55.9 | 77.6 | - | |||||||
5rf9 | 1.43 Å | 2020-03-25 | X-ray | S7D | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.20% | 21.54% | 7.70% | 1-[(2~{S})-2-methylmorpholin-4-yl]-2-pyrazol-1-yl-ethanone | 1-[(2~{S})-2-methylmorpholin-4-yl]-2-pyrazol-1-yl-ethanone | XDS | 95.40% | 7.3 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 51.4 | - | No | 69.4 | 39.8 | 68.7 | - | |||||||
5rfa | 1.52 Å | 2020-03-25 | X-ray | JGY | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 17.67% | 21.51% | 7.80% | 1-methyl-N-{[(2S)-oxolan-2-yl]methyl}-1H-pyrazole-3-carboxamide | 1-methyl-N-{[(2S)-oxolan-2-yl]methyl}-1H-pyrazole-3-carboxamide | XDS | 98.80% | 7.1 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 59.0 | - | No | 69.6 | 51.8 | 71.1 | - | |||||||
5rfb | 1.48 Å | 2020-03-25 | X-ray | K3S | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.33% | 22.35% | 7.70% | N-[(1-methyl-1H-1,2,3-triazol-4-yl)methyl]ethanamine | N-[(1-methyl-1H-1,2,3-triazol-4-yl)methyl]ethanamine | XDS | 97.90% | 6.6 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 55.8 | - | No | 61.7 | 64.3 | 60.3 | - | |||||||
5rfc | 1.40 Å | 2020-03-25 | X-ray | K1Y | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 17.95% | 21.28% | 6.90% | methyl (2-methyl-4-phenyl-1,3-thiazol-5-yl)carbamate | methyl (2-methyl-4-phenyl-1,3-thiazol-5-yl)carbamate | XDS | 92.70% | 7.7 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 57.0 | - | No | 71.8 | 48.6 | 68.2 | - | |||||||
5rfd | 1.41 Å | 2020-03-25 | X-ray | T6J | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 17.76% | 21.10% | 7.90% | 2-[(methylsulfonyl)methyl]-1H-benzimidazole | 2-[(methylsulfonyl)methyl]-1H-benzimidazole | XDS | 94.20% | 6.6 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 69.5 | - | No | 73.2 | 64.3 | 77.0 | - | |||||||
5rfe | 1.46 Å | 2020-03-25 | X-ray | JGG | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 17.69% | 21.36% | 6.00% | N-[(4-cyanophenyl)methyl]morpholine-4-carboxamide | N-[(4-cyanophenyl)methyl]morpholine-4-carboxamide | XDS | 94.40% | 9.6 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 57.3 | - | No | 71.0 | 42.5 | 75.6 | - | |||||||
5rff | 1.78 Å | 2020-03-25 | X-ray | T6M | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 19.20% | 24.74% | 18.50% | 1-{4-[(4-chlorophenyl)sulfonyl]piperazin-1-yl}ethan-1-one | 1-{4-[(4-chlorophenyl)sulfonyl]piperazin-1-yl}ethan-1-one | XDS | 99.80% | 4.5 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 26.0 | - | No | 37.7 | 26.4 | 63.4 | - | |||||||
5rfg | 2.32 Å | 2020-03-25 | X-ray | T6V | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 21.21% | 30.65% | 36.10% | N-[(3S)-1,1-dioxo-2,3-dihydro-1H-1lambda~6~-thiophen-3-yl]-N-phenylacetamide | N-[(3S)-1,1-dioxo-2,3-dihydro-1H-1lambda~6~-thiophen-3-yl]-N-phenylacetamide | XDS | 99.80% | 2.6 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 22.5 | - | No | 6.3 | 42.5 | 71.1 | - | |||||||
5rfh | 1.58 Å | 2020-03-25 | X-ray | T6Y | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.86% | 23.68% | 10.60% | 1-{4-[(5-chlorothiophen-2-yl)methyl]piperazin-1-yl}ethan-1-one | 1-{4-[(5-chlorothiophen-2-yl)methyl]piperazin-1-yl}ethan-1-one | XDS | 98.40% | 5.1 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 25.7 | - | No | 48.2 | 22.9 | 55.8 | - | |||||||
5rfi | 1.69 Å | 2020-03-25 | X-ray | T71 | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 19.33% | 24.23% | 11.60% | 1-{4-[(2,5-dimethylphenyl)sulfonyl]piperazin-1-yl}ethan-1-one | 1-{4-[(2,5-dimethylphenyl)sulfonyl]piperazin-1-yl}ethan-1-one | XDS | 98.50% | 5.3 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 37.8 | - | No | 42.7 | 45.4 | 63.6 | - | |||||||
5rfj | 1.80 Å | 2020-03-25 | X-ray | T7A | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.64% | 24.14% | 19.40% | N-(4-methoxy-1,3-benzothiazol-2-yl)acetamide | N-(4-methoxy-1,3-benzothiazol-2-yl)acetamide | XDS | 99.80% | 4.0 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 48.5 | - | No | 43.5 | 73.6 | 55.0 | - | |||||||
5rfk | 1.75 Å | 2020-03-25 | X-ray | T7D | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.75% | 23.48% | 18.10% | N-(1-acetylpiperidin-4-yl)benzamide | N-(1-acetylpiperidin-4-yl)benzamide | XDS | 99.50% | 4.2 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 47.6 | - | No | 50.3 | 59.9 | 60.3 | - | |||||||
5rfl | 1.64 Å | 2020-03-25 | X-ray | T7G | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.43% | 22.47% | 13.40% | 1-acetyl-N-(2-hydroxyphenyl)piperidine-4-carboxamide | 1-acetyl-N-(2-hydroxyphenyl)piperidine-4-carboxamide | XDS | 99.40% | 4.8 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 49.0 | - | No | 60.6 | 45.4 | 67.2 | - | |||||||
5rfm | 2.06 Å | 2020-03-25 | X-ray | T7J | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 17.79% | 25.72% | 21.60% | N-[(3R)-1,1-dioxo-2,3-dihydro-1H-1lambda~6~-thiophen-3-yl]-N-(4-methylphenyl)acetamide | N-[(3R)-1,1-dioxo-2,3-dihydro-1H-1lambda~6~-thiophen-3-yl]-N-(4-methylphenyl)acetamide | XDS | 99.80% | 4.5 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 37.9 | - | No | 28.9 | 68.7 | 54.2 | - | |||||||
5rfn | 1.80 Å | 2020-03-25 | X-ray | T7P | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.61% | 23.90% | 17.20% | N-[(3R)-1,1-dioxo-2,3-dihydro-1H-1lambda~6~-thiophen-3-yl]-N-(4-fluorophenyl)acetamide | N-[(3R)-1,1-dioxo-2,3-dihydro-1H-1lambda~6~-thiophen-3-yl]-N-(4-fluorophenyl)acetamide | XDS | 99.90% | 4.3 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 48.2 | - | No | 45.7 | 64.3 | 61.7 | - | |||||||
5rfo | 1.83 Å | 2020-03-25 | X-ray | T7S | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 20.49% | 27.75% | 23.50% | 1-[4-(piperidine-1-carbonyl)piperidin-1-yl]ethan-1-one | 1-[4-(piperidine-1-carbonyl)piperidin-1-yl]ethan-1-one | XDS | 99.90% | 3.4 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 11.4 | - | No | 15.4 | 37.3 | 40.2 | - | |||||||
5rfp | 2.03 Å | 2020-03-25 | X-ray | T7V | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 20.67% | 29.68% | 29.70% | N-[(1S)-1-(3-chlorophenyl)ethyl]acetamide | N-[(1S)-1-(3-chlorophenyl)ethyl]acetamide | XDS | 99.80% | 2.8 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 17.9 | - | No | 8.1 | 55.9 | 45.8 | - | |||||||
5rfq | 1.76 Å | 2020-03-25 | X-ray | T7Y | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.00% | 22.70% | 19.40% | N-[3-(2-oxopyrrolidin-1-yl)phenyl]acetamide | N-[3-(2-oxopyrrolidin-1-yl)phenyl]acetamide | XDS | 99.60% | 4.7 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 59.2 | - | No | 58.0 | 64.3 | 70.6 | - | |||||||
5rfr | 1.71 Å | 2020-03-25 | X-ray | T81 | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.53% | 23.77% | 13.10% | 1-{4-[(5-bromothiophen-2-yl)methyl]piperazin-1-yl}ethan-1-one | 1-{4-[(5-bromothiophen-2-yl)methyl]piperazin-1-yl}ethan-1-one | XDS | 99.20% | 5.4 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 36.5 | - | No | 47.3 | 48.6 | 53.1 | - | |||||||
5rfs | 1.70 Å | 2020-03-25 | X-ray | T84 | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.69% | 23.27% | 14.20% | 1-{4-[(thiophen-3-yl)methyl]piperazin-1-yl}ethan-1-one | 1-{4-[(thiophen-3-yl)methyl]piperazin-1-yl}ethan-1-one | XDS | 99.20% | 5.3 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 41.9 | - | No | 52.4 | 42.5 | 64.8 | - | |||||||
5rft | 1.58 Å | 2020-03-25 | X-ray | T8A | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 19.53% | 23.68% | 12.10% | 1-[(4S)-4-phenyl-3,4-dihydroisoquinolin-2(1H)-yl]ethan-1-one | 1-[(4S)-4-phenyl-3,4-dihydroisoquinolin-2(1H)-yl]ethan-1-one | XDS | 98.70% | 4.3 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 42.6 | - | No | 48.2 | 45.4 | 67.3 | - | |||||||
5rfu | 1.53 Å | 2020-03-25 | X-ray | T8D | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 17.53% | 20.98% | 9.40% | 1-{4-[(5-chlorothiophen-2-yl)sulfonyl]piperazin-1-yl}ethan-1-one | 1-{4-[(5-chlorothiophen-2-yl)sulfonyl]piperazin-1-yl}ethan-1-one | XDS | 99.20% | 6.8 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 57.9 | - | No | 74.3 | 52.1 | 63.9 | - | |||||||
5rfv | 1.48 Å | 2020-03-25 | X-ray | T8J | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.73% | 22.36% | 8.70% | 1-[4-(thiophene-2-carbonyl)piperazin-1-yl]ethan-1-one | 1-[4-(thiophene-2-carbonyl)piperazin-1-yl]ethan-1-one | XDS | 97.90% | 6.2 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 57.6 | - | No | 61.6 | 55.9 | 72.3 | - | |||||||
5rfw | 1.43 Å | 2020-03-25 | X-ray | T8M | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.95% | 22.32% | 5.80% | 1-{4-[(thiophen-2-yl)methyl]piperazin-1-yl}ethan-1-one | 1-{4-[(thiophen-2-yl)methyl]piperazin-1-yl}ethan-1-one | XDS | 97.90% | 9.0 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 31.7 | - | No | 61.9 | 16.6 | 60.8 | - | |||||||
5rfx | 1.55 Å | 2020-03-25 | X-ray | T8P | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.44% | 21.63% | 10.40% | 1-[4-(4-methoxyphenyl)piperazin-1-yl]ethan-1-one | 1-[4-(4-methoxyphenyl)piperazin-1-yl]ethan-1-one | XDS | 99.20% | 5.8 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 53.7 | - | No | 68.6 | 45.4 | 68.1 | - | |||||||
5rfy | 1.90 Å | 2020-03-25 | X-ray | T8S | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 20.98% | 27.67% | 24.00% | 1-acetyl-N-methyl-N-(propan-2-yl)piperidine-4-carboxamide | 1-acetyl-N-methyl-N-(propan-2-yl)piperidine-4-carboxamide | XDS | 99.30% | 3.6 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 34.1 | - | No | 15.8 | 68.7 | 59.7 | - | |||||||
5rfz | 1.68 Å | 2020-03-25 | X-ray | T8V | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.08% | 22.65% | 14.60% | N-(2-chloropyridin-3-yl)acetamide | N-(2-chloropyridin-3-yl)acetamide | XDS | 99.70% | 4.9 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 48.7 | - | No | 58.7 | 48.6 | 65.3 | - | |||||||
5rg0 | 1.72 Å | 2020-03-25 | X-ray | T8Y | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.81% | 23.59% | 12.80% | 1,1'-(piperazine-1,4-diyl)di(ethan-1-one) | 1,1'-(piperazine-1,4-diyl)di(ethan-1-one) | XDS | 99.10% | 5.3 | Diamond (I04-1) | REFMAC | 2020-03-15 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 47.7 | - | No | 49.1 | 64.3 | 57.2 | - | |||||||
6kl2 | 2.63 Å | 2020-03-25 | X-ray | - | MERS-CoV | Nucleocapsid | No functional ligands | 28.00% | 28.98% | 9.50% | - | HKL-2000 | 94.50% | 8.3 | NSRRC (BL13B1) | PHENIX | 2019-07-29 | 32105468 | - | - | - | - | N/A | - | - | Nucleoprotein - N-terminal domain | 22.9 | - | No | - | 10.0 | 84.9 | 26.0 | - | |||||||
6kl5 | 3.09 Å | 2020-03-25 | X-ray | DJO | MERS-CoV | Nucleocapsid | Functional ligand | 28.11% | 29.88% | 13.70% | (phenylmethyl) (2S)-2-(hydroxymethyl)-2,3-dihydroindole-1-carboxylate | (phenylmethyl) (2S)-2-(hydroxymethyl)-2,3-dihydroindole-1-carboxylate | HKL-2000 | 96.10% | 5.6 | NSRRC (BL13C1) | PHENIX | 2019-07-29 | 32105468 | - | - | - | - | N/A | - | - | Nucleoprotein - N-terminal domain | 25.5 | - | No | - | 7.5 | 91.6 | 27.2 | - | ||||||
6kl6 | 2.77 Å | 2020-03-25 | X-ray | DJU | MERS-CoV | Nucleocapsid | Functional ligand | 23.15% | 27.07% | 7.20% | N,N-dimethyl-1-(5-phenylmethoxy-1H-indol-3-yl)methanamine | N,N-dimethyl-1-(5-phenylmethoxy-1H-indol-3-yl)methanamine | HKL-2000 | 99.50% | 11.8 | SPring-8 (BL44XU) | PHENIX | 2019-07-29 | 32105468 | - | - | - | - | N/A | - | - | Nucleoprotein - N-terminal domain | - | - | No | - | 19.2 | - | 14.6 | - | ||||||
6w41 | 3.08 Å | 2020-03-25 | X-ray | NAG | SARS-CoV-2 | Spike | Functional ligand | 22.26% | 24.33% | 13.60% | 2-acetamido-2-deoxy-beta-D-glucopyranose | HKL-2000 | 100.00% | 5.0 | APS (23-ID-D) | PHENIX | 2020-03-09 | 32245784 | - | - | http://covid-19.bioreproducibility.org/static/data/6w41/6w41_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6w41/6w41_refined.mtz | 24.70% | Shifted the coordinates into the reference unit cell with ACHESYM. Flipped two peptide bonds (Tyr380 of the spike fragment and Ile98 of the antibody heavy chain). There is some evidence of the presence of another NAG group bound to Asn343 of the spike protein, but we did not attempt to model it. | The coordinates are NOT in a standardized location in the unit cell. Comparatively low-resolution structure that is highly idealized. | CR3022 Fab heavy chain; CR3022 Fab light chain; Spike protein S1 - receptor binding domain | 62.7 | minimal | Yes | Yes | - | 41.7 | 95.1 | 63.2 | - | ||||||
6w61 | 2.00 Å | 2020-03-25 | X-ray | SAM | SARS-CoV-2 | NSP10/NSP16 | Protein-protein complex | 17.06% | 19.30% | 13.90% | S-ADENOSYLMETHIONINE | S-ADENOSYLMETHIONINE | HKL-3000 | 100.00% | 37.1 | APS (19-ID) | PHENIX | 2020-03-15 | - | ZN | - | - | - | N/A | - | - | 2'-O-methyltransferase; Non-structural protein 10 | 59.8 | - | No | - | 86.1 | 39.8 | 68.1 | - | ||||||
6w63 | 2.10 Å | 2020-03-25 | X-ray | X77 | SARS-CoV-2 | NSP5 (3CLpro) | Functional ligand | 14.99% | 22.14% | N/A | N-(4-tert-butylphenyl)-N-[(1R)-2-(cyclohexylamino)-2-oxo-1-(pyridin-3-yl)ethyl]-1H-imidazole-4-carboxamide | N-(4-tert-butylphenyl)-N-[(1R)-2-(cyclohexylamino)-2-oxo-1-(pyridin-3-yl)ethyl]-1H-imidazole-4-carboxamide | HKL-2000 | 99.30% | 17.2 | APS (21-ID-G) | PHENIX | 2020-03-16 | - | - | - | http://covid-19.bioreproducibility.org/static/data/6w63/6w63_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6w63/6w63_refined.mtz | 25.01% | Placed the coordinates in a standardized location in the unit cell using ACHESYM. | The coordinates are NOT in a standardized location in the unit cell. | 3C-like proteinase | 67.3 | minimal | Yes | Yes | - | - | 63.8 | 93.3 | 52.8 | - | ||||
6w6y | 1.45 Å | 2020-03-25 | X-ray | AMP, MES | SARS-CoV-2 | NSP3: Macro | Functional ligand | 14.21% | 18.91% | 10.90% | ADENOSINE MONOPHOSPHATE; 2-(N-MORPHOLINO)-ETHANESULFONIC ACID | ADENOSINE MONOPHOSPHATE; 2-(N-MORPHOLINO)-ETHANESULFONIC ACID | HKL-3000 | 98.60% | 21.3 | APS (19-ID) | REFMAC | 2020-03-18 | 32939273 | - | - | - | - | N/A | - | - | Non-structural protein 3 - ADP ribose phosphatase (ADRP) domain (UNP residues 1024-1192) | 86.2 | - | No | - | 88.2 | 89.6 | 96.8 | - | ||||||
6w75 | 1.95 Å | 2020-03-25 | X-ray | NA, SAM, FMT | SARS-CoV-2 | NSP10/NSP16 | Protein-protein complex | 15.73% | 17.45% | 7.70% | S-ADENOSYLMETHIONINE; FORMIC ACID; SODIUM ION | SODIUM ION; S-ADENOSYLMETHIONINE; FORMIC ACID | HKL-3000 | 100.00% | 25.8 | APS (21-ID-F) | REFMAC | 2020-03-18 | 32994211 | NA; ZN | - | - | - | N/A | - | - | SARS-CoV-2 NSP16 - UNP residues 6799-7096; SARS-CoV-2 NSP10 - UNP residues 4254-4392 | 60.2 | - | No | 94.0 | 14.0 | 87.0 | - | |||||||
6yb7 | 1.25 Å | 2020-03-25 | X-ray | - | SARS-CoV-2 | NSP5 (3CLpro) | No functional ligands | 17.06% | 19.17% | 13.70% | - | DIALS | 97.10% | 9.7 | Diamond (I04-1) | BUSTER | 2020-03-16 | - | - | - | http://covid-19.bioreproducibility.org/static/data/6yb7/6yb7_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6yb7/6yb7_refined.mtz | 16.30% | Re-refinement with individual anisotropic B factors. Fixed several rotamers. Added two water molecules. Substantial improvement of the refinement statistics and better electron density map; minimal changes to the model. | Refinement statistics and electron density map can be improved with minimal changes to the model. | Replicase polyprotein 1ab | 71.8 | minimal | Yes | Yes | - | - | 92.0 | 52.3 | 75.4 | - | |||||
5r8t | 1.27 Å | 2020-04-01 | X-ray | - | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.41% | 20.81% | 6.50% | - | XDS | 86.10% | 7.1 | Diamond (I04-1) | REFMAC | 2020-03-03 | - | - | - | - | - | N/A | - | - | 3C-like proteinase | 70.3 | - | No | - | - | 75.6 | 68.7 | 72.1 | - | ||||||
6m71 | 2.90 Å | 2020-04-01 | Cryo-EM | - | SARS-CoV-2 | NSP7/NSP8/NSP12 | Protein-protein complex | N/A | N/A | N/A | - | - | - | () | PHENIX | 2020-03-16 | 32277040 | - | - | - | - | N/A | - | - | SARS-Cov-2 NSP 12; SARS-Cov-2 NSP 7; SARS-Cov-2 NSP 8 | N/A | - | No | - | N/A | N/A | N/A | - | ||||||||
6w9c | 2.70 Å | 2020-04-01 | X-ray | - | SARS-CoV-2 | NSP3: PLpro | No functional ligands | 23.50% | 27.91% | 14.00% | - | HKL-3000 | 57.30% | 4.9 | APS (19-ID) | REFMAC | 2020-03-22 | - | ZN | - | http://covid-19.bioreproducibility.org/static/data/6w9c/6w9c_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6w9c/6w9c_refined.mtz | 29.80% | Re-refinement with added NCS restraints for chains A, B and C. Fixed a few rotamer outliers. Substantial improvement of the model was not possible due to the quality of electron density. | Very low completeness of the experimental data (57.3%). Poor quality of the electron density maps. Ambiguity of model building especially in the regions of C-terminal zinc-finger-like domains. | Papain-like proteinase | 27.5 | moderate | No | Yes | - | 14.4 | 66.2 | 49.9 | - | ||||||
6waq | 2.20 Å | 2020-04-01 | X-ray | NAG | SARS-CoV | Spike | Protein-protein complex | 20.26% | 23.59% | N/A | 2-acetamido-2-deoxy-beta-D-glucopyranose | MOSFLM | 99.80% | 6.2 | APS (19-ID) | PHENIX | 2020-03-25 | 32375025 | - | - | - | - | N/A | - | - | nanobody SARS VHH-72; Spike glycoprotein | 28.8 | - | No | - | 49.1 | 39.6 | 44.7 | - | |||||||
6l5t | 1.72 Å | 2020-04-08 | X-ray | - | SADS-CoV | NSP3: PLpro | No functional ligands | 17.93% | 21.16% | 11.60% | - | XDS | 100.00% | 16.7 | SSRF (BL19U1) | PHENIX | 2019-10-24 | 32216114 | ZN | - | - | - | N/A | - | - | Peptidase C16 | 68.0 | - | No | - | 72.7 | 46.4 | 92.2 | - | |||||||
6w9q | 2.05 Å | 2020-04-08 | X-ray | PO4 | SARS-CoV-2 | NSP9 | Functional ligand | 23.27% | 24.59% | N/A | PHOSPHATE ION | PHOSPHATE ION | XDS | 100.00% | 13.7 | Australian Synchrotron (MX2) | PHENIX | 2020-03-23 | 32592996 | - | - | - | - | N/A | - | - | 3C-like proteinase peptide, Non-structural protein 9 fusion | 26.0 | - | No | - | 39.4 | 37.7 | 50.4 | - | ||||||
6yi3 | - | 2020-04-08 | NMR | - | SARS-CoV-2 | Nucleocapsid | No functional ligands | N/A | N/A | N/A | - | - | - | () | 2020-03-31 | 33264373 | - | - | - | - | N/A | - | - | Nucleoprotein | N/A | - | No | - | N/A | N/A | N/A | - | |||||||||
7btf | 2.95 Å | 2020-04-08 | Cryo-EM | - | SARS-CoV-2 | NSP7/NSP8/NSP12 | No functional ligands | N/A | N/A | N/A | - | - | - | () | 2020-04-01 | 32277040 | ZN | - | - | - | N/A | - | - | NSP12; NSP7; NSP8 | N/A | - | No | - | N/A | N/A | N/A | - | |||||||||
5rg1 | 1.65 Å | 2020-04-15 | X-ray | T9J | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 17.19% | 21.52% | 14.30% | Nalpha-acetyl-N-(3-bromoprop-2-yn-1-yl)-L-tyrosinamide | Nalpha-acetyl-N-(3-bromoprop-2-yn-1-yl)-L-tyrosinamide | XDS | 99.70% | 5.1 | Diamond (I04-1) | REFMAC | 2020-03-18 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 59.5 | - | No | - | 69.6 | 64.3 | 59.7 | - | ||||||
5rg2 | 1.63 Å | 2020-04-15 | X-ray | T9M | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.31% | 22.83% | 12.70% | N~2~-acetyl-N-prop-2-en-1-yl-D-allothreoninamide | N~2~-acetyl-N-prop-2-en-1-yl-D-allothreoninamide | XDS | 99.70% | 5.9 | Diamond (I04-1) | REFMAC | 2020-03-18 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 47.3 | - | No | - | 56.7 | 55.9 | 57.2 | - | ||||||
5rg3 | 1.58 Å | 2020-04-15 | X-ray | T9P | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 17.51% | 21.50% | 9.00% | N~2~-acetyl-N~1~-prop-2-en-1-yl-L-aspartamide | N~2~-acetyl-N~1~-prop-2-en-1-yl-L-aspartamide | XDS | 99.60% | 6.9 | Diamond (I04-1) | REFMAC | 2020-03-18 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 49.0 | - | No | - | 69.7 | 52.1 | 51.4 | - | ||||||
5rgg | 2.26 Å | 2020-04-15 | X-ray | NZD | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 16.65% | 21.65% | 33.80% | 4-methyl-N-phenylpiperazine-1-carboxamide | 4-methyl-N-phenylpiperazine-1-carboxamide | XDS | 99.40% | 4.4 | Diamond (I04-1) | REFMAC | 2020-04-07 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 51.6 | - | No | - | 68.4 | 45.4 | 64.2 | - | ||||||
5rgh | 1.70 Å | 2020-04-15 | X-ray | U0M | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 16.54% | 20.76% | 11.10% | 5-fluoro-1-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]-1,2,3,6-tetrahydropyridine | 5-fluoro-1-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]-1,2,3,6-tetrahydropyridine | XDS | 99.60% | 8.4 | Diamond (I04-1) | REFMAC | 2020-04-07 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 59.0 | - | No | - | 76.1 | 52.1 | 64.3 | - | ||||||
5rgi | 1.57 Å | 2020-04-15 | X-ray | U0P | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 17.03% | 21.17% | 9.60% | N'-cyclopropyl-N-methyl-N-[(5-methyl-1,2-oxazol-3-yl)methyl]urea | N'-cyclopropyl-N-methyl-N-[(5-methyl-1,2-oxazol-3-yl)methyl]urea | XDS | 99.40% | 7.2 | Diamond (I04-1) | REFMAC | 2020-04-07 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 54.4 | - | No | - | 72.7 | 37.3 | 73.5 | - | ||||||
5rgj | 1.34 Å | 2020-04-15 | X-ray | U0S | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 17.57% | 20.62% | 7.10% | (5S)-7-(pyrazin-2-yl)-2-oxa-7-azaspiro[4.4]nonane | (5S)-7-(pyrazin-2-yl)-2-oxa-7-azaspiro[4.4]nonane | XDS | 87.80% | 8.0 | Diamond (I04-1) | REFMAC | 2020-04-07 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 53.1 | - | No | - | 77.1 | 45.4 | 58.6 | - | ||||||
5rgk | 1.43 Å | 2020-04-15 | X-ray | U0V | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 17.42% | 20.99% | 7.80% | 2-fluoro-N-[2-(pyridin-4-yl)ethyl]benzamide | 2-fluoro-N-[2-(pyridin-4-yl)ethyl]benzamide | XDS | 97.30% | 7.4 | Diamond (I04-1) | REFMAC | 2020-04-07 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 51.6 | - | No | - | 74.2 | 29.3 | 74.6 | - | ||||||
5rgl | 1.76 Å | 2020-04-15 | X-ray | U0Y | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.04% | 22.89% | 21.50% | 1-[4-(4-methylbenzene-1-carbonyl)piperazin-1-yl]ethan-1-one | 1-[4-(4-methylbenzene-1-carbonyl)piperazin-1-yl]ethan-1-one | XDS | 99.70% | 3.9 | Diamond (I04-1) | REFMAC | 2020-04-07 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 57.3 | - | No | - | 56.3 | 52.1 | 80.8 | - | ||||||
5rgm | 2.04 Å | 2020-04-15 | X-ray | U1D | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 17.39% | 22.37% | 16.40% | N'-acetyl-4,5,6,7-tetrahydro-1-benzothiophene-2-carbohydrazide | N'-acetyl-4,5,6,7-tetrahydro-1-benzothiophene-2-carbohydrazide | XDS | 99.90% | 6.1 | Diamond (I04-1) | REFMAC | 2020-04-07 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 48.0 | - | No | - | 61.6 | 59.9 | 49.7 | - | ||||||
5rgn | 1.86 Å | 2020-04-15 | X-ray | U1A | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.36% | 23.32% | 24.30% | 1-{4-[(4-methylphenyl)sulfonyl]piperazin-1-yl}ethan-1-one | 1-{4-[(4-methylphenyl)sulfonyl]piperazin-1-yl}ethan-1-one | XDS | 99.20% | 3.9 | Diamond (I04-1) | REFMAC | 2020-04-07 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 48.9 | - | No | - | 51.8 | 55.9 | 65.4 | - | ||||||
5rgo | 1.74 Å | 2020-04-15 | X-ray | U1G | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 17.49% | 21.75% | 15.50% | 1-[4-(furan-2-carbonyl)piperazin-1-yl]ethan-1-one | 1-[4-(furan-2-carbonyl)piperazin-1-yl]ethan-1-one | XDS | 99.60% | 5.3 | Diamond (I04-1) | REFMAC | 2020-04-07 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 49.7 | - | No | - | 67.5 | 37.3 | 69.7 | - | ||||||
5rgp | 2.07 Å | 2020-04-15 | X-ray | U1M | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 16.10% | 20.19% | 13.00% | 1-{4-[(2,4-dimethylphenyl)sulfonyl]piperazin-1-yl}ethan-1-one | 1-{4-[(2,4-dimethylphenyl)sulfonyl]piperazin-1-yl}ethan-1-one | XDS | 99.50% | 6.6 | Diamond (I04-1) | REFMAC | 2020-04-07 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 76.2 | - | No | - | 80.5 | 73.6 | 77.1 | - | ||||||
5rgq | 2.15 Å | 2020-04-15 | X-ray | U1V | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.00% | 22.50% | 11.00% | 1-(4-fluoro-2-methylphenyl)methanesulfonamide | 1-(4-fluoro-2-methylphenyl)methanesulfonamide | XDS | 99.80% | 8.4 | Diamond (I04-1) | REFMAC | 2020-04-07 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 48.4 | - | No | - | 60.1 | 35.0 | 77.0 | - | ||||||
5rgr | 1.41 Å | 2020-04-15 | X-ray | K1G | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 17.28% | 20.01% | 5.70% | N,1-dimethyl-N-(propan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | N,1-dimethyl-N-(propan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | XDS | 88.50% | 8.6 | Diamond (I04-1) | REFMAC | 2020-04-07 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 69.6 | - | No | - | 81.6 | 64.3 | 69.0 | - | ||||||
5rgs | 1.72 Å | 2020-04-15 | X-ray | S7V | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.25% | 23.06% | 13.40% | [(2~{R})-4-(phenylmethyl)morpholin-2-yl]methanol | [(2~{R})-4-(phenylmethyl)morpholin-2-yl]methanol | XDS | 99.50% | 6.2 | Diamond (I04-1) | REFMAC | 2020-04-07 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 50.5 | - | No | - | 54.5 | 55.9 | 65.7 | - | ||||||
6m2n | 2.20 Å | 2020-04-15 | X-ray | 3WL | SARS-CoV-2 | NSP5 (3CLpro) | Functional ligand | 22.54% | 25.44% | 9.20% | 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one | 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one | HKL-3000 | 97.80% | 4.9 | SSRF (BL18U1) | PHENIX | 2020-02-28 | 32737471 | - | - | http://covid-19.bioreproducibility.org/static/data/6m2n/6m2n_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6m2n/6m2n_refined.mtz | 27.10% | Achesymed. Rotated residues: Gln 306A, His 41A, His 41B, His41C, His 164C, His 41D. Added few waters. | The coordinates are NOT in a standardized location in the unit cell. | SARS-CoV-2 3CL protease | 17.4 | minimal | Yes | Yes | - | 31.3 | 26.6 | 50.6 | - | |||||
6m2q | 1.70 Å | 2020-04-15 | X-ray | - | SARS-CoV-2 | NSP5 (3CLpro) | No functional ligands | 17.55% | 20.40% | 7.70% | - | HKL-2000 | 99.00% | 4.0 | SSRF (BL18U1) | PHENIX | 2020-02-28 | 32737471 | - | - | http://covid-19.bioreproducibility.org/static/data/6m2q/6m2q_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6m2q/6m2q_refined.mtz | 21.80% | Placed the coordinates in a standardized location in the unit cell using ACHESYM. | The coordinates are NOT in a standardized location in the unit cell. | SARS-CoV-2 3CL protease | 81.6 | minimal | Yes | Yes | - | 78.8 | 73.6 | 96.1 | - | ||||||
6wcf | 1.06 Å | 2020-04-15 | X-ray | MES | SARS-CoV-2 | NSP3: Macro | No functional ligands | 12.54% | 15.37% | 9.40% | 2-(N-MORPHOLINO)-ETHANESULFONIC ACID | 2-(N-MORPHOLINO)-ETHANESULFONIC ACID | HKL-3000 | 97.90% | 18.74 | APS (19-ID) | PHENIX | 2020-03-30 | 32939273 | - | - | - | - | N/A | - | - | Non-structural protein 3 | 67.1 | - | No | 97.9 | 38.1 | 73.3 | - | |||||||
6wen | 1.35 Å | 2020-04-15 | X-ray | - | SARS-CoV-2 | NSP3: Macro | No functional ligands | 10.36% | 14.41% | 8.90% | - | HKL-3000 | 95.70% | 24.13 | APS (19-ID) | REFMAC | 2020-04-02 | 32939273 | - | - | - | - | N/A | - | - | Non-structural protein 3 | 87.4 | - | No | 98.8 | 95.7 | 99.6 | - | ||||||||
6yla | 2.42 Å | 2020-04-15 | X-ray | MLI, NAG, 1PE, PG0 | SARS-CoV-2 | Spike | Pathogen-host interaction | 21.27% | 23.67% | 30.30% | MALONATE ION; 2-(2-METHOXYETHOXY)ETHANOL; PENTAETHYLENE GLYCOL | MALONATE ION; 2-acetamido-2-deoxy-beta-D-glucopyranose; PENTAETHYLENE GLYCOL; 2-(2-METHOXYETHOXY)ETHANOL | xia2 | 100.00% | 11.6 | Diamond (I03) | PHENIX; PHENIX | 2020-04-06 | 32585135 | - | - | http://covid-19.bioreproducibility.org/static/data/6yla/6yla_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6yla/6yla_refined.mtz | 23.80% | Replaced 18 buffer molecules with water molecules or PEG. | Multiple buffer molecules (DMS, MLE, MLI) with very weak electron density. | Spike glycoprotein; Heavy Chain; Light chain | 43.9 | minimal | Yes | - | 48.3 | 43.6 | 71.5 | - | ||||||
6wiq | 2.85 Å | 2020-04-22 | X-ray | - | SARS-CoV-2 | NSP7/NSP8 | Protein-protein complex | 20.82% | 25.23% | 13.00% | - | HKL-3000 | 97.90% | 18.2 | APS (19-ID) | PHENIX | 2020-04-10 | 34197805 | - | - | - | - | N/A | - | - | SARS-CoV-2 NSP7 - UNP residues 3860-3942; SARS-CoV-2 NSP8 - C-terminal domain (UNP residues 4019-4140) | 64.7 | - | No | - | 33.1 | 90.8 | 80.3 | - | |||||||
6wji | 2.05 Å | 2020-04-22 | X-ray | - | SARS-CoV-2 | Nucleocapsid | No functional ligands | 18.69% | 22.75% | 17.10% | - | HKL-3000 | 97.00% | 9.7 | APS (21-ID-F) | REFMAC | 2020-04-13 | 37191546 | - | - | - | - | N/A | - | - | SARS-CoV-2 nucleocapsid protein - C-terminal dimerization domain (UNP residues 257-364) | 67.1 | - | No | 57.6 | 82.1 | 69.5 | - | ||||||||
6wjt | 2.00 Å | 2020-04-22 | X-ray | NA, SAH, FMT | SARS-CoV-2 | NSP10/NSP16 | Functional ligand | 17.11% | 19.11% | 10.10% | SODIUM ION; FORMIC ACID; S-ADENOSYL-L-HOMOCYSTEINE | SODIUM ION; S-ADENOSYL-L-HOMOCYSTEINE; FORMIC ACID | HKL-3000 | 100.00% | 16.7 | APS (21-ID-F) | REFMAC | 2020-04-14 | 32994211 | ZN; NA | - | - | - | N/A | - | - | 2'-O-methyltransferase; Non-structural protein 10 | 59.3 | - | No | 87.1 | 14.9 | 91.1 | - | |||||||
7bqy | 1.70 Å | 2020-04-22 | X-ray | - | SARS-CoV-2 | NSP5 (3CLpro) | Functional ligand | 19.49% | 22.57% | 6.10% | N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~-((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3-YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE | - | HKL-2000 | 98.10% | 7.5 | SSRF (BL19U1) | PHENIX | 2020-03-26 | 32272481 | - | - | http://covid-19.bioreproducibility.org/static/data/7bqy/7bqy_refined.pdb | http://covid-19.bioreproducibility.org/static/data/7bqy/7bqy_refined.mtz | 23.70% | Deleted terminal benzyl group from the inhibitor (residue 010) and introduced full carboxyl COO including OXT atom in residue PJE. | Minor issues with inhibitor modeling. | main protease; N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL-L-VALYL-N~1~-((1R,2Z)-4-(BENZYLOXY)-4-OXO-1-{[(3R)-2-OXOPYRROLIDIN-3-YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE | 49.2 | minimal | Yes | Yes | - | 59.6 | 35.0 | 78.9 | - | |||||
7bv1 | 2.80 Å | 2020-04-22 | Cryo-EM | - | SARS-CoV-2 | NSP7/NSP8/NSP12 | Protein-protein complex | N/A | N/A | N/A | - | - | - | () | phenix.real_space_refine; PHENIX | 2020-04-09 | 32358203 | ZN | - | - | - | N/A | - | - | nsp12; nsp8; nsp7 | N/A | - | No | - | N/A | N/A | N/A | - | ||||||||
7bv2 | 2.50 Å | 2020-04-22 | Cryo-EM | POP, F86 | SARS-CoV-2 | NSP7/NSP8/NSP12 | Functional ligand | N/A | N/A | N/A | Templete; Primer; PYROPHOSPHATE 2-; [(2~{R},3~{S},4~{R},5~{R})-5-(4-azanylpyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-bis(oxidanyl)oxolan-2-yl]methyl dihydrogen phosphate | PYROPHOSPHATE 2-; [(2~{R},3~{S},4~{R},5~{R})-5-(4-azanylpyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-bis(oxidanyl)oxolan-2-yl]methyl dihydrogen phosphate | - | - | () | PHENIX; phenix.real_space_refine | 2020-04-09 | 32358203 | MG; ZN | - | - | - | N/A | - | - | nsp12; nsp8; nsp7; Primer; Templete | N/A | - | No | - | N/A | N/A | N/A | - | |||||||
6l70 | 1.56 Å | 2020-04-29 | X-ray | K36 | PEDV | NSP5 (3CLpro) | Functional ligand | 17.41% | 20.70% | 5.50% | (1S,2S)-2-({N-[(benzyloxy)carbonyl]-L-leucyl}amino)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid | (1S,2S)-2-({N-[(benzyloxy)carbonyl]-L-leucyl}amino)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid | 98.60% | 17.0 | SSRF (BL17U) | PHENIX | 2019-10-30 | 32098094 | - | - | - | - | N/A | - | - | PEDV main protease | 57.0 | - | No | - | 76.5 | 33.4 | 78.7 | - | |||||||
6lze | 1.50 Å | 2020-04-29 | X-ray | FHR | SARS-CoV-2 | NSP5 (3CLpro) | Functional ligand | 17.60% | 19.89% | 4.20% | ~{N}-[(2~{S})-3-cyclohexyl-1-oxidanylidene-1-[[(2~{S})-1-oxidanylidene-3-[(3~{S})-2-oxidanylidenepyrrolidin-3-yl]propan-2-yl]amino]propan-2-yl]-1~{H}-indole-2-carboxamide | ~{N}-[(2~{S})-3-cyclohexyl-1-oxidanylidene-1-[[(2~{S})-1-oxidanylidene-3-[(3~{S})-2-oxidanylidenepyrrolidin-3-yl]propan-2-yl]amino]propan-2-yl]-1~{H}-indole-2-carboxamide | XDS | 98.00% | 13.99 | NFPSS (BL19U1) | PHENIX | 2020-02-19 | 32321856 | - | - | http://covid-19.bioreproducibility.org/static/data/6lze/6lze_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6lze/6lze_refined.mtz | 18.69% | Placed the coordinates in a standardized location in the unit cell using ACHESYM. Refined inhibitor. | The coordinates are NOT in a standardized location in the unit cell. Distortions in the inhibitor. | Replicase polyprotein 1ab | 55.9 | minimal | Yes | Yes | - | 82.5 | 23.9 | 80.1 | - | |||||
6m0k | 1.50 Å | 2020-04-29 | X-ray | FJC | SARS-CoV-2 | NSP5 (3CLpro) | Functional ligand | 17.95% | 19.31% | 3.00% | ~{N}-[(2~{S})-3-(3-fluorophenyl)-1-oxidanylidene-1-[[(2~{S})-1-oxidanylidene-3-[(3~{S})-2-oxidanylidenepyrrolidin-3-yl]propan-2-yl]amino]propan-2-yl]-1~{H}-indole-2-carboxamide | ~{N}-[(2~{S})-3-(3-fluorophenyl)-1-oxidanylidene-1-[[(2~{S})-1-oxidanylidene-3-[(3~{S})-2-oxidanylidenepyrrolidin-3-yl]propan-2-yl]amino]propan-2-yl]-1~{H}-indole-2-carboxamide | XDS | 98.80% | 18.69 | NFPSS (BL19U1) | PHENIX | 2020-02-22 | 32321856 | - | - | http://covid-19.bioreproducibility.org/static/data/6m0k/6m0k_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6m0k/6m0k_refined.mtz | 17.80% | Placed the coordinates in a standardized location in the unit cell using ACHESYM. Refined inhibitor. | The coordinates are NOT in a standardized location in the unit cell. Distortions in the inhibitor. | Replicase polyprotein 1ab | 54.3 | minimal | Yes | Yes | - | 86.1 | 19.5 | 77.7 | - | |||||
6w37 | 2.90 Å | 2020-04-29 | X-ray | - | SARS-CoV-2 | ORF7a | No functional ligands | 23.59% | 26.80% | 24.90% | - | XDS | 99.90% | 9.8 | APS (21-ID-G) | PHENIX | 2020-03-09 | - | - | - | - | - | N/A | - | - | Protein 7a - H-2Kb residues 1-277 | 27.6 | - | No | - | - | 20.8 | 11.6 | 98.4 | - | ||||||
6wey | 0.95 Å | 2020-04-29 | X-ray | - | SARS-CoV-2 | NSP3: Macro | No functional ligands | 11.91% | 13.62% | 6.30% | - | DIALS | 98.20% | 13.1 | APS (21-ID-F) | PHENIX | 2020-04-03 | 32578982 | - | - | - | - | N/A | - | - | Non-structural protein 3 - Macro X domain (residues 207-377) | 83.9 | - | No | - | 99.3 | 63.8 | 96.0 | - | |||||||
6wkp | 2.67 Å | 2020-04-29 | X-ray | MES | SARS-CoV-2 | Nucleocapsid | No functional ligands | 19.73% | 24.77% | 9.10% | 2-(N-MORPHOLINO)-ETHANESULFONIC ACID | 2-(N-MORPHOLINO)-ETHANESULFONIC ACID | HKL-3000 | 97.50% | 8.2 | APS (19-ID) | PHENIX | 2020-04-16 | - | ZN | - | - | - | N/A | - | - | SARS-CoV-2 nucleocapsid protein - RNA-binding domain (UNP residues 47-173) | 55.0 | - | No | - | 37.5 | 68.6 | 78.5 | - | ||||||
6wkq | 1.98 Å | 2020-04-29 | X-ray | NA, SFG, FMT | SARS-CoV-2 | NSP10/NSP16 | Functional ligand | 16.23% | 17.99% | 7.10% | FORMIC ACID; SINEFUNGIN; SODIUM ION | SODIUM ION; SINEFUNGIN; FORMIC ACID | HKL-3000 | 100.00% | 22.2 | APS (21-ID-F) | REFMAC | 2020-04-16 | 32994211 | NA; ZN | - | - | - | N/A | - | - | SARS-CoV-2 NSP16 - UNP residues 6799-7096; SARS-CoV-2 NSP10 - UNP residues 4254-4392 | 63.1 | - | No | 92.2 | 13.7 | 94.9 | - | |||||||
6wlc | 1.82 Å | 2020-04-29 | X-ray | U5P, TRS, FMT | SARS-CoV-2 | NSP15 | Functional ligand | 17.03% | 19.49% | 14.70% | URIDINE-5'-MONOPHOSPHATE; 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL | URIDINE-5'-MONOPHOSPHATE; 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL; FORMIC ACID | HKL-3000 | 100.00% | 18.8 | APS (19-ID) | PHENIX | 2020-04-19 | 33564093 | - | - | - | - | N/A | - | - | Uridylate-specific endoribonuclease | 83.4 | - | No | - | 85.1 | 87.7 | 83.6 | - | ||||||
6yhu | 2.00 Å | 2020-04-29 | X-ray | - | SARS-CoV-2 | NSP7/NSP8 | Protein-protein complex | 21.43% | 23.93% | 7.41% | - | XDS | 99.39% | 17.1 | ROTATING ANODE () | PHENIX | 2020-03-31 | 32535228 | - | - | - | - | N/A | - | - | Replicase polyprotein 1a; Replicase polyprotein 1a | 69.9 | - | No | - | 45.5 | 70.3 | 99.7 | - | |||||||
6ym0 | 4.36 Å | 2020-04-29 | X-ray | - | SARS-CoV-2 | Spike | Pathogen-host interaction | 32.28% | 31.88% | 68.30% | - | xia2 | 100.00% | 4.0 | Diamond (I03) | REFMAC | 2020-04-07 | 32585135 | - | - | - | - | N/A | - | - | Spike glycoprotein; heavy chain; light chain | 1.0 | - | No | - | 5.1 | 28.3 | 11.2 | - | |||||||
6ynq | 1.80 Å | 2020-04-29 | X-ray | P6N | SARS-CoV-2 | NSP5 (3CLpro) | Functional ligand | 19.22% | 22.61% | N/A | (2~{S})-2-methyl-3,4-dihydro-2~{H}-naphthalen-1-one | (2~{S})-2-methyl-3,4-dihydro-2~{H}-naphthalen-1-one | XDS | 94.90% | 2.42 | PETRA III, DESY (P11) | PHENIX | 2020-04-14 | 33811162 | - | - | http://covid-19.bioreproducibility.org/static/data/6ynq/6ynq_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6ynq/6ynq_refined.mtz | 24.70% | Linked the inhibitor to both conformations of Cys124. Placed the coordinates in a standardized location in the unit cell. Fixed conformations of the following residues: 1, 4, 5, 19, 22-25, 47, 55, 60, 61, 90, 117, 123, 128, 137, 154 (cut side-chain), 162, 165, 188, 205, 217, 221, 240, 254, 279, 284, 298, 304. Removed residues 305-306. Remodeled multiple water molecules. | The inhibitor at full occupancy is linked to only one of the two conformations of Cys145. Several poorly modelled side-chains. The coordinates are NOT in a standardized location in the unit cell. Discrepancy in reported resolution: 1.8 A author-reported on the main page, 1.3 A author-reported on the "experiment" page and the cif file, and the deposited data are at 1.75 A. Very skewed cumulative intensity distribution. | Replicase polyprotein 1ab | 39.2 | moderate | Yes | Yes | 59.0 | 48.9 | 46.4 | - | ||||||
6yor | 3.30 Å | 2020-04-29 | Cryo-EM | - | SARS-CoV-2 | Spike | Pathogen-host interaction | N/A | N/A | N/A | - | - | - | () | PHENIX | 2020-04-15 | 32585135 | - | - | - | - | N/A | - | - | Spike glycoprotein; IgG H chain; IgG L chain | N/A | - | No | - | N/A | N/A | N/A | - | ||||||||
7buy | 1.60 Å | 2020-04-29 | X-ray | JRY | SARS-CoV-2 | NSP5 (3CLpro) | Functional ligand | 17.93% | 20.12% | 3.40% | hexylcarbamic acid | hexylcarbamic acid | XDS | 99.20% | 17.25 | SSRF (BL17U1) | PHENIX | 2020-04-08 | 32382072 | - | - | http://covid-19.bioreproducibility.org/static/data/7buy/7buy_refined.pdb | http://covid-19.bioreproducibility.org/static/data/7buy/7buy_refined.mtz | 20.53% | Used ACHESYM to standardize location in the unit cell. | The coordinates are NOT in a standardized location in the unit cell. | SARS-CoV-2 virus Main protease | 41.7 | minimal | Yes | Yes | - | 80.9 | 26.6 | 51.9 | - | |||||
6wks | 1.80 Å | 2020-05-06 | X-ray | SAM, ADN, GTA | SARS-CoV-2 | NSP10/NSP16 | Protein-protein complex | 15.20% | 18.80% | 13.00% | P1-7-METHYLGUANOSINE-P3-ADENOSINE-5',5'-TRIPHOSPHATE; S-ADENOSYLMETHIONINE; ADENOSINE | S-ADENOSYLMETHIONINE; ADENOSINE; P1-7-METHYLGUANOSINE-P3-ADENOSINE-5',5'-TRIPHOSPHATE | XDS | 99.90% | 13.6 | () | REFMAC | 2020-04-16 | 32709886 | ZN | - | - | - | N/A | - | - | 2'-O-methyltransferase; Non-structural protein 10 | 47.5 | - | No | - | 88.7 | 14.1 | 67.3 | - | ||||||
6wnp | 1.44 Å | 2020-05-06 | X-ray | U5G | SARS-CoV-2 | NSP5 (3CLpro) | Functional ligand | 18.07% | 19.59% | 6.43% | boceprevir (bound form) | boceprevir (bound form) | HKL-2000 | 99.00% | 19.85 | APS (21-ID-F) | PHENIX; PHENIX | 2020-04-23 | - | - | - | http://covid-19.bioreproducibility.org/static/data/6wnp/6wnp_rerefinement.pdb | http://covid-19.bioreproducibility.org/static/data/6wnp/6wnp_rerefinement.mtz | 15.84% | Used anisotropic refinement, modeled disorder for: LEU 67 A, GLN 110 A, SER 121 A, VAL 125 A, ASP 153 A, SER 267 A, MET 276 A. Chaged rotamers of: SER 1 A, ARG 76 A, GLN 127 A, THR 154 A, PRO 168 A, THR 196 A, LYS 236 A, ASN 277 A. Added 110 HOH molecules. | Missing disorder in few residues and a lot of unmodeled waters. | 3C-like proteinase | 57.1 | minimal | Yes | Yes | - | - | 84.5 | 28.0 | 76.4 | - | ||||
6woj | 2.20 Å | 2020-05-06 | X-ray | APR | SARS-CoV-2 | NSP3: Macro | Functional ligand | 19.93% | 25.19% | 13.00% | ADENOSINE-5-DIPHOSPHORIBOSE | ADENOSINE-5-DIPHOSPHORIBOSE | XDS | 99.40% | 7.3 | APS (17-ID) | PHENIX | 2020-04-24 | 33158944 | - | - | - | - | N/A | - | - | Non-structural protein 3 - UNP Residues 1023-1197 | 61.6 | - | No | - | 33.6 | 91.8 | 72.3 | - | ||||||
6wq3 | 2.10 Å | 2020-05-06 | X-ray | SAH, GTA, 8NK | SARS-CoV-2 | NSP10/NSP16 | Functional ligand | 16.61% | 18.59% | 7.50% | 7-methylguanosine 5'-diphosphate; S-ADENOSYL-L-HOMOCYSTEINE; P1-7-METHYLGUANOSINE-P3-ADENOSINE-5',5'-TRIPHOSPHATE | S-ADENOSYL-L-HOMOCYSTEINE; P1-7-METHYLGUANOSINE-P3-ADENOSINE-5',5'-TRIPHOSPHATE; 7-methylguanosine 5'-diphosphate | HKL-3000 | 98.80% | 21.1 | APS (21-ID-F) | REFMAC | 2020-04-28 | 32994211 | ZN | - | - | - | N/A | - | - | 2'-O-methyltransferase; Non-structural protein 10 | 61.5 | - | No | 89.8 | 12.8 | 94.9 | - | |||||||
6wqd | 1.95 Å | 2020-05-06 | X-ray | - | SARS-CoV-2 | NSP7/NSP8 | No functional ligands | 18.66% | 22.87% | 18.80% | - | HKL-3000 | 97.30% | 22.5 | APS (19-ID) | REFMAC; PHENIX | 2020-04-28 | 34197805 | - | - | - | - | N/A | - | - | SARS-CoV-2 NSP7 - UNP residues 3860-3942; SARS-CoV-2 NSP8 - C-terminal domain (UNP residues 4019-4140) | 62.8 | - | No | - | 56.4 | 63.4 | 80.4 | - | |||||||
6wqf | 2.30 Å | 2020-05-06 | X-ray | - | SARS-CoV-2 | NSP5 (3CLpro) | No functional ligands | 17.96% | 22.96% | 11.00% | - | CrysalisPro | 95.40% | 8.1 | ROTATING ANODE () | PHENIX | 2020-04-28 | 32581217 | - | - | http://covid-19.bioreproducibility.org/static/data/6wqf/6wqf_refined_1.pdb | http://covid-19.bioreproducibility.org/static/data/6wqf/6wqf_refined_1.mtz | 23.90% | Changed space group to C2, reindexed from h,k,l to -h-l, k, h. | Non-standard space group, while standard C2 would make it compatible with many other structures of this protein. | 3C-like proteinase | 61.9 | minimal | Yes | Yes | - | 55.5 | 45.7 | 97.3 | - | ||||||
6wrh | 1.60 Å | 2020-05-06 | X-ray | PO4 | SARS-CoV-2 | NSP3: PLpro | No functional ligands | 12.34% | 16.43% | 9.50% | PHOSPHATE ION | PHOSPHATE ION | HKL-3000 | 99.10% | 6.8 | APS (19-ID) | REFMAC | 2020-04-29 | 33531496 | ZN | - | - | - | N/A | - | - | Non-structural protein 3 | 77.3 | - | No | 96.3 | 44.0 | 94.0 | - | |||||||
6ywk | 2.20 Å | 2020-05-06 | X-ray | EPE | SARS-CoV-2 | NSP3: Macro | No functional ligands | 17.63% | 21.39% | 13.80% | 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID | 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID | XDS | 100.00% | 10.7 | SLS (X06SA) | REFMAC | 2020-04-29 | 33850605 | MG | - | - | - | N/A | - | - | NSP3 macrodomain | 78.9 | - | No | - | 70.8 | 84.4 | 83.9 | - | ||||||
6ywl | 2.50 Å | 2020-05-06 | X-ray | APR | SARS-CoV-2 | NSP3: Macro | Functional ligand | 18.89% | 22.32% | 19.90% | ADENOSINE-5-DIPHOSPHORIBOSE | ADENOSINE-5-DIPHOSPHORIBOSE | XDS | 99.40% | 6.9 | SLS (X06SA) | REFMAC | 2020-04-29 | 33850605 | MG | - | - | - | N/A | - | - | NSP3 macrodomain | 72.5 | - | No | - | 61.9 | 79.2 | 80.6 | - | ||||||
6ywm | 2.16 Å | 2020-05-06 | X-ray | MES | SARS-CoV-2 | NSP3: Macro | No functional ligands | 17.52% | 22.92% | 16.20% | 2-(N-MORPHOLINO)-ETHANESULFONIC ACID | 2-(N-MORPHOLINO)-ETHANESULFONIC ACID | XDS | 100.00% | 8.3 | SLS (X06SA) | REFMAC | 2020-04-29 | 33850605 | MG | - | - | - | N/A | - | - | NSP3 macrodomain | 70.4 | - | No | - | 55.8 | 89.7 | 71.1 | - | ||||||
6wrz | 2.25 Å | 2020-05-13 | X-ray | SAH, GTA, MGP | SARS-CoV-2 | NSP10/NSP16 | Functional ligand | 16.20% | 19.02% | 7.70% | 7-METHYL-GUANOSINE-5'-TRIPHOSPHATE; P1-7-METHYLGUANOSINE-P3-ADENOSINE-5',5'-TRIPHOSPHATE; S-ADENOSYL-L-HOMOCYSTEINE | S-ADENOSYL-L-HOMOCYSTEINE; P1-7-METHYLGUANOSINE-P3-ADENOSINE-5',5'-TRIPHOSPHATE; 7-METHYL-GUANOSINE-5'-TRIPHOSPHATE | HKL-3000 | 99.00% | 23.4 | APS (21-ID-F) | REFMAC | 2020-04-30 | 32994211 | ZN | - | - | - | N/A | - | - | 2'-O-methyltransferase; Non-structural protein 10 | 62.4 | - | No | 87.6 | 14.4 | 97.4 | - | |||||||
6wtc | 1.85 Å | 2020-05-13 | X-ray | ACY | SARS-CoV-2 | NSP7/NSP8 | No functional ligands | 18.68% | 21.41% | 8.30% | ACETIC ACID | HKL-3000 | 93.00% | 12.9 | APS (19-ID) | PHENIX | 2020-05-02 | - | - | - | - | - | N/A | - | - | SARS-CoV-2 NSP7 - UNP residues 3860-3942; SARS-CoV-2 NSP8 - C-terminal domain (UNP residues 4019-4140) | 78.2 | - | No | - | - | 70.5 | 82.4 | 84.0 | - | ||||||
6wvn | 2.00 Å | 2020-05-13 | X-ray | SAM, GTA, MGP, ADE | SARS-CoV-2 | NSP10/NSP16 | Functional ligand | 16.23% | 17.80% | 7.00% | ADENINE; S-ADENOSYLMETHIONINE; P1-7-METHYLGUANOSINE-P3-ADENOSINE-5',5'-TRIPHOSPHATE; 7-METHYL-GUANOSINE-5'-TRIPHOSPHATE | S-ADENOSYLMETHIONINE; P1-7-METHYLGUANOSINE-P3-ADENOSINE-5',5'-TRIPHOSPHATE; 7-METHYL-GUANOSINE-5'-TRIPHOSPHATE; ADENINE | HKL-3000 | 99.80% | 20.3 | APS (21-ID-F) | REFMAC | 2020-05-06 | 32994211 | ZN | - | - | - | N/A | - | - | 2'-O-methyltransferase; Non-structural protein 10 | 63.4 | - | No | 92.8 | 14.2 | 94.4 | - | |||||||
6yva | 3.18 Å | 2020-05-13 | X-ray | - | SARS-CoV-2 | NSP3: PLpro | Protein-protein complex | 24.96% | 29.02% | 5.75% | - | XDS | 99.61% | 8.58 | SLS (X06SA) | PHENIX; PHENIX | 2020-04-28 | 32726803 | ZN | - | - | - | N/A | - | - | Replicase polyprotein 1a; Ubiquitin-like protein ISG15 | 8.4 | - | No | - | 9.8 | 42.0 | 31.3 | - | |||||||
6yyt | 2.90 Å | 2020-05-13 | Cryo-EM | - | SARS-CoV-2 | NSP7/NSP8/NSP12/RNA | Functional ligand | N/A | N/A | N/A | RNA product | - | - | - | () | 2020-05-06 | 32438371 | ZN | - | - | - | N/A | - | - | nsp12; nsp8; nsp7; RNA product | N/A | - | No | - | N/A | N/A | N/A | RNA product | - | |||||||
6yz1 | 2.40 Å | 2020-05-13 | X-ray | SFG, MES | SARS-CoV-2 | NSP10/NSP16 | Functional ligand | 18.66% | 22.56% | 40.80% | SINEFUNGIN; 2-(N-MORPHOLINO)-ETHANESULFONIC ACID | SINEFUNGIN; 2-(N-MORPHOLINO)-ETHANESULFONIC ACID | XDS | 100.00% | 12.8 | LIQUID ANODE () | PHENIX | 2020-05-06 | 32709887 | ZN | - | - | - | N/A | - | - | nsp16; nsp10 | 62.8 | - | No | - | 59.7 | 87.6 | 53.1 | - | ||||||
7bro | 2.00 Å | 2020-05-13 | X-ray | - | SARS-CoV-2 | NSP5 (3CLpro) | Protein-protein complex | 22.62% | 25.90% | N/A | - | HKL-2000 | 99.60% | 70.7 | SSRF (BL17U1) | PHENIX | 2020-03-29 | 32887884 | - | - | http://covid-19.bioreproducibility.org/static/data/7bro/7bro-refmac.pdb | http://covid-19.bioreproducibility.org/static/data/7bro/7bro-refmac.mtz | 24.50% | Re-refinement and rebuilding an incorrect model; move atoms into the electron density to reduce the amount of difference density. | In some places the main chain is twisted out of density. The coordinates are NOT in a standardized location in the unit cell. | 3C-like proteinase | 29.0 | moderate | Yes | Yes | - | 27.3 | 48.2 | 58.4 | - | ||||||
7brp | 1.80 Å | 2020-05-13 | X-ray | U5G | SARS-CoV-2 | NSP5 (3CLpro) | Functional ligand | 21.56% | 23.96% | N/A | boceprevir (bound form) | boceprevir (bound form) | HKL-2000 | 99.50% | 28.4 | SSRF (BL17U1) | PHENIX | 2020-03-29 | 32887884 | - | - | http://covid-19.bioreproducibility.org/static/data/7brp/7brp_refine.pdb | http://covid-19.bioreproducibility.org/static/data/7brp/7brp_refine.mtz | 21.90% | After re-refinement with standard TLS and minor corrections of model Rfree has dropped by 4%. | The coordinates are NOT in a standardized location in the unit cell. | 3C-like proteinase | 42.3 | minimal | Yes | Yes | - | 45.3 | 50.0 | 65.0 | - | |||||
7bz5 | 1.84 Å | 2020-05-13 | X-ray | NAG | SARS-CoV-2 | Spike | Protein-protein complex | 16.71% | 19.14% | N/A | 2-acetamido-2-deoxy-beta-D-glucopyranose | HKL-2000 | 99.41% | 16.9 | SSRF (BL17U1) | PHENIX | 2020-04-26 | 32404477 | - | - | - | - | N/A | - | - | Spike protein S1; Heavy chain of B38; Light chain of B38 | 64.3 | - | No | - | 87.0 | 29.5 | 86.8 | - | |||||||
6wtj | 1.90 Å | 2020-05-20 | X-ray | K36 | SARS-CoV-2 | NSP5 (3CLpro) | Functional ligand | 19.86% | 23.48% | N/A | (1S,2S)-2-({N-[(benzyloxy)carbonyl]-L-leucyl}amino)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid | (1S,2S)-2-({N-[(benzyloxy)carbonyl]-L-leucyl}amino)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid | XDS | 97.90% | 7.18 | SSRL (BL12-2) | PHENIX | 2020-05-02 | 32855413 | - | - | http://covid-19.bioreproducibility.org/static/data/6wtj/6wtj_rerefined.pdb | http://covid-19.bioreproducibility.org/static/data/6wtj/6wtj_rerefined.mtz | 24.20% | Placed the coordinates in a standardized location in the unit cell. Modified residues 55, 151, 177, 222, 228, 235, 290, 298. Deleted 302-306. Changed Wat549 (special position) to Cl. Deleted Wat 523, 552. | Wrong number of reflections, the coordinates are not in a standard unit cell placement. | 3C-like proteinase | 27.9 | minimal | Yes | Yes | - | 50.3 | 42.8 | 38.5 | - | |||||
6wtk | 2.00 Å | 2020-05-20 | X-ray | UED | SARS-CoV-2 | NSP5 (3CLpro) | Functional ligand | 20.59% | 25.53% | N/A | N~2~-[(benzyloxy)carbonyl]-N-{(2S)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-leucinamide | N~2~-[(benzyloxy)carbonyl]-N-{(2S)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-leucinamide | XDS | 96.00% | 5.6 | SSRL (BL12-2) | PHENIX | 2020-05-03 | 32855413 | - | - | http://covid-19.bioreproducibility.org/static/data/6wtk/6wtk-refined.pdb | http://covid-19.bioreproducibility.org/static/data/6wtk/6wtk_refined.mtz | 27.42% | Achesymed. The inhibitor was designated K36, as in other structures of GC376. | The data in the PDB apparently extend to 1.2 A, although only 2 A data were used for refinement. Higher resolution data are too weak to consider them to be observed. | 3C-like proteinase | - | minimal | Yes | Yes | - | 30.5 | - | 31.0 | - | |||||
6wtm | 1.85 Å | 2020-05-20 | X-ray | - | SARS-CoV-2 | NSP5 (3CLpro) | No functional ligands | 20.77% | 25.16% | N/A | - | XDS | 97.80% | 6.42 | SSRL (BL12-2) | PHENIX | 2020-05-03 | 32855413 | - | - | http://covid-19.bioreproducibility.org/static/data/6wtm/6wtm_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6wtm/6wtm_refined.mtz | 25.70% | Placed the coordinates in a standardized location in the unit cell using ACHESYM. | The coordinates are NOT in a standardized location in the unit cell. | 3C-like proteinase | 53.3 | minimal | Yes | Yes | - | 33.8 | 83.7 | 63.9 | - | ||||||
6wtt | 2.15 Å | 2020-05-20 | X-ray | K36, B1S | SARS-CoV-2 | NSP5 (3CLpro) | Functional ligand | 21.45% | 30.01% | 11.00% | (1S,2S)-2-({N-[(benzyloxy)carbonyl]-L-leucyl}amino)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid | (1S,2S)-2-({N-[(benzyloxy)carbonyl]-L-leucyl}amino)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid; (1R,2S)-2-({N-[(benzyloxy)carbonyl]-L-leucyl}amino)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid | HKL-3000 | 100.00% | 5.2 | APS (19-ID) | REFMAC | 2020-05-03 | 32541865 | MG | - | http://covid-19.bioreproducibility.org/static/data/6wtt/6wtt_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6wtt/6wtt_refined.mtz | 28.69% | Achesymed. | The coordinates are NOT in a standardized location in the unit cell. | 3C-like proteinase | 5.6 | minimal | Yes | Yes | - | 7.2 | 20.3 | 45.0 | - | |||||
6wuu | 2.79 Å | 2020-05-20 | X-ray | - | SARS-CoV-2 | NSP3: PLpro | Functional ligand | 19.52% | 22.97% | 15.80% | VIR250 | - | XDS | 99.60% | 10.1 | APS (24-ID-C) | PHENIX | 2020-05-05 | 33067239 | MG; ZN | - | - | - | N/A | - | - | papain-like protease - UNP Residues 1563-1879; VIR250 | 64.2 | - | No | - | 55.4 | 77.2 | 70.7 | - | ||||||
6wx4 | 1.66 Å | 2020-05-20 | X-ray | - | SARS-CoV-2 | NSP3: PLpro | Functional ligand | 16.96% | 19.58% | 9.40% | VIR251 | - | XDS | 99.50% | 15.5 | APS (24-ID-C) | PHENIX | 2020-05-09 | 33067239 | ZN | - | http://covid-19.bioreproducibility.org/static/data/6wx4/6wx4_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6wx4/6wx4_refined.mtz | 18.10% | Corrected geometry of the inhibitor. Mutated Cys270 to Cso (hydroxy-cystein). Placed the coordinates in a standardized location in the unit cell. Altered conformations of the following residues: 2, 3,18, 60, 140, 270, 306, 308. Added 51 water molecules. | Incorrect geometry (flat instead of tetrahedral) of the inhibitor carbon atom linked to Cys111. Cys270 is oxidised and should be modelled as such. Many missing water molecules. Conformations of several residues can be corrected. The coordinates are NOT in a standardized location in the unit cell. | Non-structural protein 3; VIR251 | 85.6 | moderate | Yes | Yes | - | 84.5 | 89.2 | 95.5 | - | |||||
6wxc | 1.85 Å | 2020-05-20 | X-ray | CMU, PO4, FMT | SARS-CoV-2 | NSP15 | Functional ligand | 17.09% | 19.37% | 15.90% | FORMIC ACID; 5-CHLORO-6-(1-(2-IMINOPYRROLIDINYL) METHYL) URACIL; PHOSPHATE ION | 5-CHLORO-6-(1-(2-IMINOPYRROLIDINYL) METHYL) URACIL; PHOSPHATE ION; FORMIC ACID | HKL-3000 | 99.80% | 22.5 | APS (19-ID) | PHENIX | 2020-05-10 | 33564093 | - | - | - | - | N/A | - | - | Uridylate-specific endoribonuclease | 81.3 | - | No | - | 85.8 | 91.9 | 69.6 | - | ||||||
6wxd | 2.00 Å | 2020-05-20 | X-ray | - | SARS-CoV-2 | NSP9 | No functional ligands | 21.45% | 25.34% | N/A | - | XDS | 99.40% | 26.4 | Australian Synchrotron (MX2) | PHENIX | 2020-05-10 | 32592996 | - | - | - | - | N/A | - | - | Non-structural protein 9 | 11.9 | - | No | - | 32.2 | 18.2 | 43.8 | - | |||||||
6yun | 1.44 Å | 2020-05-20 | X-ray | - | SARS-CoV-2 | Nucleocapsid | No functional ligands | 14.79% | 18.88% | 3.40% | - | Aimless | 98.40% | 18.4 | SLS (X06DA) | PHENIX | 2020-04-27 | 33039147 | - | - | - | - | N/A | - | - | Nucleoprotein | 79.2 | - | No | - | 88.4 | 80.4 | 71.4 | - | |||||||
6yvf | 1.60 Å | 2020-05-20 | X-ray | A82, CA | SARS-CoV-2 | NSP5 (3CLpro) | Functional ligand | 18.69% | 20.81% | 7.30% | 2-[[(1R)-1-(7-methyl-2-morpholin-4-yl-4-oxidanylidene-pyrido[1,2-a]pyrimidin-9-yl)ethyl]amino]benzoic acid; CALCIUM ION | 2-[[(1R)-1-(7-methyl-2-morpholin-4-yl-4-oxidanylidene-pyrido[1,2-a]pyrimidin-9-yl)ethyl]amino]benzoic acid; CALCIUM ION | XDS | 95.20% | 7.48 | PETRA III, DESY (P11) | PHENIX | 2020-04-28 | 33811162 | CA | - | http://covid-19.bioreproducibility.org/static/data/6yvf/6yvf_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6yvf/6yvf_refined.mtz | 24.29% | Placed the coordinates in a standardized location in the unit cell. | The coordinates are NOT in a standardized location in the unit cell. | Replicase polyprotein 1ab | 58.9 | minimal | Yes | Yes | - | 75.6 | 56.0 | 60.6 | - | |||||
7c22 | 2.00 Å | 2020-05-20 | X-ray | - | SARS-CoV-2 | Nucleocapsid | No functional ligands | 18.87% | 23.82% | 10.70% | - | XDS | 95.60% | 5.9 | SSRF (BL19U1) | REFMAC | 2020-05-07 | 35006385 | - | - | - | - | N/A | - | - | Nucleoprotein | 46.9 | - | No | - | 46.6 | 74.6 | 47.9 | - | |||||||
5rgt | 2.22 Å | 2020-05-27 | X-ray | UHS | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 22.61% | 27.14% | 19.60% | N-[(1R)-2-(tert-butylamino)-2-oxo-1-(pyridin-3-yl)ethyl]-N-(5-tert-butyl-1,2-oxazol-3-yl)propanamide | N-[(1R)-2-(tert-butylamino)-2-oxo-1-(pyridin-3-yl)ethyl]-N-(5-tert-butyl-1,2-oxazol-3-yl)propanamide | XDS | 99.80% | 5.2 | Diamond (I04-1) | REFMAC | 2020-05-15 | - | - | - | - | - | N/A | - | - | 3C-like proteinase | 57.2 | - | No | - | - | 18.7 | 78.5 | 91.7 | - | |||||
5rgu | 2.11 Å | 2020-05-27 | X-ray | UGD | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 17.81% | 23.83% | 13.90% | N-(3-{[(2R)-4-oxoazetidin-2-yl]oxy}phenyl)-2-(pyrimidin-5-yl)acetamide | N-(3-{[(2R)-4-oxoazetidin-2-yl]oxy}phenyl)-2-(pyrimidin-5-yl)acetamide | XDS | 99.70% | 5.8 | Diamond (I04-1) | BUSTER | 2020-05-15 | - | - | - | - | - | N/A | - | - | 3C-like proteinase | 65.4 | - | No | - | - | 46.5 | 88.6 | 70.6 | - | |||||
5rgv | 1.82 Å | 2020-05-27 | X-ray | UGG | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.71% | 23.19% | 6.20% | 2-(isoquinolin-4-yl)-N-phenylacetamide | 2-(isoquinolin-4-yl)-N-phenylacetamide | XDS | 99.70% | 7.6 | Diamond (I04-1) | BUSTER | 2020-05-15 | - | - | - | - | - | N/A | - | - | 3C-like proteinase | 60.4 | - | No | - | - | 53.3 | 73.6 | 68.5 | - | |||||
5rgw | 1.43 Å | 2020-05-27 | X-ray | UGM | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 17.99% | 20.33% | 4.50% | 2-(5-cyanopyridin-3-yl)-N-(pyridin-3-yl)acetamide | 2-(5-cyanopyridin-3-yl)-N-(pyridin-3-yl)acetamide | XDS | 98.00% | 8.4 | Diamond (I04-1) | BUSTER | 2020-05-15 | - | - | - | - | - | N/A | - | - | 3C-like proteinase | 76.4 | - | No | - | - | 79.4 | 64.3 | 88.1 | - | |||||
5rgx | 1.69 Å | 2020-05-27 | X-ray | UGP | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.24% | 21.81% | 8.70% | 2-(3-cyanophenyl)-N-(4-methylpyridin-3-yl)acetamide | 2-(3-cyanophenyl)-N-(4-methylpyridin-3-yl)acetamide | XDS | 98.20% | 6.0 | Diamond (I04-1) | BUSTER | 2020-05-15 | - | - | - | - | - | N/A | - | - | 3C-like proteinase | 64.4 | - | No | - | - | 66.9 | 52.1 | 84.7 | - | |||||
5rgy | 1.98 Å | 2020-05-27 | X-ray | UGS | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 19.47% | 24.61% | 22.20% | N-(4-methoxypyridin-2-yl)-2-(naphthalen-2-yl)acetamide | N-(4-methoxypyridin-2-yl)-2-(naphthalen-2-yl)acetamide | XDS | 99.40% | 3.4 | Diamond (I04-1) | BUSTER | 2020-05-15 | - | - | - | - | - | N/A | - | - | 3C-like proteinase | 44.2 | - | No | - | - | 38.9 | 68.7 | 56.2 | - | |||||
5rgz | 1.52 Å | 2020-05-27 | X-ray | UH1 | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.01% | 20.90% | 4.90% | 2-(3-cyanophenyl)-N-(pyridin-3-yl)acetamide | 2-(3-cyanophenyl)-N-(pyridin-3-yl)acetamide | XDS | 96.90% | 8.6 | Diamond (I04-1) | BUSTER | 2020-05-15 | - | - | - | - | - | N/A | - | - | 3C-like proteinase | 69.0 | - | No | - | - | 74.8 | 68.7 | 70.0 | - | |||||
5rh0 | 1.92 Å | 2020-05-27 | X-ray | UH4 | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 19.52% | 24.05% | 9.20% | N-(5-methylthiophen-2-yl)-N'-pyridin-3-ylurea | N-(5-methylthiophen-2-yl)-N'-pyridin-3-ylurea | XDS | 99.70% | 7.1 | Diamond (I04-1) | BUSTER | 2020-05-15 | - | - | - | - | - | N/A | - | - | 3C-like proteinase | 47.3 | - | No | - | - | 44.4 | 64.3 | 61.1 | - | |||||
5rh1 | 1.96 Å | 2020-05-27 | X-ray | UGV | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.40% | 24.29% | 15.60% | 2-(5-chlorothiophen-2-yl)-N-(pyridin-3-yl)acetamide | 2-(5-chlorothiophen-2-yl)-N-(pyridin-3-yl)acetamide | XDS | 99.70% | 4.2 | Diamond (I04-1) | BUSTER | 2020-05-15 | - | - | - | - | - | N/A | - | - | 3C-like proteinase | 60.3 | - | No | - | - | 42.2 | 83.5 | 69.4 | - | |||||
5rh2 | 1.83 Å | 2020-05-27 | X-ray | UH7 | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.17% | 23.02% | 10.10% | 2-(3-chlorophenyl)-N-(4-methylpyridin-3-yl)acetamide | 2-(3-chlorophenyl)-N-(4-methylpyridin-3-yl)acetamide | XDS | 96.80% | 8.7 | Diamond (I04-1) | BUSTER | 2020-05-15 | - | - | - | - | - | N/A | - | - | 3C-like proteinase | 58.0 | - | No | - | - | 54.8 | 68.7 | 67.2 | - | |||||
5rh3 | 1.69 Å | 2020-05-27 | X-ray | UHA | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.76% | 23.17% | 9.10% | (2R)-2-(3-chlorophenyl)-N-(4-methylpyridin-3-yl)propanamide | (2R)-2-(3-chlorophenyl)-N-(4-methylpyridin-3-yl)propanamide | XDS | 99.30% | 6.5 | Diamond (I04-1) | BUSTER | 2020-05-15 | - | - | - | - | - | N/A | - | - | 3C-like proteinase | 62.0 | - | No | - | - | 53.4 | 68.7 | 76.3 | - | |||||
5rh4 | 1.34 Å | 2020-05-27 | X-ray | UHG | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.56% | 20.49% | 5.10% | (2R)-2-(6-chloro-9H-carbazol-2-yl)propanoic acid | (2R)-2-(6-chloro-9H-carbazol-2-yl)propanoic acid | XDS | 93.70% | 9.1 | Diamond (I04-1) | BUSTER | 2020-05-15 | - | - | - | - | - | N/A | - | - | 3C-like proteinase | 62.4 | - | No | - | - | 78.3 | 48.6 | 72.4 | - | |||||
5rh5 | 1.72 Å | 2020-05-27 | X-ray | UHV | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.60% | 22.29% | 8.90% | N-(5-tert-butyl-1,2-oxazol-3-yl)-N-[(1R)-2-[(4-methoxy-2-methylphenyl)amino]-2-oxo-1-(pyridin-3-yl)ethyl]propanamide | N-(5-tert-butyl-1,2-oxazol-3-yl)-N-[(1R)-2-[(4-methoxy-2-methylphenyl)amino]-2-oxo-1-(pyridin-3-yl)ethyl]propanamide | XDS | 99.80% | 8.3 | Diamond (I04-1) | BUSTER | 2020-05-15 | - | - | - | - | - | N/A | - | - | 3C-like proteinase | 64.4 | - | No | - | - | 62.4 | 64.3 | 76.9 | - | |||||
5rh6 | 1.60 Å | 2020-05-27 | X-ray | UHY | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.43% | 21.73% | 7.70% | N-[(1R)-2-[(2-ethyl-6-methylphenyl)amino]-2-oxo-1-(pyridin-3-yl)ethyl]-N-[6-(propan-2-yl)pyridin-3-yl]propanamide | N-[(1R)-2-[(2-ethyl-6-methylphenyl)amino]-2-oxo-1-(pyridin-3-yl)ethyl]-N-[6-(propan-2-yl)pyridin-3-yl]propanamide | XDS | 99.50% | 7.1 | Diamond (I04-1) | BUSTER | 2020-05-15 | - | - | - | - | - | N/A | - | - | 3C-like proteinase | 66.9 | - | No | - | - | 67.7 | 55.9 | 85.2 | - | |||||
5rh7 | 1.71 Å | 2020-05-27 | X-ray | UJ1 | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.50% | 22.02% | 10.30% | N-(5-tert-butyl-1H-pyrazol-3-yl)-N-[(1R)-2-[(2-ethyl-6-methylphenyl)amino]-2-oxo-1-(pyridin-3-yl)ethyl]propanamide | N-(5-tert-butyl-1H-pyrazol-3-yl)-N-[(1R)-2-[(2-ethyl-6-methylphenyl)amino]-2-oxo-1-(pyridin-3-yl)ethyl]propanamide | XDS | 98.90% | 6.5 | Diamond (I04-1) | BUSTER | 2020-05-15 | - | - | - | - | - | N/A | - | - | 3C-like proteinase | 68.4 | - | No | - | - | 64.8 | 64.3 | 83.1 | - | |||||
5rh8 | 1.81 Å | 2020-05-27 | X-ray | UHM | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 17.74% | 22.05% | 19.20% | 2-(cyanomethoxy)-N-[(1,2-thiazol-4-yl)methyl]benzamide | 2-(cyanomethoxy)-N-[(1,2-thiazol-4-yl)methyl]benzamide | XDS | 99.40% | 3.8 | Diamond (I04-1) | BUSTER | 2020-05-15 | - | - | - | - | - | N/A | - | - | 3C-like proteinase | 75.4 | - | No | - | - | 64.6 | 88.6 | 75.6 | - | |||||
5rh9 | 1.91 Å | 2020-05-27 | X-ray | UJ4 | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 17.23% | 22.50% | 21.00% | N-{4-[(1S)-1-methoxyethyl]phenyl}-N-[(1R)-2-[(4-methoxy-2-methylphenyl)amino]-2-oxo-1-(pyridin-3-yl)ethyl]propanamide | N-{4-[(1S)-1-methoxyethyl]phenyl}-N-[(1R)-2-[(4-methoxy-2-methylphenyl)amino]-2-oxo-1-(pyridin-3-yl)ethyl]propanamide | XDS | 99.50% | 4.0 | Diamond (I04-1) | BUSTER | 2020-05-15 | - | - | - | - | - | N/A | - | - | 3C-like proteinase | 64.2 | - | No | - | - | 60.1 | 78.5 | 64.5 | - | |||||
5rha | 1.51 Å | 2020-05-27 | X-ray | T8M | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 17.35% | 20.95% | 9.30% | 1-{4-[(thiophen-2-yl)methyl]piperazin-1-yl}ethan-1-one | 1-{4-[(thiophen-2-yl)methyl]piperazin-1-yl}ethan-1-one | XDS | 95.20% | 6.2 | Diamond (I04-1) | BUSTER | 2020-05-15 | - | - | - | - | - | N/A | - | - | 3C-like proteinase | 68.7 | - | No | - | - | 74.5 | 64.3 | 73.9 | - | |||||
6lnq | 2.24 Å | 2020-05-27 | X-ray | EJF | SARS-CoV | NSP5 (3CLpro) | Functional ligand | 19.92% | 23.91% | 12.20% | N-[(2S)-3-methyl-1-[[(2S)-4-methyl-1-oxidanylidene-1-[[(2S)-1-oxidanylidene-3-[(3S)-2-oxidanylidenepyrrolidin-3-yl]propan-2-yl]amino]pentan-2-yl]amino]-1-oxidanylidene-butan-2-yl]-1H-indole-2-carboxamide | N-[(2S)-3-methyl-1-[[(2S)-4-methyl-1-oxidanylidene-1-[[(2S)-1-oxidanylidene-3-[(3S)-2-oxidanylidenepyrrolidin-3-yl]propan-2-yl]amino]pentan-2-yl]amino]-1-oxidanylidene-butan-2-yl]-1H-indole-2-carboxamide | HKL-2000 | 99.90% | 16.88 | ROTATING ANODE () | PHENIX | 2020-01-01 | 32391184 | - | - | - | - | N/A | - | - | Severe Acute Respiratory Syndrome Coronavirus 3c Like Protease | 69.6 | - | No | - | 45.7 | 78.7 | 90.5 | - | ||||||
6lny | 2.25 Å | 2020-05-27 | X-ray | EOC | SARS-CoV | NSP5 (3CLpro) | Functional ligand | 20.41% | 25.27% | 9.00% | (2~{S})-4-methyl-~{N}-[(2~{S})-1-oxidanylidene-3-[(3~{S})-2-oxidanylidenepiperidin-3-yl]propan-2-yl]-2-[[(~{E})-3-phenylprop-2-enoyl]amino]pentanamide | (2~{S})-4-methyl-~{N}-[(2~{S})-1-oxidanylidene-3-[(3~{S})-2-oxidanylidenepiperidin-3-yl]propan-2-yl]-2-[[(~{E})-3-phenylprop-2-enoyl]amino]pentanamide | HKL-2000 | 98.70% | 21.68 | ROTATING ANODE () | PHENIX | 2020-01-02 | 32391184 | - | - | - | - | N/A | - | - | Replicase polyprotein 1a | 46.1 | - | No | - | 32.9 | 64.4 | 70.3 | - | ||||||
6lo0 | 1.94 Å | 2020-05-27 | X-ray | EOF | SARS-CoV | NSP5 (3CLpro) | Functional ligand | 22.73% | 26.84% | 10.60% | (2~{S})-4-methyl-~{N}-[(2~{S})-1-oxidanylidene-3-[(3~{S})-2-oxidanylidenepyrrolidin-3-yl]propan-2-yl]-2-[[(~{E})-3-phenylprop-2-enoyl]amino]pentanamide | (2~{S})-4-methyl-~{N}-[(2~{S})-1-oxidanylidene-3-[(3~{S})-2-oxidanylidenepyrrolidin-3-yl]propan-2-yl]-2-[[(~{E})-3-phenylprop-2-enoyl]amino]pentanamide | HKL-2000 | 99.50% | 19.21 | ROTATING ANODE () | PHENIX | 2020-01-02 | 32391184 | - | - | - | - | N/A | - | - | Replicase polyprotein 1a | 50.6 | - | No | - | 20.6 | 68.9 | 86.8 | - | ||||||
6m15 | 2.38 Å | 2020-05-27 | Cryo-EM | NAG | RH BAT CoV HKU2 | Spike | No functional ligands | N/A | N/A | N/A | 2-acetamido-2-deoxy-beta-D-glucopyranose | - | - | () | 2020-02-24 | 32555182 | - | - | - | - | N/A | - | - | Spike glycoprotein | N/A | - | No | - | N/A | N/A | N/A | - | |||||||||
6m16 | 2.83 Å | 2020-05-27 | Cryo-EM | NAG | SADS-CoV | Spike | No functional ligands | N/A | N/A | N/A | 2-acetamido-2-deoxy-beta-D-glucopyranose | - | - | () | 2020-02-24 | 32555182 | - | - | - | - | N/A | - | - | Spike glycoprotein | N/A | - | No | - | N/A | N/A | N/A | - | |||||||||
6wps | 3.10 Å | 2020-05-27 | Cryo-EM | NAG | SARS-CoV-2 | Spike | Pathogen-host interaction | N/A | N/A | N/A | 2-acetamido-2-deoxy-beta-D-glucopyranose | - | - | () | 2020-04-27 | 32422645 | - | - | - | - | N/A | - | - | spike glycoprotein - signaling sequence + ectodomain (UNP residues 14-1211) + foldon trimerization domain + TEV cleavage site + His-tag,signaling sequence + ectodomain (UNP residues 14-1211) + foldon trimerization domain + TEV cleavage site + His-tag; S309 neutralizing antibody heavy chain - Fab; S309 neutralizing antibody light chain - Fab | N/A | - | No | - | N/A | N/A | N/A | - | |||||||||
6wpt | 3.70 Å | 2020-05-27 | Cryo-EM | NAG | SARS-CoV-2 | Spike | Pathogen-host interaction | N/A | N/A | N/A | 2-acetamido-2-deoxy-beta-D-glucopyranose | - | - | () | 2020-04-27 | 32422645 | - | - | - | - | N/A | - | - | spike glycoprotein - signaling sequence + ectodomain (UNP residues 14-1211) + foldon trimerization domain + TEV cleavage site + His-tag,signaling sequence + ectodomain (UNP residues 14-1211) + foldon trimerization domain + TEV cleavage site + His-tag; S309 neutralizing antibody heavy chain - Fab; S309 neutralizing antibody light chain - Fab | N/A | - | No | - | N/A | N/A | N/A | - | |||||||||
6wzo | 1.42 Å | 2020-05-27 | X-ray | - | SARS-CoV-2 | Nucleocapsid | No functional ligands | 15.73% | 17.32% | N/A | - | XDS | 91.10% | 16.8 | APS (24-ID-E) | PHENIX | 2020-05-14 | 32654247 | - | - | - | - | N/A | - | - | Nucleoprotein | 86.0 | - | No | - | 94.3 | 88.1 | 90.4 | - | |||||||
6wzq | 1.45 Å | 2020-05-27 | X-ray | - | SARS-CoV-2 | Nucleocapsid | No functional ligands | 16.73% | 18.02% | 5.80% | - | XDS | 98.80% | 16.0 | APS (24-ID-E) | PHENIX | 2020-05-14 | 32654247 | - | - | - | - | N/A | - | - | Nucleoprotein | 67.3 | - | No | - | 92.1 | 36.7 | 81.0 | - | |||||||
6wzu | 1.79 Å | 2020-05-27 | X-ray | PO4 | SARS-CoV-2 | NSP3: PLpro | No functional ligands | 16.00% | 17.41% | 13.70% | PHOSPHATE ION | PHOSPHATE ION | HKL-3000 | 100.00% | 6.6 | APS (19-ID) | REFMAC | 2020-05-14 | 33531496 | ZN | - | - | - | N/A | - | - | Non-structural protein 3 | 66.5 | - | No | 94.1 | 32.3 | 81.7 | - | |||||||
6x1b | 1.97 Å | 2020-05-27 | X-ray | PO4 | SARS-CoV-2 | NSP15 | Functional ligand | 15.66% | 18.46% | 15.50% | DNA (5'-R(*GP*U)-3'); PHOSPHATE ION | PHOSPHATE ION | HKL-3000 | 100.00% | 16.0 | APS (19-ID) | PHENIX | 2020-05-18 | 33564093 | - | - | - | - | N/A | - | - | Uridylate-specific endoribonuclease; DNA (5'-R(*GP*U)-3') | 83.1 | - | No | - | 90.4 | 85.6 | 79.3 | - | ||||||
6x29 | 2.70 Å | 2020-05-27 | Cryo-EM | - | SARS-CoV-2 | Spike | No functional ligands | N/A | N/A | N/A | - | - | - | () | 2020-05-20 | 32699321 | - | - | - | - | N/A | - | - | Spike glycoprotein - ectodomain (UNP residues 16-1208) | N/A | - | No | - | N/A | N/A | N/A | - | |||||||||
6x2a | 3.30 Å | 2020-05-27 | Cryo-EM | - | SARS-CoV-2 | Spike | No functional ligands | N/A | N/A | N/A | - | - | - | () | 2020-05-20 | 32699321 | - | - | - | - | N/A | - | - | Spike glycoprotein - ectodomain (UNP residues 16-1208) | N/A | - | No | - | N/A | N/A | N/A | - | |||||||||
6x2b | 3.60 Å | 2020-05-27 | Cryo-EM | - | SARS-CoV-2 | Spike | No functional ligands | N/A | N/A | N/A | - | - | - | () | 2020-05-20 | 32699321 | - | - | - | - | N/A | - | - | Spike glycoprotein - ectodomain (UNP residues 16-1208) | N/A | - | No | - | N/A | N/A | N/A | - | |||||||||
6x2c | 3.20 Å | 2020-05-27 | Cryo-EM | - | SARS-CoV-2 | Spike | No functional ligands | N/A | N/A | N/A | - | - | - | () | 2020-05-20 | 32699321 | - | - | - | - | N/A | - | - | Spike glycoprotein - ectodomain (UNP residues 16-1208) | N/A | - | No | - | N/A | N/A | N/A | - | |||||||||
7bw4 | 3.70 Å | 2020-05-27 | Cryo-EM | - | SARS-CoV-2 | NSP7/NSP8/NSP12 | No functional ligands | N/A | N/A | N/A | - | - | - | () | PHENIX | 2020-04-13 | 32531208 | ZN | - | - | - | N/A | - | - | Replicase polyprotein 1ab; Replicase polyprotein 1ab; Replicase polyprotein 1ab | N/A | - | No | - | N/A | N/A | N/A | - | ||||||||
7c01 | 2.88 Å | 2020-05-27 | X-ray | NAG | SARS-CoV-2 | Spike | Functional ligand | 21.81% | 26.51% | N/A | 2-acetamido-2-deoxy-beta-D-glucopyranose | HKL-2000 | 99.90% | 12.2 | SSRF (BL17U1) | PHENIX | 2020-04-29 | 32454512 | - | - | - | - | N/A | - | - | SARS-Cov-2 Spike protein S1; CB6 heavy chain; CB6 light chain | 9.9 | - | No | - | 22.8 | 31.3 | 33.8 | - | |||||||
7c2i | 2.50 Å | 2020-05-27 | X-ray | SAM | SARS-CoV-2 | NSP10/NSP16 | Functional ligand | 17.40% | 20.88% | 20.40% | S-ADENOSYLMETHIONINE | S-ADENOSYLMETHIONINE | HKL-2000 | 100.00% | 10.67 | SSRF (BL19U1) | PHENIX | 2020-05-07 | 32728018 | ZN | - | - | - | N/A | - | - | Replicase polyprotein 1ab - nsp16; Replicase polyprotein 1ab - nsp10 | 64.3 | - | No | - | 75.1 | 39.9 | 88.5 | - | ||||||
7c2j | 2.80 Å | 2020-05-27 | X-ray | SAM | SARS-CoV-2 | NSP10/NSP16 | Functional ligand | 20.21% | 23.49% | 29.50% | S-ADENOSYLMETHIONINE | S-ADENOSYLMETHIONINE | HKL-2000 | 99.90% | 6.67 | SSRF (BL19U1) | PHENIX | 2020-05-07 | 32728018 | ZN | - | - | - | N/A | - | - | Replicase polyprotein 1ab - nsp16; Replicase polyprotein 1ab - nsp10 | 50.7 | - | No | - | 50.2 | 46.2 | 80.0 | - | ||||||
6m1v | 1.50 Å | 2020-06-03 | X-ray | - | SARS-CoV-2 | Spike | No functional ligands | 20.34% | 21.20% | N/A | - | HKL-2000 | 100.00% | 49.0 | SSRF (BL17U1) | PHENIX | 2020-02-26 | 32482145 | - | - | - | - | N/A | - | - | spike protein | 72.4 | - | No | - | 72.3 | 52.0 | 97.1 | - | |||||||
6m3w | 3.90 Å | 2020-06-03 | Cryo-EM | NAG | SARS-CoV | Spike | No functional ligands | N/A | N/A | N/A | 2-acetamido-2-deoxy-beta-D-glucopyranose | - | - | () | PHENIX | 2020-03-04 | 32681106 | - | - | - | - | N/A | - | - | Spike glycoprotein | N/A | - | No | - | N/A | N/A | N/A | - | ||||||||
6x4i | 1.85 Å | 2020-06-03 | X-ray | U3P, NA | SARS-CoV-2 | NSP15 | Functional ligand | 16.58% | 18.89% | 14.60% | 3'-URIDINEMONOPHOSPHATE; SODIUM ION | 3'-URIDINEMONOPHOSPHATE; SODIUM ION | HKL-3000 | 100.00% | 6.3 | APS (19-ID) | PHENIX | 2020-05-22 | 33564093 | - | - | - | - | N/A | - | - | Uridylate-specific endoribonuclease | 82.3 | - | No | 88.4 | 72.3 | 90.8 | - | |||||||
6yz5 | 1.80 Å | 2020-06-03 | X-ray | NAG | SARS-CoV-2 | Spike | No functional ligands | 16.58% | 19.33% | 10.90% | 2-acetamido-2-deoxy-beta-D-glucopyranose | XDS | 99.00% | 20.6 | Diamond (I03) | REFMAC | 2020-05-06 | - | - | - | - | - | N/A | - | - | Spike glycoprotein; Nanobody H11-D4 | 76.4 | - | No | - | - | 86.0 | 57.8 | 87.9 | - | ||||||
6yz7 | 3.30 Å | 2020-06-03 | X-ray | NAG | SARS-CoV-2 | Spike | No functional ligands | 23.77% | 26.88% | N/A | 2-acetamido-2-deoxy-beta-D-glucopyranose | XDS | 98.00% | 4.9 | Diamond (I03) | REFMAC | 2020-05-06 | - | - | - | - | - | N/A | - | - | Spike glycoprotein; Antibody Cr3022; Antibody light chain; Nanobody | 4.4 | - | No | - | - | 20.4 | 12.4 | 34.2 | - | ||||||
6z2m | 2.71 Å | 2020-06-03 | X-ray | NAG | SARS-CoV-2 | Spike | No functional ligands | 19.83% | 24.10% | 23.10% | 2-acetamido-2-deoxy-beta-D-glucopyranose | XDS | 99.00% | 7.4 | Diamond (I03) | PHENIX | 2020-05-17 | - | - | - | - | - | N/A | - | - | Spike glycoprotein; CR3022 antibody; CR3022 antibody; nanobody D4 | 27.7 | - | No | - | - | 43.8 | 52.0 | 35.3 | - | ||||||
6z43 | 3.30 Å | 2020-06-03 | Cryo-EM | NAG | SARS-CoV-2 | Spike | No functional ligands | N/A | N/A | N/A | 2-acetamido-2-deoxy-beta-D-glucopyranose | - | - | () | PHENIX | 2020-05-22 | - | - | - | - | - | N/A | - | - | Spike glycoprotein; Nanobody | N/A | - | No | - | - | N/A | N/A | N/A | - | |||||||
7bwj | 2.85 Å | 2020-06-03 | X-ray | NAG | SARS-CoV-2 | Spike | Protein-protein complex | 21.91% | 26.40% | 15.40% | 2-acetamido-2-deoxy-beta-D-glucopyranose | XDS | 99.90% | 14.3 | SSRF (BL17U) | PHENIX | 2020-04-14 | 32454513 | - | - | - | - | N/A | - | - | SARS-CoV-2 receptor binding domain; antibody light chain; antibody heavy chain | 29.2 | - | No | - | 23.6 | 72.3 | 38.2 | - | |||||||
7bzf | 3.26 Å | 2020-06-03 | Cryo-EM | - | SARS-CoV-2 | NSP7/NSP8/NSP12/RNA | Functional ligand | N/A | N/A | N/A | RNA (31-MER); RNA (5'-R(*UP*GP*UP*UP*CP*GP*AP*CP*GP*AP*CP*AP*CP*A)-3') | - | - | - | () | PHENIX | 2020-04-27 | 32526208 | ZN | - | - | - | N/A | - | - | RNA-directed RNA polymerase; Non-structural protein 8; Non-structural protein 7; RNA (31-MER); RNA (5'-R(*UP*GP*UP*UP*CP*GP*AP*CP*GP*AP*CP*AP*CP*A)-3') | N/A | - | No | - | N/A | N/A | N/A | RNA (5'-R(*UP*GP*UP*UP*CP*GP*AP*CP*GP*AP*CP*AP*CP*A)-3'); RNA (31-MER) | - | ||||||
7c2k | 2.93 Å | 2020-06-03 | Cryo-EM | - | SARS-CoV-2 | NSP7/NSP8/NSP12/RNA | Functional ligand | N/A | N/A | N/A | RNA (29-MER); RNA (5'-R(*UP*GP*UP*UP*CP*GP*AP*CP*GP*AP*CP*AP*CP*AP*GP*G*(F86)P*G)-3') | - | - | - | () | PHENIX | 2020-05-07 | 32526208 | ZN | - | - | - | N/A | - | - | RNA-directed RNA polymerase; Non-structural protein 8; Non-structural protein 7; RNA (29-MER); RNA (5'-R(*UP*GP*UP*UP*CP*GP*AP*CP*GP*AP*CP*AP*CP*AP*GP*G*(F86)P*G)-3') | N/A | - | No | - | N/A | N/A | N/A | RNA (29-MER); RNA (5'-R(*UP*GP*UP*UP*CP*GP*AP*CP*GP*AP*CP*AP*CP*AP*GP*G*(F86)P*G)-3') | - | ||||||
5rhb | 1.43 Å | 2020-06-10 | X-ray | USD | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 17.58% | 20.69% | 12.70% | (E)-1-(pyrimidin-2-yl)methanimine | (E)-1-(pyrimidin-2-yl)methanimine | XDS | 97.10% | 5.2 | Diamond (I04-1) | BUSTER | 2020-05-16 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 69.8 | - | No | - | 76.7 | 55.9 | 82.6 | - | ||||||
5rhc | 1.58 Å | 2020-06-10 | X-ray | USA | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 18.11% | 21.73% | 9.80% | (E)-1-(1H-imidazol-2-yl)methanimine | (E)-1-(1H-imidazol-2-yl)methanimine | XDS | 97.10% | 6.2 | Diamond (I04-1) | BUSTER | 2020-05-16 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 64.4 | - | No | - | 67.7 | 55.9 | 80.0 | - | ||||||
5rhd | 1.57 Å | 2020-06-10 | X-ray | US7 | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 17.22% | 20.59% | 8.60% | 1-[4-(methylsulfonyl)phenyl]piperazine | 1-[4-(methylsulfonyl)phenyl]piperazine | XDS | 99.50% | 7.1 | Diamond (I04-1) | BUSTER | 2020-05-16 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 72.8 | - | No | - | 77.5 | 73.6 | 71.3 | - | ||||||
5rhe | 1.56 Å | 2020-06-10 | X-ray | UPD | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 17.93% | 21.56% | 7.60% | 1-acetyl-N-(6-methoxypyridin-3-yl)piperidine-4-carboxamide | 1-acetyl-N-(6-methoxypyridin-3-yl)piperidine-4-carboxamide | XDS | 98.40% | 8.1 | Diamond (I04-1) | BUSTER | 2020-05-16 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 71.2 | - | No | - | 69.3 | 59.9 | 89.3 | - | ||||||
5rhf | 1.76 Å | 2020-06-10 | X-ray | UPJ | SARS-CoV-2 | NSP5 (3CLpro) | PanDDA fragment screening | 17.47% | 22.77% | 13.80% | 1-acetyl-N-methyl-N-phenylpiperidine-4-carboxamide | 1-acetyl-N-methyl-N-phenylpiperidine-4-carboxamide | XDS | 99.40% | 5.4 | Diamond (I04-1) | BUSTER | 2020-05-16 | 33028810 | - | - | - | - | N/A | - | - | 3C-like proteinase | 67.6 | - | No | - | 57.5 | 78.5 | 74.5 | - | ||||||
6x6p | 3.22 Å | 2020-06-10 | Cryo-EM | NAG | SARS-CoV-2 | Spike | No functional ligands | N/A | N/A | N/A | 2-acetamido-2-deoxy-beta-D-glucopyranose | - | - | () | PHENIX; phenix.real_space_refine | 2020-05-28 | 32587972 | - | - | - | - | N/A | - | - | SARS-CoV-2 spike glycoprotein | N/A | - | No | - | N/A | N/A | N/A | - | ||||||||
7byr | 3.84 Å | 2020-06-10 | Cryo-EM | NAG | SARS-CoV-2 | Spike | Pathogen-host interaction | N/A | N/A | N/A | 2-acetamido-2-deoxy-beta-D-glucopyranose | - | - | () | PHENIX | 2020-04-24 | 32425270 | - | - | - | - | N/A | - | - | SARS-CoV-2 Spike glycoprotein; Ab23-Fab-Heavy Chain; Ab23-Fab-Light Chain | N/A | - | No | - | N/A | N/A | N/A | - | ||||||||
6m5i | 2.50 Å | 2020-06-17 | X-ray | - | SARS-CoV-2 | NSP7/NSP8 | No functional ligands | 20.80% | 29.17% | N/A | - | 99.70% | 8.01 | SSRF (BL17U) | PHENIX | 2020-03-10 | - | - | - | - | - | N/A | - | - | SARS-CoV-2 nsp8; SARS-CoV-2 nsp7 | 6.3 | - | No | - | - | 9.5 | 49.1 | 17.0 | - | |||||||
6xa4 | 1.65 Å | 2020-06-17 | X-ray | - | SARS-CoV-2 | NSP5 (3CLpro) | Functional ligand | 19.82% | 23.93% | 6.50% | inhibitor UAW241 | - | HKL-3000 | 98.20% | 8.2 | APS (19-ID) | REFMAC | 2020-06-03 | 33158912 | - | - | http://covid-19.bioreproducibility.org/static/data/6xa4/6xa4_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6xa4/6xa4_refined.mtz | 24.80% | Achesymed, flipped His41 for proper H-bonding. | The coordinates are NOT in a standardized location in the unit cell. | main protease - UNP residues 3264-3569; inhibitor UAW241 | 56.2 | minimal | Yes | Yes | - | 45.5 | 60.2 | 81.4 | - | |||||
6xa9 | 2.90 Å | 2020-06-17 | X-ray | - | SARS-CoV-2 | NSP3: PLpro | No functional ligands | 19.97% | 23.05% | 16.30% | - | XDS | 100.00% | 10.5 | Australian Synchrotron (MX2) | PHENIX | 2020-06-04 | 32845033 | ZN | - | - | - | N/A | - | - | Papain-like protease - UNP residues 1563-1878; ISG15 CTD-propargylamide - C-terminal domain (UNP residues 79-157) | 40.5 | - | No | - | 54.5 | 22.9 | 79.3 | - | |||||||
6xaa | 2.70 Å | 2020-06-17 | X-ray | - | SARS-CoV-2 | NSP3: PLpro | No functional ligands | 20.96% | 25.99% | 15.20% | - | XDS | 98.10% | 6.8 | Australian Synchrotron (MX2) | PHENIX | 2020-06-04 | 32845033 | ZN | - | http://covid-19.bioreproducibility.org/static/data/6xaa/6xaa_refined_tls.pdb | http://covid-19.bioreproducibility.org/static/data/6xaa/6xaa_refined.mtz | 26.00% | Shifted the coordinates into the reference unit cell with ACHESYM. Added side-chains for residues: 23A, 25A, 30A, 43A, 47A, 53A, 60A, 65A, 70A, 143A, 218A, 24B. 291A - rotated. Added 18 water molecules | Many missing side-chains. Not in the standard position in the unit cell | Papain-like protease - UNP residues 1563-1878; Ubiquitin-propargylamide | 18.6 | moderate | Yes | Yes | - | 26.8 | 20.3 | 64.3 | - | ||||||
6xb0 | 1.80 Å | 2020-06-17 | X-ray | - | SARS-CoV-2 | NSP5 (3CLpro) | No functional ligands | 15.45% | 20.10% | N/A | - | CrysalisPro | 97.20% | 10.2 | ROTATING ANODE () | PHENIX | 2020-06-05 | 33063790 | - | - | http://covid-19.bioreproducibility.org/static/data/6xb0/6xb0_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6xb0/6xb0_refined.mtz | 20.25% | Reindexed from I2 to C2 (-h-l,k,h); transformed by ACHESYM; changed DMSO to HOH. | Non-standard space group, while standard C2 would make it compatible with many other structures of this protein. | 3C-like proteinase | 71.5 | minimal | Yes | Yes | - | 81.0 | 52.2 | 86.1 | - | ||||||
6xb1 | 1.80 Å | 2020-06-17 | X-ray | NEN | SARS-CoV-2 | NSP5 (3CLpro) | Functional ligand | 15.87% | 20.19% | N/A | 1-ETHYL-PYRROLIDINE-2,5-DIONE | 1-ETHYL-PYRROLIDINE-2,5-DIONE | CrysalisPro | 94.80% | 10.0 | ROTATING ANODE () | PHENIX | 2020-06-05 | 33063790 | - | - | http://covid-19.bioreproducibility.org/static/data/6xb1/6xb1_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6xb1/6xb1_refined.mtz | 21.02% | Reindexed from I2 to C2 (-h-l,k,h); transformed by ACHESYM; removed inhibitor NEN from Cys156. | Non-standard space group, while standard C2 would make it compatible with many other structures of this protein. | 3C-like proteinase | 72.6 | significant | Yes | Yes | - | 80.5 | 60.1 | 81.3 | - | |||||
6xb2 | 2.10 Å | 2020-06-17 | X-ray | NEN | SARS-CoV-2 | NSP5 (3CLpro) | Functional ligand | 19.56% | 25.72% | N/A | 1-ETHYL-PYRROLIDINE-2,5-DIONE | 1-ETHYL-PYRROLIDINE-2,5-DIONE | CrysalisPro | 99.90% | 11.3 | ROTATING ANODE () | PHENIX | 2020-06-05 | 33063790 | - | - | http://covid-19.bioreproducibility.org/static/data/6xb2/6xb2_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6xb2/6xb2_refined.mtz | 28.23% | Reindexed from I2 to C2 (-h-l,k,h); transformed by ACHESYM; removed inhibitor NEN from Cys145 & Cys156; changed DMSO to HOH. | Non-standard space group, while standard C2 would make it compatible with many other structures of this protein. | 3C-like proteinase | 14.7 | significant | Yes | Yes | - | 28.9 | 26.6 | 46.5 | - | |||||
6xbg | 1.45 Å | 2020-06-17 | X-ray | - | SARS-CoV-2 | NSP5 (3CLpro) | Functional ligand | 18.14% | 20.57% | 8.60% | inhibitor UAW246; SODIUM ION | SODIUM ION | HKL-3000 | 98.70% | 9.5 | APS (19-ID) | REFMAC | 2020-06-05 | 33158912 | - | - | http://covid-19.bioreproducibility.org/static/data/6xbg/6xbg_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6xbg/6xbg_refined.mtz | 18.10% | Achesymed, used anisotropic ADPs. | The coordinates are NOT in a standardized location in the unit cell. | main protease - UNP residues 3264-3569; inhibitor UAW246 | 47.3 | minimal | Yes | Yes | - | 77.6 | 24.4 | 67.8 | - | |||||
6xbh | 1.60 Å | 2020-06-17 | X-ray | - | SARS-CoV-2 | NSP5 (3CLpro) | Functional ligand | 17.35% | 22.07% | 6.80% | SODIUM ION; inhibitor UAW247 | SODIUM ION | HKL-3000 | 95.10% | 8.8 | APS (19-ID) | REFMAC | 2020-06-06 | 33158912 | - | - | http://covid-19.bioreproducibility.org/static/data/6xbh/6xbh_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6xbh/6xbh_refined.mtz | 20.70% | Achesymed. Na changed to HOH. Single orientation of glycerol. His41 flipped. TLS applied (6 TLS groups). | The coordinates are NOT in a standardized location in the unit cell. | main protease - UNP residues 3264-3569; inhibitor UAW247 | 67.6 | minimal | Yes | Yes | - | 64.5 | 68.7 | 77.2 | - | |||||
6xbi | 1.70 Å | 2020-06-17 | X-ray | - | SARS-CoV-2 | NSP5 (3CLpro) | Functional ligand | 17.32% | 21.66% | 8.30% | inhibitor UAW248; SODIUM ION | SODIUM ION | HKL-3000 | 85.20% | 23.99 | APS (19-ID) | REFMAC | 2020-06-06 | 33158912 | - | - | http://covid-19.bioreproducibility.org/static/data/6xbi/6xbi_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6xbi/6xbi_refined.mtz | 22.60% | Achesymed. | The coordinates are NOT in a standardized location in the unit cell. | main protease - UNP residues 3264-3569; inhibitor UAW248 | 73.8 | minimal | Yes | Yes | - | 68.4 | 83.7 | 72.8 | - | |||||
6xch | 2.20 Å | 2020-06-17 | X-ray | - | SARS-CoV-2 | NSP5 (3CLpro) | Functional ligand | 19.70% | 23.70% | N/A | Leupeptin | - | CrysalisPro | 98.30% | 6.3 | ROTATING ANODE () | PHENIX | 2020-06-08 | 33152262 | - | - | http://covid-19.bioreproducibility.org/static/data/6xch/6xch_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6xch/6xch_refined.mtz | 24.03% | Reindexed from I2 to C2 (-h-l,k,h); transformed by ACHESYM. | Non-standard space group, while standard C2 would make it compatible with many other structures of this protein. | 3C-like proteinase; Leupeptin | 45.5 | minimal | Yes | Yes | - | 47.7 | 45.9 | 72.7 | - | |||||
6xdc | 2.90 Å | 2020-06-17 | Cryo-EM | - | SARS-CoV-2 | ORF3a | No functional ligands | N/A | N/A | N/A | - | - | - | () | PHENIX; phenix.real_space_refine | 2020-06-10 | 34158638 | - | - | - | - | N/A | - | - | Protein 3a | N/A | - | No | - | N/A | N/A | N/A | - | ||||||||
6xdh | 2.35 Å | 2020-06-17 | X-ray | FMT | SARS-CoV-2 | NSP15 | No functional ligands | 15.72% | 18.25% | 7.70% | FORMIC ACID | FORMIC ACID | XDS | 100.00% | 22.57 | APS (21-ID-F) | PHENIX | 2020-06-10 | - | - | - | - | - | N/A | - | - | Uridylate-specific endoribonuclease - BewuA.18928.a.MX151 | 80.0 | - | No | - | 91.2 | 62.3 | 89.3 | - | ||||||
6z2e | 1.70 Å | 2020-06-17 | X-ray | Q5T, NA | SARS-CoV-2 | NSP5 (3CLpro) | Functional ligand | 19.20% | 24.34% | 7.40% | (4~{S})-4-[[(2~{S})-2-[[(2~{S})-2-[[(2~{S})-2-[3-[2-[2-[2-[2-[5-[(3~{a}~{S},4~{R},6~{a}~{R})-2-oxidanylidene-3,3~{a},4,6~{a}-tetrahydro-1~{H}-thieno[3,4-d]imidazol-4-yl]pentanoylamino]ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]butanoyl]amino]-3,3-dimethyl-butanoyl]amino]-4-methyl-pentanoyl]amino]-6-methylsulfonyl-hexanamide; SODIUM ION | (4~{S})-4-[[(2~{S})-2-[[(2~{S})-2-[[(2~{S})-2-[3-[2-[2-[2-[2-[5-[(3~{a}~{S},4~{R},6~{a}~{R})-2-oxidanylidene-3,3~{a},4,6~{a}-tetrahydro-1~{H}-thieno[3,4-d]imidazol-4-yl]pentanoylamino]ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]butanoyl]amino]-3,3-dimethyl-butanoyl]amino]-4-methyl-pentanoyl]amino]-6-methylsulfonyl-hexanamide; SODIUM ION | XDS | 100.00% | 32.4 | PETRA III, DESY (P11) | REFMAC | 2020-05-15 | - | - | - | http://covid-19.bioreproducibility.org/static/data/6z2e/6z2e_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6z2e/6z2e_refined.mtz | 25.50% | Achesymed. Na 404 removed. Cl 403 changed to HOH. Q5T from C42 removed. Inserted EDO at the end of the inhibitor. | The coordinates are NOT in a standardized location in the unit cell. | Main Protease | 49.1 | minimal | Yes | Yes | - | - | 41.6 | 56.1 | 75.6 | - | ||||
6z4u | 1.95 Å | 2020-06-17 | X-ray | 15P | SARS-CoV-2 | ORF9B | No functional ligands | 21.75% | 25.67% | 12.30% | POLYETHYLENE GLYCOL (N=34) | POLYETHYLENE GLYCOL (N=34) | DIALS | 99.30% | 8.5 | NSLS-II (17-ID-2) | REFMAC | 2020-05-25 | - | - | - | - | - | N/A | - | - | Protein 9b | 28.8 | - | No | - | - | 29.4 | 55.3 | 48.7 | - | |||||
7bq7 | 2.37 Å | 2020-06-17 | X-ray | SAM | SARS-CoV-2 | NSP10/NSP16 | Protein-protein complex | 17.98% | 20.85% | N/A | S-ADENOSYLMETHIONINE | S-ADENOSYLMETHIONINE | HKL-3000 | 99.70% | 18.8 | SSRF (BL17U) | PHENIX | 2020-03-24 | - | ZN | - | - | - | N/A | - | - | SARS-CoV-2 nsp16; SARS-CoV-2 nsp10 | 46.4 | - | No | - | - | 75.3 | 48.2 | 44.6 | - | |||||
7c8r | 2.30 Å | 2020-06-17 | X-ray | TG3 | SARS-CoV-2 | NSP5 (3CLpro) | Functional ligand | 20.02% | 24.83% | N/A | ethyl (4R)-4-[[(2S)-4-methyl-2-[[(2S,3R)-3-[(2-methylpropan-2-yl)oxy]-2-(phenylmethoxycarbonylamino)butanoyl]amino]pentanoyl]amino]-5-[(3S)-2-oxidanylidenepyrrolidin-3-yl]pentanoate | ethyl (4R)-4-[[(2S)-4-methyl-2-[[(2S,3R)-3-[(2-methylpropan-2-yl)oxy]-2-(phenylmethoxycarbonylamino)butanoyl]amino]pentanoyl]amino]-5-[(3S)-2-oxidanylidenepyrrolidin-3-yl]pentanoate | HKL-3000 | 99.80% | 22.9 | NSRRC (TPS 05A) | REFMAC | 2020-06-03 | - | - | - | http://covid-19.bioreproducibility.org/static/data/7c8r/7c8r_refined.pdb | http://covid-19.bioreproducibility.org/static/data/7c8r/7c8r_refined.mtz | 26.10% | Very minimal adjustments to bonds and angles of the inhibitor only. | Very minimal adjustments to bonds and angles of the inhibitor required. | 3C-like proteinase | 17.3 | minimal | Yes | Yes | - | - | 36.8 | 37.0 | 34.5 | - | ||||
7c8t | 2.05 Å | 2020-06-17 | X-ray | NOL | SARS-CoV-2 | NSP5 (3CLpro) | Functional ligand | 18.43% | 23.34% | N/A | N-[(BENZYLOXY)CARBONYL]-O-(TERT-BUTYL)-L-THREONYL-3-CYCLOHEXYL-N-[(1S)-2-HYDROXY-1-{[(3S)-2-OXOPYRROLIDIN-3-YL]METHYL}ETHYL]-L-ALANINAMIDE | N-[(BENZYLOXY)CARBONYL]-O-(TERT-BUTYL)-L-THREONYL-3-CYCLOHEXYL-N-[(1S)-2-HYDROXY-1-{[(3S)-2-OXOPYRROLIDIN-3-YL]METHYL}ETHYL]-L-ALANINAMIDE | HKL-2000 | 99.90% | 39.5 | NSRRC (TPS 05A) | REFMAC | 2020-06-03 | - | - | - | http://covid-19.bioreproducibility.org/static/data/7c8t/7c8t_refined.pdb | http://covid-19.bioreproducibility.org/static/data/7c8t/7c8t_refined.mtz | 25.20% | Achesymed, changed TLS to 6 groups. | The coordinates are NOT in a standardized location in the unit cell. | 3C-like proteinase | 21.0 | minimal | Yes | Yes | - | - | 51.6 | 19.2 | 45.9 | - | ||||
6xdg | 3.90 Å | 2020-06-24 | Cryo-EM | - | SARS-CoV-2 | Spike | Pathogen-host interaction | N/A | N/A | N/A | - | - | - | () | PHENIX | 2020-06-10 | 32540901 | - | - | - | - | N/A | - | - | Spike glycoprotein - receptor binding domain (UNP residues 319-541); REGN10933 antibody Fab fragment light chain; REGN10933 antibody Fab fragment heavy chain; REGN10987 antibody Fab fragment heavy chain; REGN10987 antibody Fab fragment light chain | N/A | - | No | - | N/A | N/A | N/A | - | ||||||||
6xfn | 1.70 Å | 2020-06-24 | X-ray | - | SARS-CoV-2 | NSP5 (3CLpro) | Functional ligand | 19.54% | 22.82% | 6.50% | UAW243 | - | HKL-3000 | 98.90% | 8.7 | APS (19-ID) | REFMAC | 2020-06-15 | 33158912 | - | - | http://covid-19.bioreproducibility.org/static/data/6xfn/6xfn_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6xfn/6xfn_refined.mtz | 23.33% | Achesymed and added TLS. The incorrect chirality of the P1’ norleucine of the inhibitor was corrected. | Incorrect chirality of the P1’ norleucine of the inhibitor. The coordinates are NOT in a standardized location in the unit cell. | main protease - UNP residues 3264-3569; UAW243 | 53.4 | minimal | Yes | Yes | - | 56.8 | 56.0 | 68.9 | - | |||||
6xg3 | 2.48 Å | 2020-06-24 | X-ray | PO4 | SARS-CoV-2 | NSP3: PLpro | No functional ligands | 15.13% | 19.30% | 16.70% | PHOSPHATE ION | PHOSPHATE ION | HKL-3000 | 100.00% | 3.7 | APS (19-ID) | REFMAC | 2020-06-16 | 33531496 | ZN | - | - | - | N/A | - | - | Peptidase C16 | 69.6 | - | No | 86.1 | 46.6 | 82.0 | - | |||||||
6zct | 2.55 Å | 2020-06-24 | X-ray | - | SARS-CoV-2 | NSP10 | No functional ligands | 18.95% | 19.46% | 11.40% | - | XDS | 100.00% | 11.42 | MAX IV (BioMAX) | PHENIX | 2020-06-12 | 33036230 | ZN | - | - | - | N/A | - | - | nsp10 | 68.1 | - | No | - | 85.2 | 53.1 | 73.3 | - | |||||||
6zcz | 2.65 Å | 2020-06-24 | X-ray | NAG | SARS-CoV-2 | Spike | Protein-protein complex | 21.46% | 25.95% | 20.90% | 2-acetamido-2-deoxy-beta-D-glucopyranose | xia2 | 99.20% | 5.0 | Diamond (I03) | PHENIX; PHENIX | 2020-06-12 | 32737466 | MG | - | - | - | N/A | - | - | Spike glycoprotein; Nanobody; EY6A heavy chain; EY6A light chain | 23.7 | - | No | - | 27.0 | 30.8 | 64.8 | - | |||||||
6zer | 3.80 Å | 2020-06-24 | X-ray | NAG, PO4 | SARS-CoV-2 | Spike | Protein-protein complex | 21.19% | 25.11% | 22.70% | PHOSPHATE ION | 2-acetamido-2-deoxy-beta-D-glucopyranose; PHOSPHATE ION | xia2 | 100.00% | 7.3 | Diamond (I03) | PHENIX | 2020-06-16 | 32737466 | - | - | - | - | N/A | - | - | RBD; heavy chain; light chain | 13.0 | - | No | - | 34.1 | 14.7 | 48.4 | - | ||||||
7c8u | 2.35 Å | 2020-06-24 | X-ray | K36 | SARS-CoV-2 | NSP5 (3CLpro) | Protein-protein complex | 21.15% | 27.28% | 6.50% | (1S,2S)-2-({N-[(benzyloxy)carbonyl]-L-leucyl}amino)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid | (1S,2S)-2-({N-[(benzyloxy)carbonyl]-L-leucyl}amino)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid | XDS | 99.20% | 9.7 | CLSI (08ID-1) | REFMAC | 2020-06-03 | - | - | - | http://covid-19.bioreproducibility.org/static/data/7c8u/7c8u_refined.pdb | http://covid-19.bioreproducibility.org/static/data/7c8u/7c8u_refined.mtz | N/A | - | - | Replicase polyprotein 1ab | 27.2 | - | Yes | - | - | 18.0 | 42.1 | 69.8 | - | |||||
7c8v | 2.15 Å | 2020-06-24 | X-ray | NAG | SARS-CoV-2 | Spike | Protein-protein complex | 18.36% | 22.39% | 16.30% | 2-acetamido-2-deoxy-beta-D-glucopyranose | XDS | 100.00% | 10.2 | SSRF (BL19U1) | PHENIX; PHENIX | 2020-06-03 | 34330908 | - | - | - | - | N/A | - | - | Synthetic nanobody SR4; Spike glycoprotein - Receptor binding domain (RBD) | 68.1 | - | No | - | 61.4 | 79.2 | 71.0 | - | |||||||
7c8w | 2.77 Å | 2020-06-24 | X-ray | - | SARS-CoV-2 | Spike | Protein-protein complex | 20.50% | 26.68% | 27.60% | - | XDS | 100.00% | 11.1 | SSRF (BL19U1) | PHENIX; PHENIX | 2020-06-03 | 34330908 | - | - | - | - | N/A | - | - | Synthetic nanobody MR17; Spike glycoprotein - Receptor binding domain | 16.9 | - | No | - | 21.8 | 41.1 | 44.4 | - | |||||||
7can | 2.94 Å | 2020-06-24 | X-ray | - | SARS-CoV-2 | Spike | Protein-protein complex | 21.44% | 26.71% | 22.70% | - | XDS | 99.90% | 12.4 | SSRF (BL19U1) | PHENIX | 2020-06-09 | 34330908 | - | - | - | - | N/A | - | - | sybody MR17-K99Y; Spike glycoprotein - Receptor-binding domain (RBD) | 14.1 | - | No | - | 21.4 | 40.7 | 38.3 | - | |||||||
6xcm | 3.42 Å | 2020-07-01 | Cryo-EM | NAG | SARS-CoV-2 | Spike | Pathogen-host interaction | N/A | N/A | N/A | 2-acetamido-2-deoxy-beta-D-glucopyranose | - | - | () | PHENIX | 2020-06-08 | 32645326 | - | - | - | - | N/A | - | - | Spike glycoprotein; C105 Fab Heavy Chain; C105 Fab Light Chain | N/A | - | No | - | N/A | N/A | N/A | - | ||||||||
6xcn | 3.66 Å | 2020-07-01 | Cryo-EM | NAG | SARS-CoV-2 | Spike | Pathogen-host interaction | N/A | N/A | N/A | 2-acetamido-2-deoxy-beta-D-glucopyranose | - | - | () | PHENIX | 2020-06-08 | 32645326 | - | - | - | - | N/A | - | - | Spike glycoprotein; C105 Fab Heavy Chain; C105 Fab Light Chain | N/A | - | No | - | N/A | N/A | N/A | - | ||||||||
6xe1 | 2.75 Å | 2020-07-01 | X-ray | NAG | SARS-CoV-2 | Spike | Protein-protein complex | 21.16% | 23.94% | 3.07% | 2-acetamido-2-deoxy-beta-D-glucopyranose | XDS | 99.93% | 13.01 | APS (19-ID) | PHENIX | 2020-06-11 | 33110068 | - | - | - | - | N/A | - | - | CV30 Fab Heavy chain; CV30 Fab Kappa chain; Spike protein S1 - receptor binding domain | 36.5 | - | No | - | 45.4 | 33.5 | 70.1 | - | |||||||
6xhu | 1.80 Å | 2020-07-01 | X-ray | - | SARS-CoV-2 | NSP5 (3CLpro) | No functional ligands | 20.21% | 24.64% | N/A | - | CrysalisPro | 99.20% | 0.026 | ROTATING ANODE () | PHENIX | 2020-06-19 | 33063790 | - | - | http://covid-19.bioreproducibility.org/static/data/6xhu/6xhu_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6xhu/6xhu_refined.mtz | 24.70% | Placed the coordinates in a standardized location in the unit cell using ACHESYM. | The coordinates are NOT in a standardized location in the unit cell. | 3C-like proteinase | 46.6 | minimal | Yes | Yes | - | 38.7 | 44.2 | 85.6 | - | ||||||
6xip | 1.50 Å | 2020-07-01 | X-ray | - | SARS-CoV-2 | NSP7/NSP8 | Protein-protein complex | 16.07% | 19.91% | 5.80% | - | HKL-3000 | 97.70% | 30.2 | APS (19-ID) | PHENIX | 2020-06-20 | 34197805 | - | - | - | - | N/A | - | - | Non-structural protein 7; Non-structural protein 8 | 64.2 | - | No | - | 82.3 | 38.7 | 82.3 | - | |||||||
6z97 | 3.40 Å | 2020-07-01 | Cryo-EM | NAG | SARS-CoV-2 | Spike | No functional ligands | N/A | N/A | N/A | 2-acetamido-2-deoxy-beta-D-glucopyranose | - | - | () | PHENIX | 2020-06-03 | 32585135 | - | - | - | - | N/A | - | - | Spike glycoprotein,Fibritin | N/A | - | No | - | N/A | N/A | N/A | - | ||||||||
6zco | 1.36 Å | 2020-07-01 | X-ray | - | SARS-CoV-2 | Nucleocapsid | No functional ligands | 14.95% | 19.62% | N/A | - | XDS | 97.80% | 20.2 | SLS (X06DA) | REFMAC | 2020-06-11 | 33039147 | - | - | - | - | N/A | - | - | Nucleoprotein - Dimerization domain | 64.0 | - | No | - | 84.2 | 26.9 | 91.7 | - | |||||||
6zdh | 3.70 Å | 2020-07-01 | Cryo-EM | NAG | SARS-CoV-2 | Spike | Pathogen-host interaction | N/A | N/A | N/A | 2-acetamido-2-deoxy-beta-D-glucopyranose | - | - | () | PHENIX | 2020-06-14 | 32737466 | - | - | - | - | N/A | - | - | Spike glycoprotein; EY6A heavy chain; EY6A light chain | N/A | - | No | - | N/A | N/A | N/A | - | ||||||||
6zge | 2.60 Å | 2020-07-01 | Cryo-EM | NAG | SARS-CoV-2 | Spike | No functional ligands | N/A | N/A | N/A | 2-acetamido-2-deoxy-beta-D-glucopyranose | - | - | () | PHENIX | 2020-06-18 | 32647346 | - | - | - | - | N/A | - | - | Spike glycoprotein | N/A | - | No | - | N/A | N/A | N/A | - | ||||||||
6zgf | 3.10 Å | 2020-07-01 | Cryo-EM | NAG | Bat-CoV-RaTG13 | Spike | No functional ligands | N/A | N/A | N/A | 2-acetamido-2-deoxy-beta-D-glucopyranose | - | - | () | 2020-06-18 | 32647346 | - | - | - | - | N/A | - | - | Spike glycoprotein | N/A | - | No | - | N/A | N/A | N/A | - | |||||||||
6zgg | 3.80 Å | 2020-07-01 | Cryo-EM | - | SARS-CoV-2 | Spike | No functional ligands | N/A | N/A | N/A | - | - | - | () | 2020-06-18 | 32647346 | - | - | - | - | N/A | - | - | Spike glycoprotein | N/A | - | No | - | N/A | N/A | N/A | - | |||||||||
6zgh | 6.80 Å | 2020-07-01 | Cryo-EM | - | SARS-CoV-2 | Spike | No functional ligands | N/A | N/A | N/A | - | - | - | () | 2020-06-18 | 32647346 | - | - | - | - | N/A | - | - | Receptor-type tyrosine-protein phosphatase S,Spike glycoprotein,Fibritin | N/A | - | No | - | N/A | N/A | N/A | - | |||||||||
6zgi | 2.90 Å | 2020-07-01 | Cryo-EM | NAG | SARS-CoV-2 | Spike | No functional ligands | N/A | N/A | N/A | 2-acetamido-2-deoxy-beta-D-glucopyranose | - | - | () | PHENIX | 2020-06-18 | 32647346 | - | - | - | - | N/A | - | - | Spike glycoprotein | N/A | - | No | - | N/A | N/A | N/A | - | ||||||||
7c2l | 3.10 Å | 2020-07-01 | Cryo-EM | NAG | SARS-CoV-2 | Spike | Protein-protein complex | N/A | N/A | N/A | 2-acetamido-2-deoxy-beta-D-glucopyranose | - | - | () | 2020-05-08 | 32571838 | - | - | - | - | N/A | - | - | Spike glycoprotein; heavy chain of 4A8; light chain of 4A8 | N/A | - | No | - | N/A | N/A | N/A | - | |||||||||
6xc2 | 3.11 Å | 2020-07-08 | X-ray | NAG | SARS-CoV-2 | Spike | Protein-protein complex | 21.34% | 26.74% | 16.00% | 2-acetamido-2-deoxy-beta-D-glucopyranose | HKL-2000 | 88.30% | 7.4 | SSRL (BL12-1) | PHENIX | 2020-06-08 | 32661058 | - | - | - | - | N/A | - | - | Spike protein S1; CC12.1 light chain; CC12.1 heavy chain | 25.9 | - | No | - | 21.3 | 69.4 | 36.6 | - | |||||||
6xc3 | 2.70 Å | 2020-07-08 | X-ray | - | SARS-CoV-2 | Spike | Protein-protein complex | 17.73% | 22.53% | 16.70% | - | HKL-2000 | 99.90% | 5.0 | SSRL (BL12-1) | PHENIX | 2020-06-08 | 32661058 | - | - | - | - | N/A | - | - | CR3022 heavy chain; CR3022 light chain; CC12.1 light chain; CC12.1 heavy chain; Spike protein S1 | 63.1 | - | No | - | 59.9 | 84.3 | 56.9 | - | |||||||
6xc4 | 2.34 Å | 2020-07-08 | X-ray | NAG | SARS-CoV-2 | Spike | Protein-protein complex | 18.40% | 21.92% | 14.30% | 2-acetamido-2-deoxy-beta-D-glucopyranose | HKL-2000 | 98.70% | 10.2 | SSRL (BL12-1) | PHENIX | 2020-06-08 | 32661058 | - | - | - | - | N/A | - | - | Spike protein S1; CC12.3 heavy chain; CC12.3 light chain | 46.1 | - | No | - | 65.8 | 37.7 | 64.1 | - | |||||||
6xc7 | 2.88 Å | 2020-07-08 | X-ray | - | SARS-CoV-2 | Spike | Protein-protein complex | 21.89% | 25.91% | 12.90% | - | HKL-2000 | 99.90% | 5.7 | SSRL (BL12-1) | PHENIX | 2020-06-08 | 32661058 | - | - | - | - | N/A | - | - | Spike protein S1; CR3022 heavy chain; CR3022 light chain; CC12.3 heavy chain; CC12.3 light chain | 28.7 | - | No | - | 27.2 | 65.0 | 40.9 | - | |||||||
6xhl | 1.47 Å | 2020-07-08 | X-ray | V2M | SARS-CoV | NSP5 (3CLpro) | Functional ligand | 20.35% | 22.29% | 4.70% | N-[(2S)-1-({(2S)-4-hydroxy-3-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl}amino)-4-methyl-1-oxopentan-2-yl]-4-methoxy-1H-indole-2-carboxamide | N-[(2S)-1-({(2S)-4-hydroxy-3-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl}amino)-4-methyl-1-oxopentan-2-yl]-4-methoxy-1H-indole-2-carboxamide | autoPROC | 74.20% | 12.6 | APS (17-ID) | BUSTER | 2020-06-19 | 33054210 | - | - | - | - | N/A | - | - | 3C-like proteinase | 43.4 | - | No | - | 62.4 | 34.6 | 65.5 | - | ||||||
6xhm | 1.41 Å | 2020-07-08 | X-ray | V2M | SARS-CoV-2 | NSP5 (3CLpro) | Functional ligand | 19.08% | 20.96% | 4.70% | N-[(2S)-1-({(2S)-4-hydroxy-3-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl}amino)-4-methyl-1-oxopentan-2-yl]-4-methoxy-1H-indole-2-carboxamide | N-[(2S)-1-({(2S)-4-hydroxy-3-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl}amino)-4-methyl-1-oxopentan-2-yl]-4-methoxy-1H-indole-2-carboxamide | autoPROC | 75.00% | 12.3 | APS (17-ID) | BUSTER | 2020-06-19 | 33054210 | - | - | http://covid-19.bioreproducibility.org/static/data/6xhm/6xhm_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6xhm/6xhm_refined.mtz | 19.20% | Added 2 residues at the C terminus of chain A and 15 waters. Fixed a number of fairly crazy problems with residue occupancies and modified residues A: 41, 106, 110, 125, 139, 222, B: 6, 22, 86, 108, 117, 121, 123, 125. Achesymed and refined with anisotropic B factors. | Missing residues at the C terminus, occupancy problems, coordinates not in standardized location. | 3C-like proteinase | 69.0 | minimal | Yes | Yes | - | 74.4 | 48.4 | 90.7 | - | |||||
6xhn | 1.38 Å | 2020-07-08 | X-ray | V3D | SARS-CoV | NSP5 (3CLpro) | Functional ligand | 22.20% | 24.67% | 5.70% | (3S)-3-{[N-(4-methoxy-1H-indole-2-carbonyl)-L-leucyl]amino}-2-oxo-4-[(3S)-2-oxopyrrolidin-3-yl]butyl 2-cyanobenzoate | (3S)-3-{[N-(4-methoxy-1H-indole-2-carbonyl)-L-leucyl]amino}-2-oxo-4-[(3S)-2-oxopyrrolidin-3-yl]butyl 2-cyanobenzoate | autoPROC | 77.90% | 11.6 | APS (17-ID) | BUSTER | 2020-06-19 | 33054210 | - | - | - | - | N/A | - | - | 3C-like proteinase | 24.9 | - | No | - | 38.5 | 15.7 | 71.0 | - | ||||||
6xho | 1.45 Å | 2020-07-08 | X-ray | V34 | SARS-CoV | NSP5 (3CLpro) | Functional ligand | 21.09% | 23.87% | 4.70% | ethyl (2E,4S)-4-{[N-(4-methoxy-1H-indole-2-carbonyl)-L-leucyl]amino}-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate | ethyl (2E,4S)-4-{[N-(4-methoxy-1H-indole-2-carbonyl)-L-leucyl]amino}-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate | autoPROC | 67.00% | 11.5 | APS (17-ID) | BUSTER | 2020-06-19 | 33054210 | - | - | - | - | N/A | - | - | 3C-like proteinase | 30.6 | - | No | - | 46.2 | 25.7 | 65.2 | - | ||||||
6xkf | 1.80 Å | 2020-07-08 | X-ray | - | SARS-CoV-2 | NSP5 (3CLpro) | No functional ligands | 18.98% | 23.90% | 8.90% | - | HKL-3000 | 96.50% | 19.0 | APS (19-ID) | PHENIX | 2020-06-26 | - | - | - | http://covid-19.bioreproducibility.org/static/data/6xkf/6xkf_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6xkf/6xkf_refined.mtz | 24.50% | Placed the coordinates in a standardized location in the unit cell using ACHESYM. Added TLS. | Coordinates not in standardized location. | 3C-like proteinase | 56.8 | minimal | Yes | Yes | - | - | 45.7 | 76.2 | 66.2 | - | |||||
6xkh | 1.28 Å | 2020-07-08 | X-ray | FMT | SARS-CoV-2 | NSP5 (3CLpro) | No functional ligands | 15.63% | 17.49% | 5.90% | FORMIC ACID | FORMIC ACID | HKL-3000 | 98.60% | 40.75 | APS (19-ID) | PHENIX | 2020-06-26 | - | - | - | http://covid-19.bioreproducibility.org/static/data/6xkh/6xkh_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6xkh/6xkh_refined.mtz | 17.20% | Placed the coordinates in a standardized location in the unit cell using ACHESYM. Deleted EDO401, EDO402. Substituted FMT403 > HOH740, FMT404 > HOH741, FMT405 > HOH742, FMT406 > HOH743, ACT407 > HOH744. Fixed rotamers: His41, Csd145. Added double conformation to Val86, Lys100, Val104, Gln110, Val125, Cys128, Phe134, Arg188, Asn238, Ser267, Glu288. | Coordinates not in standardized location, incorrect rotamers, missing doble conformations. | 3C-like proteinase | 60.3 | moderate | Yes | Yes | - | - | 93.9 | 22.9 | 78.4 | - | ||||
6xkm | 2.25 Å | 2020-07-08 | X-ray | SAM | SARS-CoV-2 | NSP10/NSP16 | Functional ligand | 20.65% | 21.26% | N/A | S-ADENOSYLMETHIONINE | S-ADENOSYLMETHIONINE | DIALS | 100.00% | 2.68 | APS (19-ID) | REFMAC | 2020-06-26 | 33972410 | ZN | - | - | - | N/A | - | - | 2'-O-methyltransferase; Non-structural protein 10 | 84.3 | - | No | - | 71.9 | 94.4 | 95.0 | - | ||||||
6xmk | 1.70 Å | 2020-07-08 | X-ray | QYS, PG4 | SARS-CoV-2 | NSP5 (3CLpro) | Functional ligand | 17.91% | 21.16% | 7.70% | (1S,2S)-2-[(N-{[(4,4-difluorocyclohexyl)methoxy]carbonyl}-L-leucyl)amino]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid | (1S,2S)-2-[(N-{[(4,4-difluorocyclohexyl)methoxy]carbonyl}-L-leucyl)amino]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid; TETRAETHYLENE GLYCOL | XDS | 98.20% | 8.6 | APS (17-ID) | PHENIX | 2020-06-30 | 32747425 | - | - | http://covid-19.bioreproducibility.org/static/data/6xmk/6xmk_refined.pdb | http://covid-19.bioreproducibility.org/static/data/6xmk/6xmk_refined.mtz | 21.40% | Achesymed. Added Phe3 to chain A. Added side chains to residues 47, 49, 74 in chain A. Added side chains to residues 47, 49, 154 in chain B. Added 12 waters, deleted water A623 (now part of Tyr154). Put TLS groups as each chain+inhibitor. | Missing sidechains, non-standardized coordinates. | 3C-like proteinase - Full Length | 70.9 | minimal | Yes | Yes | - | 72.7 | 55.4 | 89.6 | - | |||||
6zfo | 4.40 Å | 2020-07-08 | Cryo-EM | NAG | SARS-CoV-2 | Spike | Pathogen-host interaction | N/A | N/A | N/A | 2-acetamido-2-deoxy-beta-D-glucopyranose | - | - | () | PHENIX | 2020-06-17 | 32737466 | - | - | - | - | N/A | - | - | Spike glycoprotein; EY6A heavy chain; EY6A light chain | N/A | - | No | - | N/A | N/A | N/A | - | ||||||||
6xkl | 3.21 Å | 2020-07-15 | Cryo-EM | NAG | SARS-CoV-2 | Spike | No functional ligands | N/A | N/A | N/A | 2-acetamido-2-deoxy-beta-D-glucopyranose | - | - | () | 2020-06-26 | 32703906 | - | - | - | - | N/A | - | - | Spike glycoprotein | N/A | - | No | - | N/A | N/A |